Benzylamine or benzylalcohol derivatives and their uses
Benzylamine or benzyl alcohol derivatives with specific structures address the limitations of current Nav1.8 inhibitors by providing selective and effective treatment for various types of pain, including chronic and neuropathic pain, through targeted inhibition of Nav1.8 ion channels.
Patent Information
- Application Number
- JP2023529004
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2021-05-08
- Filing Date
- 2021-10-20
- Publication Date
- 2024-11-28
- Estimated Expiration
- 2041-10-20
AI Technical Summary
Current Nav1.8 inhibitors suffer from issues such as low selectivity, insufficient pharmacokinetic data, poor bioavailability, and dissolution and absorption problems, limiting their effectiveness in treating chronic pain.
Development of benzylamine or benzyl alcohol derivatives with specific structures represented by formulas I, II, III, or their tautomers, mesomers, racemates, enantiomers, diastereomers, or mixtures, which act as potent and selective Nav1.8 inhibitors.
These derivatives provide a strong inhibitory effect on Nav1.8 ion channels, effectively treating chronic pain, neuropathic pain, musculoskeletal pain, acute pain, inflammatory pain, cancer pain, and other related conditions with improved specificity and pharmacokinetics.
Smart Images

Figure 0007591240000001 
Figure 0007591240000002 
Figure 0007591240000003
Abstract
Description
[Technical field]
[0001] The present invention relates to the technical field of medicine, and in particular to a compound used as a voltage-gated sodium ion channel subtype Nav1.8-specific inhibitor and its use. [Background technology]
[0002] With the advent of a global aging society, the scope of the impact of chronic pain diseases has gradually expanded, and more than one-third of the world's population suffers from chronic pain. The number of arthritis patients in China has exceeded 120 million. At the same time, there are at least 80 to 90 million patients with neuropathic chronic pain in China, and the number is on the rise. In addition, cancer will eventually become a chronic disease, and cancer pain will accompany patients for a long time. According to reports, more than half of cancer patients in China have not received cancer pain treatment. Pain is a self-protection mechanism for the animal or human body, but many persistent pains exceed their usefulness and cause great suffering to the physical or mental health of patients. Pain treatment is an important factor in improving the quality of life of patients, and the market prospects are also very large.
[0003] In 2005, the global painkiller market exceeded $80 billion, with prescription drug sales of about $20 billion. According to statistics from the National Institutes of Health (NIH), more than 25 million people in the United States suffer from pain every day, of which 23 million adults suffer from severe pain. In China, as China's status as a major manufacturing country continues to improve, the number of industrial workers is expanding rapidly, and long working hours are prone to various physical tensions and joint pain, making this group another large group that consumes painkillers. Statistics show that painkillers are growing rapidly in China's over-the-counter drug market, with sales second only to cold medicines, accounting for about 20% of the total.
[0004] However, the abuse of opioid painkillers has a staggering impact on society, with the WHO estimating that 69,000 people die from opioid overdose each year worldwide and 15 million people are dependent on opioids (i.e., opioid addiction), underscoring the importance of developing new safe and effective painkillers.
[0005] The inward current of voltage-gated sodium ion channels (Navs) is a key link in the generation and transmission of action potentials in central and peripheral neurons, and increased neuronal excitability or increased responsiveness to stimuli is an important mechanism for the development of various pain conditions. Therefore, the effects of voltage-gated sodium ion channels in pain transmission pathways, especially in peripheral sensory neurons, have always been a hot topic in pain research.
[0006] There are nine types of sodium ion channels in humans, Nav1.1 to Nav1.9, respectively, and Nav1.5, Nav1.8 and Nav1.9 are tetrodotoxin (TTX) insensitive sodium channels, where Nav1.8 is an important ion channel involved in chronic pain, atrial fibrillation, and Budd-Chiari syndrome, and is a highly selective target for pain treatment. Nav1.8 is mainly expressed in small-diameter nociceptive neurons and is involved in action potentials and rhythmic discharges of sensory neurons. Nav1.8 is regulated by inflammatory mediators, and at the same time, its expression is upregulated in sciatic nerve injury models, and gene knockout and silencing studies of Nav1.8 have shown that it is involved in the regulation of neuropathic and inflammatory pain. Because Nav1.8 is mainly restricted to pain-sensing neurons, selective Nav1.8 blockers are less likely to induce adverse reactions common to nonselective Nav blockers. Therefore, research on screening specific inhibitors of the Nav1.8 pain target has already become a hotspot in the field of pain, but the known Nav inhibitors suffer from shortcomings, mainly including a low therapeutic window, which may be due to the lack of subtype selectivity.
[0007] Currently, known Nav1.8 inhibitors include PF-01247324, A803467, PF-06305591, and VX150. Here, the first three compounds have all been discontinued in the preclinical stage due to insufficient selectivity, insufficient pharmacokinetic data, and low bioavailability. VX-150 is currently in Phase II clinical trials and has achieved primary clinical endpoints in clinical trials for acute pain after surgery, chronic pain in osteoarthritis, and neuropathic pain. VX-150 is well tolerated and no serious adverse reactions occur. The FDA has granted VX-150 a breakthrough therapy designation for treating moderate to severe pain. However, the clinical dosage of VX-150 is relatively large, with an initial dose of 1500 mg and then 750 mg every 12 hours, and its activity needs to be further improved. At the same time, the dissolution and absorption of the compound also poses major problems, which previous medical methods have partially solved but are still not fully ideal.
[0008] Therefore, developing Nav1.8 inhibitors with higher affinity, higher specificity, and better pharmacokinetics is of great social and economic value. Summary of the Invention [Problem to be solved by the invention]
[0009] The technical problem primarily solved by the present invention is to provide benzylamine or benzylalcohol derivatives that have a potent and selective inhibitory effect on Nav1.8. [Means for solving the problem]
[0010] In order to solve the above technical problems, the present invention provides a compound characterized by having the structure shown in Formula I, or a tautomer, mesomeric, racemic, enantiomer, diastereomer or mixture form thereof, a pharma- ceutically acceptable hydrate, solvate or salt thereof. JPEG0007591240000001.jpg46170A1 and A3 are each independently selected from CR1 or N; A2 is NR 10 R 11 OR 12 is selected from R1, R2, R3, R4, and R5 are each independently selected from hydrogen, halogen, hydroxyl, cyano, amino, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted amide, ester, acyl, carboxyl, sulfonyl, sulfonamide, boric acid, boric acid ester, phosphoryl, substituted or unsubstituted alkenyl, and substituted or unsubstituted alkynyl; R 10 , R 11 , R 12 are each independently selected from hydrogen, halogen, hydroxyl, cyano, amino, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, ester, acyl, carboxyl, amide, sulfonyl, sulfonamide, boric acid, boric acid ester, and phosphoryl; or R4 and R5 together with the atom to which they are attached form a substituted or unsubstituted 3- to 10-membered cycloalkyl group, =O, or R4 and R5 together with the atom to which they are attached form a substituted or unsubstituted 3- to 10-membered heterocycloalkyl group, or R5 and R 11 form a substituted or unsubstituted 3- to 10-membered heterocycloalkyl group together with the atom to which they are attached, or R and R 12 form a substituted or unsubstituted 3- to 10-membered heterocycloalkyl group together with the atom to which they are attached; Here, R1, R2, R3, R4, R5, R 10 , R 11 , R5 and R 11and the substituents in the heterocycloalkyl group formed by the atoms bonded thereto are each independently selected from deuterium, halogen, hydroxyl, amino, alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, cyano, ester, acyl, carboxyl, amido, aryl, heteroaryl, sulfonyl, and sulfonamide; z is selected from 0, 1, 2, 3, 4, 5; n is selected from 0, 1, 2, 3, 4; and m is selected from 0, 1, 2, 3, 4, 5.
[0011] The present invention further provides a structure of formula II or II' or a tautomer, mesomeric, racemic, enantiomer, diastereomer or mixture thereof, in the form of a pharma- ceutically acceptable hydrate, solvate or salt thereof. JPEG0007591240000002.jpg42170
[0012] The present invention further provides a structure of formula III or III', or an isomer, tautomer, mesomeric, racemic, enantiomer, diastereomer or mixture thereof, or a pharma- ceutically acceptable hydrate, solvate or salt thereof, JPEG0007591240000003.jpg41170A1 is selected from CR1 or N, A2 is NR 10 R 11 OR 12 is selected from R1 is selected from hydrogen, halogen, hydroxyl, cyano, amino, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted heterocycloalkyl, ester, acyl, carboxyl, amide, sulfonyl, sulfonamide, boric acid, boric acid ester, and phosphoryl; R6, R7, R8, and R9 are each independently selected from hydrogen, halogen, hydroxyl, cyano, amino, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, ester, acyl, carboxyl, amide, sulfonyl, sulfonamide, boric acid, boric acid ester, phosphoryl, substituted or unsubstituted alkenyl, and substituted or unsubstituted alkynyl, wherein the substituents are selected from deuterium, halogen, hydroxyl, amino, alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, cyano, ester, acyl, carboxyl, amide, aryl, heteroaryl, sulfonyl, and sulfonamide. Further, n is selected from 0, 1, and 2. Further, m is selected from 0, 1, and 2. Further, z is selected from 0, 1, 2, and 3. Here, the values of n, m, and z can be freely combined.
[0013] R1 is selected from hydrogen, halogen, hydroxyl group, cyano group, amino group, substituted or unsubstituted alkyl group, substituted or unsubstituted cycloalkyl group, substituted or unsubstituted heteroalkyl group, substituted or unsubstituted heterocycloalkyl group, substituted or unsubstituted amide group, ester group, acyl group, carboxyl group, sulfonyl group, sulfonamide group, boric acid group, borate ester group, and phosphoryl group, where the substituent is selected from halogen, hydroxyl group, amino group, C1-C6 alkyl group, 3-6 membered cycloalkyl group, 2-7 membered heteroalkyl group, 3-6 membered heterocycloalkyl group, cyano group, ester group, acyl group, carboxyl group, amide group, aryl group, heteroaryl group, sulfonyl group, and sulfonamide group; wherein R1 is selected from hydrogen, halogen, hydroxyl group, cyano group, amino group, substituted or unsubstituted C1-C6 alkyl group, substituted or unsubstituted 3- to 6-membered cycloalkyl group, substituted or unsubstituted 2- to 7-membered heteroalkyl group, substituted or unsubstituted 3- to 6-membered heterocycloalkyl group, substituted or unsubstituted amide group, ester group, and acyl group, wherein the substituent is selected from halogen, hydroxyl group, amino group, C1-C6 alkyl group, 3- to 6-membered cycloalkyl group, 2- to 7-membered heteroalkyl group, 3- to 6-membered heterocycloalkyl group, cyano group, ester group, acyl group, carboxyl group, amide group, sulfonyl group, and sulfonamide group; Furthermore, R1 is selected from hydrogen, halogen, a substituted or unsubstituted C1-C3 alkyl group, a substituted or unsubstituted 2-4 membered heteroalkyl group, where the substituents are selected from halogen, a hydroxyl group, an amino group, a C1-C3 alkyl group, a 2-4 membered heteroalkyl group, and an acyl group. Further, R1 is selected from hydrogen and halogen. More preferably, R1 is selected from H, F.
[0014] In one embodiment, n is 1 or 2, and each R2 is independently selected from hydrogen, halogen, a substituted or unsubstituted C1-C3 alkyl group, and a substituted or unsubstituted cyclopropyl group.
[0015] Further, each R2 is independently selected from hydrogen, halogen, a trifluoromethyl group, and a substituted or unsubstituted cyclopropyl group, and when n is 1, R2 is not H, and when n is 2, both R2 are not H at the same time.
[0016] In one aspect, m is 2 or 3, and each R3 is independently selected from a halogen, a substituted or unsubstituted alkyl group, a substituted or unsubstituted cycloalkyl group, a substituted or unsubstituted heteroalkyl group, and a substituted or unsubstituted heterocycloalkyl group, where the substituents are selected from deuterium, a C1-C6 alkyl group, a 2- to 7-membered heteroalkyl group, a 3- to 6-membered cycloalkyl group, a 3- to 6-membered heterocycloalkyl group, a halogen, a hydroxyl group, and an amide group, and each R3 is different.
[0017] Further, each R3 is independently selected from hydrogen, halogen, a substituted or unsubstituted C1-C6 alkyl group, and a substituted or unsubstituted C1-C6 alkoxy group, where the substituents are selected from deuterium, halogen, a C1-C6 alkyl group, a 2- to 7-membered heteroalkyl group, a 3- to 6-membered cycloalkyl group, a 3- to 6-membered heterocycloalkyl group, a hydroxyl group, and an amide group.
[0018] Further still, each R3 is independently selected from a halogen, a substituted or unsubstituted C1-C3 alkyl group, and a substituted or unsubstituted C1-C3 alkoxy group.
[0019] JPEG0007591240000004.jpg74170
[0020] JPEG0007591240000005.jpg32170
[0021] In one aspect, the present invention further provides a structure of formula IV, IV' or IV'', or an isomer, tautomer, mesomeric, racemic, enantiomer, diastereomer or mixture thereof, a pharma- ceutically acceptable hydrate, solvate or salt thereof, JPEG0007591240000006.jpg50170, where A1 is selected from N or -CR1, R 15 , R 16 are each independently selected from hydrogen, a C1-C3 alkyl group, and further selected from hydrogen and a methyl group; JPEG0007591240000007.jpg36170JPEG0007591240000008.jpg77170
[0022] JPEG0007591240000009.jpg18170
[0023] In another embodiment, the present invention further provides a structure of formula V or V' or an isomer, tautomer, mesomeric, racemic, enantiomer, diastereomer or mixture thereof, a pharma- ceutically acceptable hydrate, solvate or salt thereof, JPEG0007591240000010.jpg48170, where A1, A3 are selected from CR1, or A1 is selected from N, and A3 is selected from N or CR1; JPEG0007591240000011.jpg19170
[0024] The present invention further provides a pharmaceutical composition, the active ingredient of which is selected from one or a combination of two or more of the compounds according to any one of claims 1 to 21 or their stereoisomers, solvates, hydrates, pharma- ceutically acceptable salts, or cocrystals.
[0025] The present invention further provides the use of a compound of the present invention or a stereoisomer, solvate, hydrate, pharma- ceutically acceptable salt or co-crystal thereof in the preparation of a sodium ion channel modulator.
[0026] Further, the sodium ion channel modulator is a Nav1.8 inhibitor.
[0027] The present invention further provides the use of a compound of the present invention or a stereoisomer, solvate, hydrate, pharma- ceutically acceptable salt or co-crystal thereof in the preparation of a medicament for treating a disease causing overexpression of Nav1.8.
[0028] The present invention further provides the use of a compound of the present invention or a stereoisomer, solvate, hydrate, pharma- ceutically acceptable salt or co-crystal thereof in the preparation of a medicament for treating a disease caused by overexpression of Nav1.8.
[0029] The present invention further provides the use of a compound of the present invention or a stereoisomer, solvate, hydrate, pharma- ceutically acceptable salt or co-crystal thereof in the preparation of a medicament for treating any one or more of chronic pain, intestinal pain, neuropathic pain, musculoskeletal pain, acute pain, inflammatory pain, cancer pain, primary pain, multiple sclerosis, Charcot-Marie-Tooth syndrome, incontinence and arrhythmia.
[0030] Further, the neuropathic pain is selected from one or more of the following: post-herpetic neuralgia, diabetic neuralgia, painful HIV-associated sensory neuropathy, trigeminal neuralgia, burning mouth syndrome, post-amputation pain, phantom limb pain, painful neuroma, traumatic neuroma, Morton neuroma, nerve contusion, spinal stenosis, carpal tunnel syndrome, radicular pain, sciatica, nerve avulsion, brachial plexus avulsion, complex regional pain syndrome, medication-induced neuralgia, cancer chemotherapy-induced neuralgia, antiretroviral therapy-induced neuralgia, post-spinal cord injury pain, primary small fiber neuropathy, primary sensory neuropathy, trigeminal autonomic headache; the musculoskeletal pain is selected from one or more of osteoarthritis pain, back pain, cold pain, burn pain, and dental pain; the inflammatory pain is selected from rheumatoid arthritis pain and / or vulvodynia; The primary pain is selected from fibromyalgia.
[0031] A pharmaceutical composition comprising a compound of the invention or a stereoisomer, solvate, hydrate, pharma- ceutically acceptable salt, or co-crystal thereof may contain a pharma- ceutically acceptable adjuvant.
[0032] According to the present invention, "pharmacologically acceptable" refers to any substance that does not interfere with the effectiveness of the biological activity of the active ingredients and that is non-toxic to the host to which it is administered.
[0033] The pharma- ceutically acceptable adjuvants described in the present invention are a collective term for all additives in drugs other than the main drug, and the adjuvants should have the following properties: (1) no toxicity to the human body and almost no side effects, (2) stable chemical properties and not susceptible to temperature, pH, storage time, etc., (3) no miscibility with the main drug and no effect on the therapeutic effect and quality inspection of the main drug, and (4) no interaction with the packaging material. The adjuvants in the present invention include, but are not limited to, fillers (diluents), lubricants (glidants or anti-adherents), dispersants, wetting agents, binders, regulators, solubilizers, antioxidants, antibacterial agents, emulsifiers, disintegrants, etc.Binders include syrup, gum arabic, gelatin, sorbitol, tragacanth, cellulose and its derivatives (e.g., microcrystalline cellulose, sodium carboxymethylcellulose, ethylcellulose, or hydroxypropylmethylcellulose), gelatin slurry, syrup, starch slurry, or polyvinylpyrrolidone, fillers include lactose, powdered sugar, dextrin, starch and its derivatives, cellulose and its derivatives, inorganic calcium salts (e.g., calcium sulfate, calcium phosphate, calcium hydrogen phosphate, precipitated calcium carbonate, or the like), sorbitol, or glycine, lubricants include micronized silica gel, magnesium stearate, talc, aluminum hydroxide, boric acid, hydrogenated vegetable oil, polyethylene glycol, or the like, disintegrants include starch and its derivatives (e.g., sodium carboxymethyl starch, sodium carboxymethyl cellulose ... starch, sodium starch glycolate, pregelatinized starch, modified starch, hydroxypropyl starch, corn starch, etc.), polyvinylpyrrolidone or microcrystalline cellulose, etc.; wetting agents include sodium lauryl sulfate, water or alcohol, etc.; antioxidants include sodium sulfite, sodium bisulfite, sodium metabisulfite, dibutyl benzoic acid, etc.; antioxidants include 0.5% phenol, 0.3% cresol, 0.5% chlorobutanol, etc.; regulators include hydrochloric acid, citric acid, potassium (sodium) hydroxide, sodium citrate, and buffers (sodium dihydrogen phosphate, disodium hydrogen phosphate), etc.; emulsifiers include polysorbate-80, sorbitan monolate, Pluronic® F-68, lecithin, soy lecithin, etc.; solubilizers include Tween-80, bile, glycerin, etc.
[0034] The term "pharmaceutical acceptable salt" refers to the salt formed by the compound of the present invention and acid or base, which is suitable for use as a drug.The above-mentioned acid and base are Lewis acids and Lewis bases in the broad sense.The acid suitable for salt formation includes, but is not limited to, inorganic acids such as hydrochloric acid, hydrobromic acid, hydrofluoric acid, sulfuric acid, nitric acid, phosphoric acid, etc., organic acids such as formic acid, acetic acid, propionic acid, oxalic acid, malonic acid, succinic acid, fumaric acid, maleic acid, lactic acid, malic acid, tartaric acid, citric acid, picric acid, methanesulfonic acid, benzenemethanesulfonic acid, benzenesulfonic acid, etc., and acidic amino acids such as aspartic acid, glutamic acid, etc.
[0035] The mode of administration of the compounds or pharmaceutical compositions of the present invention is not particularly limited, and representative modes of administration include, but are not limited to, oral, parenteral (intravenous, intramuscular, or subcutaneous), and topical administration.
[0036] Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules. In these solid dosage forms, the active compound is mixed with at least one conventional inert excipient (or vector), such as, for example, sodium citrate or dicalcium phosphate, or with ingredients such as (a) fillers or compatibilizers, such as starch, lactose, sucrose, glucose, mannitol, and silicic acid; (b) binders, such as hydroxymethylcellulose, alginates, gelatin, polyvinylpyrrolidone, sucrose, and gum arabic; (c) humectants, such as glycerin; (d) disintegrants, such as agar-agar, calcium carbonate, potato starch or tapioca starch, alginic acid, certain complex silicates, and sodium carbonate; (e) retarders, such as paraffin; (f) absorption accelerators, such as quaternary amine compounds; (g) wetting agents, such as cetyl alcohol and glyceryl monostearate; (h) adsorbents, such as kaolin; and (i) lubricants, such as talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, or mixtures thereof. In the case of capsules, tablets and pills, the dosage forms may also comprise buffering agents.
[0037] Solid dosage forms such as tablets, sugar pills, capsules, pills and granules can be prepared with coating and shell materials, such as enteric coatings and other materials known in the art.They can contain opacifying agents, and the release of the active compound or compounds of such compositions can be delayed in a certain part of the digestive tract.Examples of embedding components that can be used are polymeric substances and waxes.If necessary, the active compound can be formed into microcapsules with one or more of the above-mentioned excipients.
[0038] Liquid dosage forms for oral administration include pharma- ceutically acceptable emulsions, solutions, suspensions, syrups, or tinctures. In addition to the active compound, liquid dosage forms can contain inert diluents conventionally used in the art, such as water or other solvents, and solubilizers and emulsifiers, such as, for example, ethanol, isopropanol, ethyl carbonate, ethyl acetate, propylene glycol, 1,3-butanediol, dimethylformamide, and oils, particularly cottonseed oil, peanut oil, corn germ oil, olive oil, castor oil, and sesame oil, or mixtures of these substances.
[0039] Besides these inert diluents, compositions can also include adjuvants, such as wetting agents, emulsifying and suspending agents, sweetening, flavoring and perfuming agents.
[0040] In addition to the active compound, suspensions may contain suspending agents such as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and dehydrated sorbitan esters, microcrystalline cellulose, aluminum methoxide, and agar-agar, or mixtures of these substances.
[0041] Compositions for parenteral injection can include physiologically acceptable sterile aqueous or anhydrous solutions, dispersions, suspensions or emulsions, and sterile powders for reconstitution into sterile injectable solutions or dispersions. Suitable aqueous and non-aqueous vehicles, diluents, solvents or excipients include water, ethanol, polyols and suitable mixtures thereof.
[0042] The dosage forms of the compounds of the present invention used for topical administration include ointments, powders, patches, sprays and inhalants. The active ingredient is mixed under sterile conditions with a physiologically acceptable vector and any preservatives, buffers or propellants that may be required.
[0043] The compound of the present invention can also be used in an injectable preparation, wherein the injectable is selected from liquid injection (water injection), sterile powder for injection (powder injection) or injectable tablet (referring to powder tablet or machine-compressed tablet drug prepared by aseptic operation, dissolved in water for injection before use and used for subcutaneous or intramuscular injection).
[0044] Wherein, in addition to the above compounds, said powder for injection further comprises at least an excipient. The excipient according to the present invention is an ingredient intentionally added to the drug, and should not have pharmacological properties in the amount used, but the excipient can aid in the processing, dissolution and dissolution, delivery by the targeted administration route or stability of the drug.
[0045] Functional isomers produced by the rapid migration of an atom in a molecule between two positions are called tautomers.
[0046] Mesomeric molecules contain asymmetric atoms, but because of the symmetry factor, the total optical rotation within the molecule is zero, ie, there is no optical rotation.
[0047] A racemate is an equimolar mixture of a chiral molecule (see chirality) with optical activity (see optical isomerism) and its enantiomers.
[0048] Stereoisomers that are mirror images of the real thing but are not superimposable are called enantiomers, and because one enantiomer has left-handed optical activity and the other has right-handed optical activity, enantiomers are also called optical isomers.
[0049] Diastereoisomers refer to stereoisomers in which the molecules have two or more chiral centers and are not mirror images.
[0050] "Substitution" refers to the replacement of a hydrogen atom in a molecule with another, different atom or molecule.
[0051] "Membered" refers to the number of skeletal atoms that constitute the ring or heteroalkyl group.
[0052] The term "one bond" as used herein refers to the fact that there is only one connecting bond, and can also be understood as "none."
[0053] "Alkyl group" refers to an aliphatic hydrocarbon group, and refers to a saturated hydrocarbon group. The alkyl group portion can be a straight chain alkyl group or a branched chain alkyl group. Typical alkyl groups include, but are not limited to, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, pentyl, hexyl, and the like.
[0054] C1-Cn as used in the present invention includes C1-C2, C1-C3....C1-Cn, where n is an integer greater than 1, and the prefix as a substituent indicates the minimum and maximum numbers of carbon atoms in the substituent, for example, "C1-C6 alkyl group" refers to a straight or branched alkyl group containing 1 to 6 carbon atoms.
[0055] "Heteroalkyl groups" refers to alkyl groups that contain heteroatoms, including alkoxy groups.
[0056] The term "alkenyl group" refers to an aliphatic hydrocarbon group having at least one carbon-carbon double bond. The alkenyl group may be straight-chained or branched.
[0057] The term "alkynyl group" refers to an aliphatic hydrocarbon group containing at least one carbon-carbon triple bond. The alkynyl group may be straight-chained or branched.
[0058] An "amide group" is a chemical structure having the formula -C(O)NHR or -NHC(O)R, where R can be selected from alkyl groups, heteroalkyl groups, cycloalkyl groups, heterocycloalkyl groups, aryl groups, heteroaryl groups, and the like.
[0059] A "sulfonyl group" is a chemical structure having the formula -S(=O)R, including a sulfonamide group, where R can be selected from alkyl groups, heteroalkyl groups, cycloalkyl groups, heterocycloalkyl groups, aryl groups, heteroaryl groups, amino groups, and the like.
[0060] A "phosphoryl group" is a chemical structure having the formula -P(=O)RR', where R, R' are each independently selected from alkyl groups, heteroalkyl groups, cycloalkyl groups, heterocycloalkyl groups, aryl groups, heteroaryl groups, hydroxyl groups, amino groups, and the like.
[0061] An "ester group" refers to a chemical structure having the formula -COOR, where R is selected from alkyl groups, heteroalkyl groups, cycloalkyl groups, heterocycloalkyl groups, aryl groups, heteroaryl groups, and the like.
[0062] An "acyl group" refers to a chemical structure having the formula -C(O)R, where R is selected from alkyl groups, heteroalkyl groups, cycloalkyl groups, heterocycloalkyl groups, aryl groups, heteroaryl groups, and the like.
[0063] "Cycloalkyl group" refers to a saturated or unsaturated cyclic hydrocarbon substituent.
[0064] The term "heterocycloalkyl group" refers to a cycloalkyl group that contains at least one heteroatom in the backbone of the ring.
[0065] Heteroatoms include, but are not limited to, O, S, N, P, Si, and the like.
[0066] "Ring" refers to any covalently closed structure including, for example, a carbocyclic ring (e.g., an aryl or cycloalkyl group), a heterocyclic ring (e.g., a heteroaryl or heterocycloalkyl group), an aromatic group (e.g., an aryl or heteroaryl group), or a non-aromatic group (e.g., a cycloalkyl or heterocycloalkyl group). A "ring" according to the present invention may be monocyclic or polycyclic, and may be parallel, spiro, or bridged.
[0067] JPEG0007591240000012.jpg18170
[0068] Exemplary heterocycloalkyl groups are: JPEG0007591240000013.jpg44170
[0069] An "aryl group" refers to a planar ring having a delocalized pi-electron system and containing 4n+2 pi-electrons, where n is an integer. Aryl rings are composed of 5, 6, 7, 8, 9 or more than 9 atoms. Aryl groups include, but are not limited to, phenyl, naphthyl, phenanthrenyl, anthracenyl, fluorenyl, indenyl, and the like.
[0070] Exemplary heteroaryl groups include: JPEG0007591240000014.jpg38170
[0071] "Halogen" or "halo" refers to fluorine, chlorine, bromine or iodine.
[0072] "Deuterium" refers to an isotope of hydrogen (H), also known as heavy hydrogen, and its atomic symbol is generally D or 2 H, and deuterium can be substituted for the H position of the present invention.
[0073] The alkyl group, heteroalkyl group, cyclic group, heterocyclic group, amino group, ester group, carbonyl group, amido group, sulfonyl group, phosphoryl group, boric acid group, boric acid ester group, aryl group, heteroaryl group, and the like described in this specification may be an unsubstituted alkyl group, heteroalkyl group, cyclic group, heterocyclic group, amino group, ester group, carbonyl group, amido group, sulfonyl group, phosphoryl group, boric acid group, boric acid ester group, aryl group, or heteroaryl group, or may be a substituted alkyl group, heteroalkyl group, cyclic group, heterocyclic group, amino group, ester group, carbonyl group, amido group, sulfonyl group, phosphoryl group, boric acid group, boric acid ester group, aryl group, or heteroaryl group.
[0074] In the above, unless otherwise specified, the term "substituted" refers to the group being referred to can be substituted with one or more additional groups, each of which is independently selected from an alkyl group, a cycloalkyl group, an aryl group, a carboxyl group, a heteroaryl group, a heterocycloalkyl group, a hydroxyl group, an alkoxy group, an alkylthio group, an aryloxy group, O=, a guanidino group, a cyano group, a nitro group, an acyl group, a halogen, a haloalkyl group, an amino group, and the like.
[0075] An inhibitor refers to a product that reduces the biological activity of a protein, for example, the compounds of the present invention can reduce the activity of the Nav1.8 ion channel, ie, are Nav1.8 inhibitors. Effect of the Invention
[0076] The beneficial effects of the present invention are as follows: the present invention provides a series of compounds with obvious inhibitory effects on Nav1.8 ion channel activity, providing a new scheme for treating diseases that target Nav1.8 for treatment, such as chronic pain, intestinal pain, neuropathic pain, musculoskeletal pain, acute pain, inflammatory pain, cancer pain, primary pain, multiple sclerosis, Charcot-Marie-Tooth syndrome, incontinence or arrhythmia disease, and can be used to prepare drugs for treating related diseases, with broad application prospects. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0077] The technical solutions of the present invention will be described below clearly and completely, and obviously, the described embodiments are only a part of the embodiments of the present invention, but are not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by those skilled in the art without any creative efforts are all within the protection scope of the present invention.
[0078] In the present invention, the structure of a compound can be determined by mass spectrometry (MS) and / or nuclear magnetic resonance ( 1 The chemical abbreviations have the following meanings: DMF: N,N-dimethylformamide THF: Tetrahydrofuran DIAD: Diisopropyl azodicarboxylate DIPEA: N,N-diisopropylethylamine PE: Petroleum Ether EA: Ethyl acetate DCM: dichloromethane HATU: O-(7-azabenzotriazol-1-yl)-N,N,N′,N′-tetramethylurea DMSO: Dimethyl sulfoxide DAST: Diethylaminosulfur trifluoride TBAF: Tetrabutylammonium fluoride NMP: N-methylpyrrolidone CDI: N,N'-carbonyldiimidazole LiHMDS: Lithium bistrimethylsilylamide
[0079] Synthesis of intermediates Intermediate 1 2-(4-fluoro-2-methylphenoxy)-4-(trifluoromethyl)benzoic acid JPEG0007591240000015.jpg37170
[0080] Step 1: Synthesis of methyl 2-fluoro-4-(trifluoromethyl)benzoate A reaction flask was charged with 2-fluoro-4-(trifluoromethyl)benzoic acid (2.08 g, 10 mmol), potassium carbonate (2.76 g, 20 mmol) and 20 mL of acetonitrile, and iodomethane (1.70 g, 12 mmol) was added at room temperature, and the reaction mixture was heated to reflux and stirred for 6 hours. TLC showed the reaction was complete. After the reaction was cooled to room temperature, it was filtered, and the filtrate was spun dry to obtain 2.10 g of the desired product. Yield: 95%.
[0081] Step 2: Synthesis of methyl 2-(4-fluoro-2-methylphenoxy)-4-(trifluoromethyl)benzoate Methyl 2-fluoro-4-(trifluoromethyl)benzoate (1.11g, 5mmol), 4-fluoro-2-methylphenol (0.63g, 5mmol), potassium carbonate (1.38g, 10mmol) and 10mL of N-methylpyrrolidone were added to a reaction flask, and the reaction mixture was heated to 120°C and stirred for 20 hours. TLC showed the completion of the reaction. After the reaction system was cooled to room temperature, it was poured into 50mL of water, extracted with ethyl acetate, the organic phase was dried and spin-dried, and then purified by silica gel column chromatography (PE / EA=20 / 1) to obtain 1.3g of the desired product. Yield: 79%.
[0082] Step 3: Synthesis of 2-(4-fluoro-2-methylphenoxy)-4-(trifluoromethyl)benzoic acid Methyl 2-(4-fluoro-2-methylphenoxy)-4-(trifluoromethyl)benzoate (656 mg, 2 mmol), sodium hydroxide (320 mg, 8 mmol), 10 mL of water and 10 mL of methanol were added to a reaction flask, and the reaction mixture was stirred at room temperature for 8 hours. TLC showed the reaction was complete. The reaction was poured into 50 mL of water, adjusted to pH 5 with 1 M hydrochloric acid, extracted with ethyl acetate, the organic phase was dried and spun to obtain 620 mg of the desired product. Yield: 99%.
[0083] Intermediate 2 2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzoic acid JPEG0007591240000016.jpg32170 The operation is the same as for intermediate 1.
[0084] Intermediate 3 4-Cyclopropyl-2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzoic acid JPEG0007591240000017.jpg63170
[0085] Step 1: Synthesis of 4-bromo-2-fluoro-5-(trifluoromethyl)aniline 2-Fluoro-5-(trifluoromethyl)aniline (3.58g, 20mmol) was dissolved in 50mL of DMF, NBS (3.56g, 20mmol) was added at room temperature, and the reaction mixture was stirred at room temperature overnight. The reaction mixture was poured into 200mL of water, extracted with ethyl acetate, the organic phase was dried, and then spun dry. The product was purified by silica gel column chromatography (PE / EA=2 / 1) to obtain 4.80g of the desired product. Yield: 93%.
[0086] Step 2: Synthesis of 4-cyclopropyl-2-fluoro-5-(trifluoromethyl)aniline 4-Bromo-2-fluoro-5-(trifluoromethyl)aniline (2.58g, 10mmol), cyclopropylboronic acid (3.44g, 40mmol), sodium carbonate (5.30g, 50mmol) and 30mL of DMF were added to a reaction flask, and after nitrogen gas replacement, Pd(dppf)Cl2 (220mg, 0.3mmol) was added, and the reaction mixture was heated to 90°C and stirred overnight under nitrogen gas protection. After cooling to room temperature, the reaction system was poured into 200mL of water, extracted with ethyl acetate, the organic phase was dried and spin-dried, and then purified by silica gel column chromatography (PE / EA=2 / 1) to obtain 1.62g of the desired product. Yield: 74%.
[0087] Step 3: Synthesis of 1-iodo-4-cyclopropyl-2-fluoro-5-(trifluoromethyl)benzene 4-Cyclopropyl-2-fluoro-5-(trifluoromethyl)aniline (1.10g, 5mmol) was dissolved in 15mL of acetonitrile, and isoamyl nitrite (0.70g, 6mmol) was added dropwise at 0°C. After completion of the addition, the system was stirred at room temperature for 1 hour. A 5mL aqueous solution of potassium iodide (1.66g, 10mmol) was added, and the reaction mixture was stirred at room temperature for 6 hours. The reaction system was poured into 50mL of water, extracted with ethyl acetate, and the organic phase was backwashed with 1M diluted hydrochloric acid, 1M aqueous sodium carbonate solution, and saturated saline solution in turn, dried, and spin-dried to obtain 1.05g of the desired product. Yield: 61%.
[0088] Step 4: Synthesis of 4-cyclopropyl-2-fluoro-5-(trifluoromethyl)benzoic acid 1-Iodo-4-cyclopropyl-2-fluoro-5-(trifluoromethyl)benzene (660 mg, 2 mmol) and triethylamine (404 mg, 4 mmol) were dissolved in DMF / H2O (10 mL / 1 mL), Pd(dppf)Cl2 (73 mg, 0.1 mmol) was added, and the air in the system was replaced with carbon monoxide. The reaction mixture was heated to 90°C under carbon monoxide pressure of 1 MPa and stirred overnight. After cooling the reaction system to room temperature, it was poured into 50 mL of water, extracted with ethyl acetate, the organic phase was dried and spin-dried, and then purified by silica gel column chromatography (DCM / MeOH=10 / 1) to obtain 190 mg of the desired product. Yield: 38%.
[0089] Step 5: Synthesis of 4-cyclopropyl-2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzoic acid Using the product of the above step as a substrate, intermediate 3 was obtained by the same method as intermediate 1.
[0090] Intermediate 4 5-Chloro-2-(4-fluoro-2-methylphenoxy)-4-(trifluoromethyl)benzoic acid JPEG0007591240000018.jpg31170
[0091] Step 1: Synthesis of 4-bromo-2-fluoro-5-(trifluoromethyl)aniline 1-Chloro-4-fluoro-2-(trifluoromethyl)benzene (2.0g, 10.1mmol) was dissolved in 20mL of dry THF, and the system was cooled to -70°C under nitrogen gas protection, and lithium 2,2,6,6-tetramethylpiperidine (11.1mL, 1.0M n-hexane solution, 11.1mmol) was added dropwise, and the reaction solution was stirred at -70°C for 0.5 hours, after which excess dry ice was added. The temperature was naturally raised to room temperature, 100mL of water was added, and the system was adjusted to acidity with hydrochloric acid, extracted with ethyl acetate, the organic phase was dried, and spin-dried, followed by purification by silica gel column chromatography (DCM / MeOH=20 / 1) to obtain 1.8g of the desired product. Yield: 75%.
[0092] Step 2: Synthesis of 5-chloro-2-(4-fluoro-2-methylphenoxy)-4-(trifluoromethyl)benzoic acid Using the product of the above step as a substrate, intermediate 3 was obtained by the same method as intermediate 1.
[0093] <Example 1> N-(3-(1,3-diamino-3-oxopropyl)-4-fluorophenyl)-2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzamide JPEG0007591240000019.jpg56170
[0094] Step 1: Synthesis of 3-amino-3-(2-fluoro-5-nitrophenyl)propionic acid A reaction flask was charged with 2-fluoro-5-nitrobenzaldehyde (2000 mg, 11.8 mmol), malonic acid (1477 mg, 14.2 mmol), ammonium acetate (1823 mg, 10 mmol) and 20 mL of ethanol, and the reaction mixture was heated to 80° C. and stirred overnight. TLC showed the reaction was complete. After the reaction was cooled to room temperature, it was filtered, the filter cake was washed with ethanol three times, and the resulting solid was spin-dried to give about 3000 mg of a yellow solid, and the crude product was used directly in the next step reaction.
[0095] Step 2: Synthesis of 3-((t-butoxycarbonyl)amino)-3-(2-fluoro-5-nitrophenyl)propionic acid 3-Amino-3-(2-fluoro-5-nitrophenyl)propionic acid (3000 mg, crude product), (Boc)2O (4716 mg, 21.6 mmol) and 30 mL of water were added to a reaction flask, sodium hydroxide (1154 mg, 28.9 mmol) was added, the reaction mixture was stirred at room temperature overnight, the reaction was directly spun dry and purified by silica gel column chromatography (DCM / MeOH=20 / 1) to give 780 mg of a pale yellow solid. The two-step yield was 20%.
[0096] Step 3: Synthesis of (3-amino-1-(2-fluoro-5-nitrophenyl)-3-oxopropyl)carbamic acid t-butyl ester A reaction flask was charged with 3-((t-butoxycarbonyl)amino)-3-(2-fluoro-5-nitrophenyl)propionic acid (100 mg, 0.35 mmol), ammonium chloride (185 mg, 3.5 mmol), DIPEA (89 mg, 0.69 mmol) and 2 mL of tetrahydrofuran, HBTU (261 mg, 0.69 mmol) was added, and the reaction mixture was stirred at room temperature overnight. The reaction was poured into 10 mL of water, extracted with ethyl acetate, the organic phase was dried and spun dry, and purified by Prep-TLC (DCM / MeOH=20 / 1) to give 75 mg of a pale yellow solid. Yield: 75%.
[0097] Step 4: Synthesis of (3-amino-1-(5-amino-2-fluorophenyl)-3-oxopropyl)carbamic acid t-butyl ester A reaction flask was charged with (3-amino-1-(2-fluoro-5-nitrophenyl)-3-oxopropyl)carbamic acid t-butyl ester (75 mg, 0.23 mmol) and 2 mL of ethanol, 10% Pd / C (50 mg) was added, and the reaction was stirred overnight at room temperature under hydrogen gas atmosphere. Suction filtration was performed, the filter cake was washed with ethanol, and the filtrate was spin-dried to give 70 mg of a white solid. Yield: 103%.
[0098] Step 5: Synthesis of t-butyl (3-amino-1-(2-fluoro-5-(2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzamido)phenyl)-3-oxopropyl)carbamate 2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzoic acid (89 mg, 0.28 mmol), (3-amino-1-(5-amino-2-fluorophenyl)-3-oxopropyl)carbamic acid t-butyl ester (70 mg, 0.23 mmol), DIPEA (61 mg, 0.47 mmol) and 2 mL of tetrahydrofuran were added to a reaction flask, HBTU (179 mg, 0.47 mmol) was added and the reaction mixture was stirred at room temperature overnight. The reaction was poured into 10 mL of water, extracted with ethyl acetate, the organic phase was dried and spun dry, and purified by Prep-TLC (DCM / MeOH=50 / 1) to give 50 mg of a pale yellow solid. Yield: 36%.
[0099] Step 6: Synthesis of N-(3-(1,3-diamino-3-oxopropyl)-4-fluorophenyl)-2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzoyl t-Butyl (3-amino-1-(2-fluoro-5-(2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzamido)phenyl)-3-oxopropyl)carbamate (50 mg, 0.084 mmol) was dissolved in 2 mL of dichloromethane, and trifluoroacetic acid (2 mL) was added at room temperature and stirred overnight. The reaction system was poured into 10 mL of water, and the pH value was adjusted to basic with sodium carbonate, and extracted with ethyl acetate. The organic phase was dried and spin-dried, and then purified by Prep-TLC (DCM / MeOH=20 / 1) to obtain 8 mg of a white solid. Yield: 20%. LC / MS: m / z=494.2[M+H] + . 1 H NMR(400MHz,d6-DMSO)δ 2.16(3H,s),2.53-2.55(2H,m),4.46(1H,brs),6.77(1H,d,J=8.4Hz),7.10-7.24(4H,m) ,7.17-7.19(1H,m),7.27(1H,d,J=8.8Hz),7.80-7.85(1H,m),7.95(1H,s),10.61(1H,s).
[0100] <Example 2> 3-Amino-3-(2-fluoro-5-(2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzamido)phenyl)propionic acid JPEG0007591240000020.jpg34170
[0101] Step 1: Synthesis of 3-(5-amino-2-fluorophenyl)-3-((t-butoxycarbonyl)amino)propionic acid A reaction flask was charged with 3-((t-butoxycarbonyl)amino)-3-(2-fluoro-5-nitrophenyl)propionic acid (100 mg, 0.34 mmol) and 5 mL of ethanol, 10% Pd / C (70 mg) was added, and the reaction was stirred overnight at room temperature under hydrogen gas. The mixture was filtered under suction, the filter cake was washed with ethanol, and the filtrate was spun dry to give 95 mg of a white solid. Yield: 100%.
[0102] Step 2: Synthesis of 3-((t-butoxycarbonyl)amino)-3-(2-fluoro-5-(2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzamido)phenyl)propionic acid 2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzoic acid (110 mg, 0.0.35 mmol) and 2 mL of thionyl chloride were added to a reaction flask, stirred at 80° C. for 2 hours, then spun dry. The resulting solid was dissolved in 2 mL of tetrahydrofuran, and then dropped into 1 mL of tetrahydrofuran solution containing 3-(5-amino-2-fluorophenyl)-3-((t-butoxycarbonyl)amino)propionic acid (95 mg, 0.31 mmol) and DIPEA (82 mg, 0.64 mmol) at room temperature. The reaction mixture was stirred at room temperature for 2 hours. Poured into 10 mL of water, extracted with ethyl acetate, dried the organic phase, spun dry, and purified by Prep-TLC (DCM / MeOH=20 / 1) to obtain 100 mg of a pale yellow solid. Yield: 53%.
[0103] Step 3: Synthesis of (3-amino-3-(2-fluoro-5-(2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzamido)phenyl)propionic acid 3-((t-butoxycarbonyl)amino)-3-(2-fluoro-5-(2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzamido)phenyl)propionic acid (100 mg, 0.17 mmol) was dissolved in 1 mL of dichloromethane, and trifluoroacetic acid (1 mL) was added at room temperature and stirred overnight. The reaction system was poured into 10 mL of water, the pH value was adjusted to basic with sodium carbonate, and extracted with ethyl acetate. The organic phase was dried and spin-dried, and then purified by Prep-TLC (DCM / MeOH=20 / 1) to obtain 9 mg of a white solid. Yield: 11%. LC / MS: m / z=495.1[M+H] + . 1H NMR(400MHz,d6-DMSO)δ 2.16(3H,s),2.47-2.49(2H,m),4.45(1H,brs),6.78(1H,d,J=8.4Hz),7.10-7.24(5H,m),7.17-7 .19(1H,m),7.25(1H,d,J=8.4Hz),7.82-7.85(1H,m),7.95(1H,s),10.55(1H,s),13.08(1H,brs).
[0104] <Example 3> N-(3-(1-amino-3-hydroxypropyl)-4-fluorophenyl)-4-cyclopropyl-2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzamide JPEG0007591240000021.jpg34170
[0105] Step 1: Synthesis of (1-(2-fluoro-5-nitrophenyl)-3-hydroxypropyl)carbamic acid t-butyl ester 3-((t-butoxycarbonyl)amino)-3-(2-fluoro-5-nitrophenyl)propionic acid (50 mg, 0.15 mmol) was dissolved in 1 mL of tetrahydrofuran, and borane tetrahydrofuran solution (1 M, 1 mL) was added at 0° C., and the reaction mixture was stirred at room temperature overnight. The reaction mixture was poured into 10 mL of water, extracted with ethyl acetate, and the organic phase was dried and spun dry, and then purified by Prep-TLC (DCM / MeOH=30 / 1) to obtain 30 mg of a white solid. Yield: 63%.
[0106] Step 2: Synthesis of (1-(5-amino-2-fluorophenyl)-3-hydroxypropyl)carbamic acid t-butyl ester A reaction flask was charged with (1-(2-fluoro-5-nitrophenyl)-3-hydroxypropyl)carbamic acid t-butyl ester (30 mg, 0.096 mmol) and 2 mL of ethanol, 10% Pd / C (20 mg) was added, and the reaction was stirred overnight at room temperature under hydrogen gas atmosphere. Suction filtration was performed, the filter cake was washed with ethanol, and the filtrate was spin-dried to give 25 mg of a white solid. Yield: 93%.
[0107] Step 3: Synthesis of (1-(5-(4-(4-cyclopropyl-2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzamido)-2-fluorophenyl)-3-hydroxypropyl)carbamic acid tert-butyl ester A reaction flask was charged with 4-cyclopropyl-2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzoic acid (30 mg, 0.085 mmol), 1-(5-amino-2-fluorophenyl)-3-hydroxypropyl)carbamic acid t-butyl ester (25 mg, 0.088 mmol), DIPEA (23 mg, 0.18 mmol) and 2 mL of tetrahydrofuran, HATU (67 mg, 0.18 mmol) was added, and the reaction mixture was stirred at room temperature overnight. The reaction was poured into 10 mL of water, extracted with ethyl acetate, the organic phase was dried and spun dry, and purified by Prep-TLC (DCM / MeOH=50 / 1) to give 35 mg of a white solid. Yield: 66%.
[0108] Step 4: Synthesis of N-(3-(1-amino-3-hydroxypropyl)-4-fluorophenyl)-4-cyclopropyl-2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzamide (1-(5-(4-(4-cyclopropyl-2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzamido)-2-fluorophenyl)-3-hydroxypropyl)carbamic acid t-butyl ester (35 mg, 0.056 mmol) was dissolved in 1 mL of dichloromethane, and trifluoroacetic acid (1 mL) was added at room temperature and stirred overnight. The reaction system was poured into 10 mL of water, and the pH value was adjusted to basic with sodium carbonate, and extracted with ethyl acetate. The organic phase was dried and spin-dried, and then purified by Prep-TLC (DCM / MeOH=20 / 1) to obtain 18 mg of a white solid. Yield: 62%. LC / MS: m / z=521.2[M+H] + . 1 H NMR(400MHz,d6-DMSO)δ 0.55-0.57(2H,m),1.01-1.04(2H,m),1.79-1.82(2H,m),2.12-2.14(1H,m),2.16(3H,s),3.37-3.40(2H,m),4.14-4.17(1H, m),6.35(1H,s),7.02-7.12(3H,m),7.20(1H,d,J=8.4Hz),7.49-7.52(1H,m),7.74-7.76(1H,m),7.90(1H,s),10.43(1H,s).
[0109] <Example 4> N-(3-(1,3-diamino-2-methyl-3-oxopropyl)-4-fluorophenyl)-2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzamide JPEG0007591240000022.jpg47170
[0110] Step 1: Synthesis of (3-amino-3-(2-fluoro-5-nitrophenyl)-2-methylpropanoic acid 2-Fluoro-5-nitrobenzaldehyde (2000mg, 11.8mmol), 2-methylmalonic acid (1676mg, 14.2mmol), ammonium acetate (1823mg, 10mmol) and 20mL of ethanol were added to a reaction flask, and the reaction mixture was heated to 80°C and stirred overnight. TLC showed the reaction was complete. After the reaction was cooled to room temperature, it was filtered, and the filter cake was washed with ethanol three times, and the obtained solid was purified by Prep-HPLC to obtain 620mg of a white solid. Yield: 23%.
[0111] Step 2: Synthesis of N-(3-(1,3-diamino-2-methyl-3-oxopropyl)-4-fluorophenyl)-2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzamide Starting from the products of the above steps and other reagents, the compound of Example 4 can be prepared in a similar manner to Example 1. LC / MS: m / z=508.2[M+H] + . 1 H NMR(400MHz,d6-DMSO)δ 1.04(3H,d,J=7.2Hz),2.16(3H,s),2.48-2.53(1H,m),4.25(1H,d,J=6.0Hz),6.70(1H,s),6.81(1H,d,J =8.4Hz),7.07-7.30(5H,m),7.60-7.64(1H,m),7.76-7.79(2H,m),7.96(1H,d,J=2.4Hz),10.51(1H,s).
[0112] <Example 5> N-(3-(1-amino-3-methoxypropyl)-4-fluorophenyl)-4-cyclopropyl-2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzamide JPEG0007591240000023.jpg53170
[0113] Step 1: Synthesis of (t-butyl(1-(5-(4-cyclopropyl-2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzamido)-2-fluorophenyl)-3-methoxypropyl)carbamate 1-(5-(4-(4-cyclopropyl-2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzamido)-2-fluorophenyl)-3-hydroxypropyl)carbamic acid t-butyl ester (100 mg, 0.16 mmol), DIPEA (41 mg, 0.32 mmol) and 5 mL of dichloromethane were added to a reaction flask, methylflavinyl chloride (22 mg, 0.19 mmol) was added dropwise at room temperature, and the reaction mixture was stirred at room temperature for 1 hour. The reaction system was spun dry, 5 mL of a methanolic solution of sodium methanol (7 M) was added, and the system was heated to 70° C. and stirred overnight. The reaction solution was poured into 10 mL of water, extracted with ethyl acetate, the organic phase was dried and spun dry to obtain 80 mg of a yellow oil, which was used directly in the next step reaction.
[0114] Step 2: Synthesis of (N-(3-(1-amino-3-methoxypropyl)-4-fluorophenyl)-4-cyclopropyl-2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzamide (t-Butyl (1-(5-(4-cyclopropyl-2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzamido)-2-fluorophenyl)-3-methoxypropyl)carbamate (70 mg, the crude product of the above step) in 2 mL of hydrogen chloride / dioxane solution (2 M) was stirred at room temperature for 2 hours, the system was spin-dried, added to 10 mL of water, the pH value was adjusted to basic with sodium carbonate, extracted with ethyl acetate, the organic phase was dried and spin-dried, and then purified by Prep-HPLC to obtain 3 mg of a white solid. The two-step yield was 4%. LC / MS: m / z=535.2[M+H] + . 1H NMR(400MHz,d6-DMSO)δ 0.56-0.57(2H,m),1.02-1.04(2H,m),1.74-1.76(2H,m),2.13-2.15(1H,m),2.16(3H,s),3.19(3H,s),3.20-3.30(2H,m),4.14-4. 16(1H,m),6.35(1H,s),7.05-7.10(3H,m),7.20(1H,d,J=8.8Hz),7.49-7.52(1H,m),7.74-7.76(1H,m),7.90(1H,s),10.37(1H,s).
[0115] <Example 6> N-(3-(1-acetylamino-3-hydroxypropyl)-4-fluorophenyl)-4-cyclopropyl-2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzamide JPEG0007591240000024.jpg65170N-(3-(1-amino-3-hydroxypropyl)-4-fluorophenyl)-4-cyclopropyl-2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzamide (50mg, 0.096mmol) and DIPEA (32mg, 0.29mmol) in 2mL of dichloromethane solution was added dropwise with acetyl chloride (9mg, 0.12mmol), stirred at room temperature for 1 hour, and then added to 10mL of water, extracted with ethyl acetate, dried the organic phase, and spun dry, then purified by Prep-HPLC to obtain 8mg of white solid. Yield: 15%. LC / MS: m / z=563.2[M+H] + . 1H NMR (400MHz, d6-DMSO) δ 0.55-0.57(2H,m),1.01-1.04(2H,m),1.75-1.80(2H,m),1.82(3H,s),2.07 -2.10(1H,m),2.16(3H,s),3.37-3.39(2H,m),4.51-4.53(1H,m),5.04-5.09 (1H,m),6.33(1H,s),7.06-7.10(3H,m),7.20(1H,d,J=8.8Hz),7.49-7.52( 1H,m),7.62-7.66(1H,m),7.90(1H,s),8.33(1H,d,J=7.6Hz),10.40(1H,s).
[0116] <Example 7> 4-Cyclopropyl-2-(4-fluoro-2-methylphenoxy)-N-(4-fluoro-3-(3-hydroxy-1-(methylamino)propyl)phenyl)-5-(trifluoromethyl)benzamide
[0117] <Example 8> 4-Cyclopropyl-N-(3-(1-(dimethylamino)-3-hydroxypropyl)-4-fluorophenyl)-2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzamide JPEG0007591240000025.jpg52170N-(3-(1-amino-3-hydroxypropyl)-4-fluorophenyl)-4-cyclopropyl-2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzamide (50 mg, 0.096 mmol) and potassium carbonate (26 mg, 0.19 mmol) were added to a 2 mL acetonitrile solution of iodomethane (13 mg, 0.096 mmol). The mixture was stirred at room temperature for 6 hours, and then added to 10 mL of water. The mixture was extracted with ethyl acetate. The organic phase was dried and spin-dried, and then purified by Prep-HPLC to obtain the product. Data for Example 7: 5 mg of white solid, yield: 10%. LC / MS: m / z=535.2[M+H] + . 1H NMR(400MHz,d6-DMSO)δ 0.56-0.58(2H,m),1.03-1.05(2H,m),1.74-1.77(1H,m),1.90-2.00( 1H,m),2.13-2.15(1H,m),2.16(3H,s),2.24(3H,s),3.35-3.43(2H,m ),4.08(1H,brs),6.36(1H,s),7.06-7.10(2H,m),7.15-7.22(2H,m),7.51-7.55(1H,m),7.83(1H,d,J=4.4Hz),7.92(1H,s),10.45(1H,s). Data for Example 8: 6 mg of white solid, yield: 12%. LC / MS: m / z=549.2[M+H] + . 1 H NMR(400MHz,d6-DMSO)δ 0.56-0.58(2H,m),1.04-1.07(2H,m),1.74-1.83(2H,m),2.13-2.15(1H,m),2.16(3H,s),2.20(6H,s),3.35-3.43(2H,m),4.11 (1H,brs),6.37(1H,s),7.06-7.10(2H,m),7.16-7.22(2H,m),7.51-7.55(1H,m),7.81-7.83(1H,m),7.91(1H,s),10.39(1H,s).
[0118] <Example 9> 4-Cyclopropyl-N-(3-(1,2-diamino-2-oxoethyl)-4-fluorophenyl)-2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzamide
[0119] <Example 10> N-(3-(2-amino-1-(methylamino)-2-oxoethyl)-4-fluorophenyl)-4-cyclopropyl-2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzamide JPEG0007591240000026.jpg79170
[0120] Step 1: Synthesis of N-(3-acetyl-4-fluorophenyl)-4-cyclopropyl-2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzamide HATU (175 mg, 0.46 mmol) was added to a solution of 4-cyclopropyl-2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzoic acid (81 mg, 0.23 mmol), 5-amino-2-fluorophenethyl ketone (70 mg, 0.46 mmol) and DIPEA (89 mg, 0.69 mmol) in 3 mL of DMF, and the reaction mixture was stirred at room temperature overnight. The reaction was poured into 10 mL of water, extracted with ethyl acetate, the organic phase was dried and spun dry, and purified by TLC (PE / EA=10 / 1) to give 125 mg of a white solid.
[0121] Step 2: Synthesis of 2-(5-(4-cyclopropyl-2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzamido)-2-fluorophenyl)-2-oxoacetic acid Selenium dioxide (57 mg, 0.51 mmol) was added to a solution of N-(3-acetyl-4-fluorophenyl)-4-cyclopropyl-2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzamide (125 mg, 0.26 mmol) in 3 mL of pyridine, and the reaction mixture was stirred overnight at 100° C. After the reaction system was spin-dried, 10 mL of water was added, and the pH value was adjusted to acidic with 1 M dilute hydrochloric acid, extracted with ethyl acetate, the organic phase was dried and spin-dried, and purified by Prep-TLC (DCM / MeOH=10 / 1) to obtain 100 mg of a white solid. Yield: 75%.
[0122] Step 3: Synthesis of N-(3-(2-amino-2-oxoacetyl)-4-fluorophenyl)-4-cyclopropyl-2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzamide HATU (144 mg, 0.38 mmol) was added to a solution of 4-cyclopropyl-2-(5-(4-cyclopropyl-2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzamido)-2-fluorophenyl)-2-oxoacetic acid (100 mg, 0.19 mmol), ammonium chloride (102 mg, 1.9 mmol) and DIPEA (50 mg, 0.38 mmol) in 3 mL of DMF, and the reaction mixture was stirred at room temperature overnight. The reaction was poured into 10 mL of water, extracted with ethyl acetate, the organic phase was dried and spun dry, and purified by Prep-TLC (PE / EA=10 / 1) to give 50 mg of a white solid. Yield: 50%.
[0123] Step 4: Synthesis of 4-cyclopropyl-N-(3-(1,2-diamino-2-oxoethyl)-4-fluorophenyl)-2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzamide A solution of N-(3-(2-amino-2-oxoacetyl)-4-fluorophenyl)-4-cyclopropyl-2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzamide (50 mg, 0.096 mmol) and hydroxylamine hydrochloride (27 mg, 0.38 mmol) in 3 mL of methanol was stirred at 60° C. for 20 minutes. Sodium acetate (32 mg, 0.38 mmol) was added, and the reaction mixture was allowed to cool to room temperature. Then, 2 mL of formic acid and 100 mg of zinc powder were added and stirred at room temperature for 2 hours. The reaction was poured into 10 mL of water, extracted with ethyl acetate, the organic phase was dried and spun dry, and purified by Prep-TLC (DCM / MeOH=10 / 1) to give 12 mg of a white solid. Yield: 25%. LC / MS: m / z=520.2[M+H] + . 1H NMR(400MHz,d6-DMSO)δ 0.55-0.57(2H,m),1.01-1.04(2H,m),2.10-2.12(1H,m),2.14(3H,s),4.48(1H,s),6.33(1H,s),7.07-7.1 3(3H,m),7.18-7.22(2H,m),7.46(1H,s),7.55-7.58(1H,m),7.68-7.71(1H,m),7.89(1H,s),10.44(1H,s).
[0124] Step 5: Synthesis of N-(3-(2-amino-1-(methylamino)-2-oxoethyl)-4-fluorophenyl)-4-cyclopropyl-2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzamide 4-Cyclopropyl-N-(3-(1,2-diamino-2-oxoethyl)-4-fluorophenyl)-2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzamide (10mg, 0.019mmol) and potassium carbonate (6mg, 0.043mmol) were added to 2mL of acetonitrile solution, and iodomethane (2.6mg, 0.018mmol) was added. After stirring at room temperature for 6 hours, the system was added to 10mL of water, extracted with ethyl acetate, the organic phase was dried, and spin-dried, and then purified by Prep-HPLC to obtain 4mg of white solid. Yield: 33%. LC / MS: m / z=534.2[M+H] + . 1 H NMR(400MHz,d6-DMSO)δ 0.55-0.57(2H,m),1.02-1.04(2H,m),2.10-2.12(1H,m),2.14(3H,s),2.22(3H,s),4.20(1H,s),6.33(1 H,s),7.07-7.27(5H,m),7.47(1H,s),7.55-7.58(1H,m),7.68-7.71(1H,m),7.90(1H,s),10.42(1H,s).
[0125] <Example 11> N-(3-(1-amino-2-hydroxyethyl)-4-fluorophenyl)-4-cyclopropyl-2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzamide JPEG0007591240000027.jpg53170
[0126] Step 1: Synthesis of 4-cyclopropyl-2-(4-fluoro-2-methylphenoxy)-N-(4-fluoro-3-(2-hydroxyacetyl)phenyl)-5-(trifluoromethyl)benzamide 2-(5-(4-cyclopropyl-2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzamido)-2-fluorophenyl)-2-oxoacetic acid (52 mg, 0.1 mmol) was dissolved in 1 mL of tetrahydrofuran, and borane tetrahydrofuran solution (1 M, 1 mL) was added at 0° C., and the reaction mixture was stirred at room temperature for 2 hours. The reaction system was poured into 10 mL of water, extracted with ethyl acetate, and the organic phase was dried and spin-dried, and then purified by Prep-TLC (DCM / MeOH=30 / 1) to obtain 23 mg of a white solid. Yield: 45%.
[0127] Step 2: Synthesis of N-(3-(1-amino-2-hydroxyethyl)-4-fluorophenyl)-4-cyclopropyl-2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzamide A solution of 4-cyclopropyl-2-(4-fluoro-2-methylphenoxy)-N-(4-fluoro-3-(2-hydroxyacetyl)phenyl)-5-(trifluoromethyl)benzamide (25 mg, 0.05 mmol) and hydroxylamine hydrochloride (14 mg, 0.2 mmol) in 2 mL of methanol was stirred at 60° C. for 20 minutes. Sodium acetate (16 mg, 0.2 mmol) was added, and the reaction mixture was allowed to cool to room temperature. Then, 2 mL of formic acid and 100 mg of zinc powder were added and stirred at room temperature for 2 hours. The reaction was poured into 10 mL of water, extracted with ethyl acetate, the organic phase was dried and spun dry, and purified by Prep-TLC (DCM / MeOH=10 / 1) to give 7 mg of a white solid. Yield: 28%. LC / MS: m / z=507.2[M+H] + . 1 H NMR(400MHz,d6-DMSO)δ 0.53-0.56(2H,m),1.01-1.05(2H,m),2.12-2.14(1H,m),2.15(3H,s),3.44-3.47(2H,m),4.19-4.21(1H,m),6.37( 1H,s),7.03-7.12(3H,m),7.21(1H,d,J=8.4Hz),7.50-7.52(1H,m),7.74-7.76(1H,m),7.90(1H,s),10.40(1H,s).
[0128] <Example 12> N-(3-(aminomethyl)-4-fluorophenyl)-2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzamide
[0129] <Example 13> N-(3-((((2-amino-2-oxoethyl)amino)methyl)-4-fluorophenyl)-2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzamide JPEG0007591240000028.jpg34170
[0130] Step 1: Synthesis of N-(3-cyano-4-fluorophenyl)-2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzamide 2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzoic acid (94 mg, 0.3 mmol), 5-amino-2-fluorobenzonitrile (41 mg, 0.3 mmol), DIPEA (77 mg, 0.6 mmol) and 2 mL of tetrahydrofuran were added to a reaction flask, HATU (190 mg, 0.5 mmol) was added, and the reaction mixture was stirred at room temperature overnight. The reaction was poured into 10 mL of water, extracted with ethyl acetate, the organic phase was dried and spun dry, and purified by Prep-TLC (PE / EA=3 / 1) to give 110 mg of a white solid. Yield: 85%.
[0131] Step 2: Synthesis of N-(3-(aminomethyl)-4-fluorophenyl)-2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzamide A reaction flask was charged with N-(3-cyano-4-fluorophenyl)-2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzamide (110 mg, 0.25 mmol) and 2 mL of methanol, 10% Pd / C (30 mg) was added, and the reaction system was stirred overnight at 50° C. under a hydrogen gas atmosphere (1 MPa). The reaction was filtered under suction, the filter cake was washed with methanol, and the filtrate was spin-dried to give 100 mg of a white solid. Yield: 91%. LC / MS: m / z=437.1 [M+H] + . 1 H NMR(400MHz,d6-DMSO)δ 2.15(3H,s),3.73(2H,s),6.81(1H,d,J=8.4Hz),7.09-7.26(4H,m),7.5 7-7.59(1H,m),7.76-7.79(2H,m),7.97(1H,d,J=1.6Hz),10.55(1H,s).
[0132] Step 3: Synthesis of N-(3-((((2-amino-2-oxoethyl)amino)methyl)-4-fluorophenyl)-2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzamide Bromoacetamide (14 mg, 0.1 mmol) was added to a 2 mL acetonitrile solution of N-(3-(aminomethyl)-4-fluorophenyl)-2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzamide (44 mg, 0.1 mmol) and potassium carbonate (28 mg, 0.2 mmol), and the mixture was stirred at room temperature overnight. After suction filtration and spin drying of the filtrate, the mixture was purified by Prep-TLC (PE / EA=1 / 1) to obtain 15 mg of a white solid. The yield was 31%. LC / MS: m / z=494.1[M+H] + . 1 H NMR(400MHz,d6-DMSO)δ 2.15(3H,s),3.06(2H,s),3.70(2H,s),6.81(1H,d,J=8.8Hz),7.08-7.27 (6H,m),7.61-7.63(1H,m),7.76-7.78(2H,m),7.95(1H,s),10.55(1H,s).
[0133] <Example 14> N-(3-(1-aminoethyl)-4-fluorophenyl)-2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzamide JPEG0007591240000029.jpg50170
[0134] N-(3-acetyl-4-fluorophenyl)-4-cyclopropyl-2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzamide (45 mg, 0.1 mmol, obtained by the same method as in the first step of Example 9 through the corresponding raw material) and 0.1 mL of ammonia water in 2 mL of tetrahydrofuran solution were stirred for 6 hours, and sodium triacetoxyborohydride (42 mg, 0.2 mmol) was added. The reaction mixture was directly spun dry after stirring for 2 hours, and the crude product was purified by Prep-TLC (PE / EA=1 / 1) to obtain 6 mg of white solid. Yield: 13%. LC / MS: m / z=451.1[M+H] + . 1 H NMR(400MHz,d6-DMSO)δ 1.26(3H,d,J=6.4Hz),2.15(3H,s),4.28(1H,q,J=6.4Hz),6.82(1H,d,J=8.8Hz),7.07-7.26(4H,m),7.56-7. 60(1H,m),7.77(1H,dd,J=8.4Hz,1.6Hz),7.88(1H,dd,J=8.0Hz,2.4Hz),7.96(1H,d,J=2.4Hz),10.52(1H,s).
[0135] <Example 15> 2-(4-fluoro-2-methylphenoxy)-N-(4-fluoro-3-(pyrrolidin-2-yl)phenyl)-5-(trifluoromethyl)benzamide JPEG0007591240000030.jpg28170
[0136] Step 1: Synthesis of N-(3-bromo-4-fluorophenyl)-2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzamide 2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzoic acid (94 mg, 0.3 mmol), 3-bromo-4-fluoroaniline (57 mg, 0.3 mmol), DIPEA (77 mg, 0.6 mmol) and 2 mL of tetrahydrofuran were added to a reaction flask, HATU (190 mg, 0.5 mmol) was added, and the reaction mixture was stirred at room temperature overnight. The reaction was poured into 10 mL of water, extracted with ethyl acetate, the organic phase was dried and spun dry, and purified by Prep-TLC (PE / EA=10 / 1) to give 120 mg of a white solid. Yield: 82%.
[0137] Step 2: Synthesis of 2-(2-fluoro-5-(2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzamido)phenyl) t-butyl-1-H-pyrrole-1-formic acid t-butyl ester N-(3-bromo-4-fluorophenyl)-2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzamide (97 mg, 0.2 mmol), (1-(t-butoxycarbonyl)-1H-pyrrol-2-yl)boronic acid (42 mg, 0.2 mmol), potassium carbonate (55 mg, 0.4 mmol) and 2 mL of DMF were added to a reaction flask, and after nitrogen gas replacement, Pd(dppf)Cl2 (7 mg, 0.01 mmol) was added, and the reaction mixture was heated to 90 ° C. and stirred for 6 hours under nitrogen gas protection. The reaction system was cooled to room temperature, poured into 10 mL of water, extracted with ethyl acetate, the organic phase was dried and spin-dried, and then purified by Prep-TLC (PE / EA=4 / 1) to obtain 90 mg of white solid. Yield: 79%.
[0138] Step 3: Synthesis of 2-(2-fluoro-5-(2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzamido)phenyl)pyrrolidine-1-carboxylic acid tert-butyl ester A reaction flask was charged with 2-(2-fluoro-5-(2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzamido)phenyl) t-butyl-1-H-pyrrole-1-formic acid t-butyl ester (90 mg, 0.16 mmol) and 5 mL of methanol, 10% Pd / C (20 mg) was added, and the reaction system was stirred overnight at room temperature under a hydrogen gas atmosphere (1 MPa). Suction filtration was performed, the filter cake was washed with methanol, and the filtrate was spin-dried to obtain 85 mg of a white solid. Yield: 94%.
[0139] Step 4: Synthesis of 2-(4-fluoro-2-methylphenoxy)-N-(4-fluoro-3-(pyrrolidin-2-yl)phenyl)-5-(trifluoromethyl)benzamide 2-(2-fluoro-5-(2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzamido)phenyl)pyrrolidine-1-carboxylic acid t-butyl ester (58 mg, 0.1 mmol) in 2 mL of hydrogen chloride / dioxane solution (2 M) was stirred at room temperature for 2 hours, the system was spin-dried, and then added to 10 mL of water, the pH value was adjusted to basic with sodium carbonate, and extracted with ethyl acetate. The organic phase was dried and spin-dried, and then purified by Prep-HPLC to obtain 25 mg of white solid. Yield: 52%. LC / MS: m / z=477.2[M+H] + . 1 H NMR(400MHz,d6-DMSO)δ 1.44-1.53(1H,m),1.74-1.78(2H,m),2.16(3H,s),2.17-2.20(1H,m),2.97-3.00(2H,m),4.33(1H,t,J=7.6Hz),6.81(1H,d,J=8.4Hz),7 .09-7.26(4H,m),7.58-7.61(1H,m),7.77(1H,dd,J=8.8Hz,2.4Hz),7.77(1H,dd,J=8.4Hz,4.0Hz),7.96(1H,d,J=2.8Hz),10.51(1H,s).
[0140] <Example 16> 5-(2-fluoro-5-(2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzamido)phenyl)pyrrolidine-2-carboxamide JPEG0007591240000031.jpg60170
[0141] Step 1: Synthesis of 2-((t-butoxycarbonyl)amino)-5-(2-fluoro-5-(2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzamido)phenyl)-5-oxopentanoic acid methyl ester At -70°C, n-butyllithium (1.6M, 3.1mL) was added dropwise to a solution of N-(3-bromo-4-fluorophenyl)-2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzamide (486mg, 1.0mmol) in 5mL of anhydrous tetrahydrofuran, and after stirring at this temperature for 1 hour, a solution of Nt-butoxycarbonyl-DL-pyroglutamic acid methyl ester (1215mg, 5.0mmol) in 2mL of tetrahydrofuran was added dropwise, and after stirring for 1 hour, it was poured into 20mL of water. Extraction was performed with ethyl acetate, and the organic phase was dried and spin-dried, followed by purification by silica gel column chromatography (PE / EA=4 / 1) to obtain 210mg of a white solid. Yield: 32%.
[0142] Step 2: Synthesis of 5-(2-fluoro-5-(2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzamido)phenyl)-3,4-dihydro-2H-pyrrole-2-carboxylic acid methyl ester 2-((t-butoxycarbonyl)amino)-5-(2-fluoro-5-(2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzamido)phenyl)-5-oxopentanoic acid methyl ester (210 mg, 0.32 mmol) was dissolved in 5 mL of dichloromethane and 2 mL of trifluoroacetic acid was added followed by stirring at room temperature overnight. The reaction was directly spun down to give ∼200 mg of crude product.
[0143] Step 3: Synthesis of 5-(2-fluoro-5-(2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzamido)phenyl)-3,4-dihydro-2H-pyrrole-2-carboxylic acid The crude product obtained in the above step was dissolved in 5 mL of tetrahydrofuran, and 2 mL of 1 M aqueous sodium hydroxide solution was added and stirred at room temperature for 6 hours. After adjusting the pH value of the reaction system to 5 with dilute hydrochloric acid, it was directly purified by Prep-HPLC to obtain 90 mg of the desired product. The two-step yield was 54%.
[0144] Step 4: Synthesis of 5-(2-fluoro-5-(2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzamido)phenyl)-3,4-dihydro-2H-pyrrole-2-carboxamide A reaction flask was charged with 5-(2-fluoro-5-(2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzamido)phenyl)-3,4-dihydro-2H-pyrrole-2-carboxylic acid (52 mg, 0.1 mmol), ammonium chloride (53 mg, 1.0 mmol), DIPEA (39 mg, 0.3 mmol) and 2 mL of tetrahydrofuran, HBTU (76 mg, 0.2 mmol) was added, and the reaction mixture was stirred at room temperature overnight. The reaction was poured into 10 mL of water, extracted with ethyl acetate, the organic phase was dried and spun dry, and purified by Prep-TLC (DCM / MeOH=20 / 1) to give 30 mg of a white solid. Yield: 58%.
[0145] Step 5: Synthesis of 2-(4-fluoro-2-methylphenoxy)-N-(4-fluoro-3-(pyrrolidin-2-yl)phenyl)-5-(trifluoromethyl)benzamide 20mg of sodium borohydride was added to 2mL of methanol solution of 5-(2-fluoro-5-(2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzamido)phenyl)-3,4-dihydro-2H-pyrrole-2-carboxamide (30mg, 0.058mmol), and stirred at room temperature for 2 hours. The reaction system was poured into 10mL of water, extracted with ethyl acetate, the organic phase was dried and spun dry, and purified by Prep-TLC (DCM / MeOH=10 / 1) to obtain 6mg of white solid. Yield: 20%. LC / MS: m / z=520.2[M+H] + . 1 H NMR(400MHz,d6-DMSO)δ 1.55-1.74(2H,m),1.87-2.00(1H,m),2.05(3H,s),2.16-2.22(1H,m), 3.45-3.46(0.6H,m),3.65-3.66(0.4H,m),4.10-4.42(1H,m),6.57-6. 64(1H,m),7.01-7.11(2H,m),7.18-7.22(2H,m),7.25-7.45(1H,m),7. 50-7.69(1H,m),7.71-7.77(3H,m),7.98(1H,s),10.63-10.74(1H,m).
[0146] <Example 17> N-(3-(2,3-diamino-3-oxypropyl)-4-fluorophenyl)-2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzamide JPEG0007591240000032.jpg65170
[0147] Step 1: Synthesis of 2-(4-fluoro-2-methylphenoxy)-N-(4-fluoro-3-(hydroxymethyl)phenyl)-5-(trifluoromethyl)benzamide 2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzoic acid (94 mg, 0.3 mmol), (5-amino-2-fluorophenyl)methanol (42 mg, 0.3 mmol), DIPEA (77 mg, 0.6 mmol) and 2 mL of tetrahydrofuran were added to a reaction flask, HATU (190 mg, 0.5 mmol) was added, and the reaction mixture was stirred at room temperature overnight. The reaction was poured into 10 mL of water, extracted with ethyl acetate, the organic phase was dried and spun dry, and purified by Prep-TLC (PE / EA=10 / 1) to give 95 mg of a white solid. Yield: 73%.
[0148] Step 2: Synthesis of N-(3-(chloromethyl)-4-fluorophenyl)-2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzamide A solution of 2-(4-fluoro-2-methylphenoxy)-N-(4-fluoro-3-(hydroxymethyl)phenyl)-5-(trifluoromethyl)benzamide (95 mg, 0.22 mmol) in phosphorus oxychloride was stirred at 60° C. for 1 hour, the reaction solution was directly spun dry, and the remaining phosphorus oxychloride was stripped twice with chloroform to give 100 mg of a yellow solid. Yield: 100%.
[0149] Step 3: Synthesis of methyl 3-(2-fluoro-5-(2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzamido)phenyl)-2-nitropropanoate N-(3-(chloromethyl)-4-fluorophenyl)-2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzamide (100 mg, 0.22 mmol), methyl nitroacetate (52 mg, 0.44 mmol), benzyltriethylammonium chloride (50 mg, 0.22 mmol) and potassium bicarbonate (44 mg, 0.44 mmol) in 3 mL of DMF was stirred at 60° C. overnight, the reaction was poured into 10 mL of water, extracted with ethyl acetate, the organic phase was dried and spun dry, and purified by Prep-TLC (PE / EA=3 / 1) to give 25 mg of white solid. Yield: 21%.
[0150] Step 4: Synthesis of N-(3-(3-amino-2-nitro-3-oxopropyl)-4-fluorophenyl)-2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzamide Methyl 3-(2-fluoro-5-(2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzamido)phenyl)-2-nitropropionate (25 mg, 0.046 mmol) and 4 mL of ammonia in methanol (1 M) were stirred at room temperature overnight, and the reaction was spun to dryness to give 25 mg of a white solid. Yield: 100%.
[0151] Step 5: Synthesis of N-(3-(2,3-diamino-3-oxypropyl)-4-fluorophenyl)-2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzamide N-(3-(3-amino-2-nitro-3-oxopropyl)-4-fluorophenyl)-2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzamide (25 mg, 0.046 mmol) and 5 mL of methanol were added to a reaction flask, 10% Pd / C (10 mg) was added, and the reaction system was stirred overnight at room temperature under a hydrogen gas atmosphere (1 MPa). Suction filtration was performed, the filter cake was washed with methanol, and the filtrate was spin-dried and then purified by Prep-HPLC to obtain 9 mg of a white solid. Yield: 38%. LC / MS: m / z=494.1[M+H] + .
[0152] <Example 18> 2-(4-fluoro-2-methylphenoxy)-N-(4-fluoro-3-(3-oxopiperazin-2-yl)phenyl)-5-(trifluoromethyl)benzamide JPEG0007591240000033.jpg50170
[0153] (2-(2-(2-fluoro-5-(2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzamido)phenyl)-2-oxoacetamido)ethyl)carbamic acid t-butyl ester (45 mg, 0.072 mmol, prepared by the same method as in Example 9 through the corresponding raw material) in 3 mL of HCl / EA (4M) solution was stirred at room temperature for 2 hours, and 5 mL of methanol and 50 mg of sodium cyanoborohydride were added after spin drying. The reaction mixture was stirred overnight at room temperature and then poured into 20 mL of water, extracted with ethyl acetate, the organic phase was dried and spin dried, and purified by Prep-HPLC to obtain 8 mg of white solid. Yield: 22%. LC / MS: m / z=506.1[M+H] + . 1 H NMR(400MHz,d6-DMSO)δ 2.16(3H,s),2.78-2.82(1H,m),2.88-3.01(2H,m),3.15-3.19(1H,m),4.52(1H,s),6.78(1H,d,J=8.0 Hz),7.10-7.26(4H,m),7.63-7.66(1H,m),7.74-7.78(2H,m),7.81(1H,s),7.93(1H,s),10.52(1H,s).
[0154] <Example 19> N-(3-(amino(2-oxopyrrolidin-3-yl)methyl)-4-fluorophenyl)-4-cyclopropyl-2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzamide JPEG0007591240000034.jpg95170
[0155] Step 1: Synthesis of N-(2-fluoro-5-nitrobenzylidene)-2-methylpropane-2-sulfinamide A solution of 2-fluoro-5-nitrobenzaldehyde (333 mg, 2.0 mmol), t-butylsulfinamide (268 mg, 2.2 mmol) and cesium carbonate (987 mg, 3.0 mmol) in 10 mL of dichloromethane was stirred at room temperature overnight. The reaction was poured into 10 mL of water, extracted with ethyl acetate, the organic phase was dried and spun to dryness to give 573 mg of a yellow solid.
[0156] Step 2: Synthesis of 3-((((t-butylsulfinyl)amino)(2-fluoro-5-nitrophenyl)methyl)-2-oxopyrrolidine-1-carboxylic acid t-butyl ester Under nitrogen gas protection, n-butyllithium (2.5M, 0.9mL) was added dropwise to a solution of N-BOC-2-pyrrolidone (545mg, 2.94mmol) in 5mL of anhydrous tetrahydrofuran at -70℃. After the completion of the addition, the mixture was stirred for 0.5 hours, and a solution of N-(2-fluoro-5-nitrobenzylidene)-2-methylpropane-2-sulfinamide (200mg, 0.73mmol) in 1mL of tetrahydrofuran was added dropwise to the reaction system, and the temperature of the system was controlled to be less than -60℃. After stirring for 1.5 hours, the reaction system was poured into 20mL of aqueous ammonium chloride solution, extracted with ethyl acetate, the organic phase was dried and spin-dried, and purified by silica gel column (DCM / MeOH=20 / 1) to obtain 280mg of yellow oil. Yield: 83%.
[0157] Step 3: Synthesis of 3-((5-amino-2-fluorophenyl)((t-butylsulfinyl)amino)methyl)-2-oxopyrrolidine-1-carboxylic acid t-butyl ester A reaction flask was charged with 3-((((t-butylsulfinyl)amino)(2-fluoro-5-nitrophenyl)methyl)-2-oxopyrrolidine-1-carboxylic acid t-butyl ester (110 mg, 0.24 mmol) and 5 mL of ethanol, 10% Pd / C (20 mg) was added, and the reaction was stirred overnight at room temperature under a hydrogen gas atmosphere. The mixture was filtered under suction, the filter cake was washed with ethanol, and the filtrate was spun dry to give 100 mg of a yellow solid. Yield: 97%.
[0158] Step 4: Synthesis of 3-(((t-butylsulfinyl)amino)(5-(4-cyclopropyl-2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzamido)-2-fluorophenyl)methyl)-2-oxopyrrolidine-1-carboxylic acid t-butyl ester A reaction flask was charged with 4-cyclopropyl-2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzoic acid (82 mg, 0.23 mmol), 3-((5-amino-2-fluorophenyl)((t-butylsulfinyl)amino)methyl)-2-oxopyrrolidine-1-carboxylic acid t-butyl ester (98 mg, 0.23 mmol), DIPEA (106 mg, 0.82 mmol) and 5 mL of tetrahydrofuran, HATU (163 mg, 0.42 mmol) was added, and the reaction mixture was stirred at room temperature overnight. The reaction was poured into 20 mL of water, extracted with ethyl acetate, the organic phase was dried and spun dry, and purified by Prep-TLC (DCM / MeOH=15 / 1) to give 25 mg of a white solid. Yield: 14%.
[0159] Step 5: Synthesis of N-(3-(amino(2-oxopyrrolidin-3-yl)methyl)-4-fluorophenyl)-4-cyclopropyl-2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzamide 3-(((t-butylsulfinyl)amino)(5-(4-cyclopropyl-2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzamido)-2-fluorophenyl)methyl)-2-oxopyrrolidine-1-carboxylic acid t-butyl ester (25 mg, 0.033 mmol) in 2 mL of hydrogen chloride / ethyl acetate solution (2M) was stirred at room temperature overnight, the system was spin-dried, and then added to 10 mL of water, the pH value was adjusted to basic with sodium carbonate, extracted with ethyl acetate, the organic phase was dried, and spin-dried, and then purified by Prep-HPLC to obtain 12 mg of white solid. Yield: 67%. LC / MS: m / z=560.2[M+H] + . 1H NMR (400MHz, d6-DMSO) δ 0.54-0.60(2H,m),1.00-1.06(2H,m),1.61-1.71(1H,m),2.13-2.12(2H,m) ,2.15(3H,s),2.52-2.58(1H,m),3.07-3.13(2H,m),4.60(1H,d,J=3.2Hz),6 .37(1H,s),7.05-7.09(3H,m),7.20(1H,dd,J=9.2Hz,2.7Hz),7.51-7.57(1H ,m),7.69(1H,s),7.79(1H,dd,J=6.6Hz,2.4Hz),7.90(1H,s),10.40(1H,s).
[0160] <Example 20> N-(3-(1-amino-3-hydroxybutyl)-4-fluorophenyl)-4-cyclopropyl-2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzamide JPEG0007591240000035.jpg40170
[0161] Step 1: Synthesis of t-butyl (1-(5-(4-cyclopropyl-2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzamido)-2-fluorophenyl)-3-oxobutyl)carbamate At 0°C, methyllithium (1M, 0.4mL) was added to a solution of 3-((t-butoxycarbonyl)amino)-3-(5-(4-cyclopropyl-2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzamido)-2-fluorophenyl)propionic acid (63mg, 0.10mmol) in 2mL of anhydrous tetrahydrofuran, and the mixture was stirred at room temperature for 1 hour, and then poured into 10mL of water. Extraction was performed with ethyl acetate, and the organic phase was dried and spun dry, and purified by Prep-TLC (PE / EA=2 / 1) to obtain 30mg of a white solid. The yield was 47%.
[0162] Step 2: Synthesis of t-butyl (1-(5-(4-cyclopropyl-2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzamido)-2-fluorophenyl)-3-hydroxylbutyl)carbamate At room temperature, 5 mg of sodium borohydride was added to a 2 mL methanol solution of t-butyl (1-(5-(4-cyclopropyl-2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzamido)-2-fluorophenyl)-3-oxobutyl)carbamate (30 mg, 0.047 mmol), and the system was poured into 10 mL of water after stirring at room temperature for 1 hour. Extraction with ethyl acetate was performed, and the organic phase was dried and spun dry, and purified by Prep-TLC (PE / EA=1 / 1) to obtain 18 mg of a white solid. Yield: 60%.
[0163] Step 3: Synthesis of N-(3-(1-amino-3-hydroxylbutyl)-4-fluorophenyl)-4-cyclopropyl-2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzamide t-Butyl (1-(5-(4-cyclopropyl-2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzamido)-2-fluorophenyl)-3-hydroxylbutyl)carbamate (18 mg, 0.028 mmol) in 2 mL of hydrogen chloride / ethyl acetate solution (2 M) was stirred at room temperature overnight, the system was spin-dried, and then added to 10 mL of water, the pH value was adjusted to basic with sodium carbonate, and extracted with ethyl acetate. The organic phase was dried and spin-dried, and then purified by Prep-HPLC to obtain 10 mg of white solid. Yield: 67%. LC / MS: m / z=535.2[M+H] + . 1H NMR(400MHz,d6-DMSO)δ 0.56-0.58(2H,m),1.00-1.07(5H,m),1.55-1.57(1H,m),2.12-2.14(1H,m),2.16(3H,s),3.68-3.76(2H,m),4.19-4.28(1H,m), 6.35(1H,s),7.06-7.10(3H,m),7.22(1H,dd,J=9.2Hz,2.0Hz),7.49-7.55(1H,m),7.73-7.80(1H,m),7.91(1H,s),10.39(1H,s).
[0164] <Example 21> N-(3-(1-amino-3-fluoropropyl)-4-fluorophenyl)-4-cyclopropyl-2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzamide JPEG0007591240000036.jpg57170
[0165] DAST (24 mg, 0.15 mmol) was added to a solution of N-(3-(1-amino-3-hydroxypropyl)-4-fluorophenyl)-4-cyclopropyl-2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzamide (52 mg, 0.10 mmol) in 2 mL of dichloromethane, and the reaction mixture was stirred at room temperature overnight. The reaction was poured into 10 mL of water, extracted with ethyl acetate, the organic phase was dried and spun dry, and purified by Prep-TLC (DCM / MeOH=10 / 1) to give 20 mg of a white solid. Yield: 38%. LC / MS: m / z=521.2[M+H] + . 1 H NMR(400MHz,d6-DMSO)δ 0.53-0.60(2H,m),1.00-1.06(2H,m),1.94-2.16(7H,m),4.31-4.33(1H,m),4.40-4.68(1H,m),6.3 4(1H,s),7.03-7.10(2H,m),7.14-7.23(2H,m),7.49-7.56(1H,m),7.84-7.92(2H,m),10.45(1H,s).
[0166] <Example 22> N-(3-(1-amino-2-fluoro-3-hydroxypropyl)-4-fluorophenyl)-4-cyclopropyl-2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzamide JPEG0007591240000037.jpg37170
[0167] Step 1: Synthesis of 3-((t-butylsulfinyl)amino)-2-fluoro-3-(2-fluoro-5-nitrophenyl)propionic acid ethyl ester Under nitrogen gas protection, at -70°C, LiHMDS (1.3M, 3.2mL) was added dropwise to 5mL of anhydrous tetrahydrofuran solution of ethyl fluoroacetate (480mg, 4.53mmol), and after the completion of the addition, stirring was continued for 0.5 hours, and 1mL of tetrahydrofuran solution of N-(2-fluoro-5-nitrobenzylidene)-2-methylpropane-2-sulfinamide (230mg, 0.85mmol) was added dropwise to the reaction system, and the temperature of the system was controlled to be less than -60°C. After stirring for 1.5 hours, the reaction system was poured into 20mL of aqueous ammonium chloride solution, extracted with ethyl acetate, the organic phase was dried and spin-dried, and purified by silica gel column (PE / EA=2 / 1) to obtain 216mg of yellow solid. Yield: 68%.
[0168] Step 2: Synthesis of 3-(5-amino-2-fluorophenyl)-3-((t-butylsulfinyl)amino)-2-fluoropropionic acid ethyl ester A reaction flask was charged with 3-((t-butylsulfinyl)amino)-2-fluoro-3-(2-fluoro-5-nitrophenyl)propionic acid ethyl ester (216 mg, 0.57 mmol) and 5 mL of ethanol, 10% Pd / C (30 mg) was added, and the reaction was stirred overnight at room temperature under hydrogen gas. Suction filtration was performed, the filter cake was washed with ethanol, and the filtrate was spun dry to give 200 mg of a yellow solid. Yield: 100%.
[0169] Step 3: Synthesis of 3-((t-butylsulfinyl)amino)-3-(5-(4-cyclopropyl-2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzamido)-2-fluorophenyl)-2-fluoropropionic acid ethyl ester A reaction flask was charged with 4-cyclopropyl-2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzoic acid (82 mg, 0.23 mmol), 3-(5-amino-2-fluorophenyl)-3-((t-butylsulfinyl)amino)-2-fluoropropionic acid ethyl ester (80 mg, 0.23 mmol), DIPEA (106 mg, 0.82 mmol) and 5 mL of tetrahydrofuran, HATU (163 mg, 0.42 mmol) was added, and the reaction mixture was stirred at room temperature overnight. The reaction was poured into 20 mL of water, extracted with ethyl acetate, the organic phase was dried and spun dry, and purified by Prep-TLC (DCM / MeOH=20 / 1) to give 35 mg of a white solid. Yield: 29%.
[0170] Step 4: Synthesis of N-(3-(1-((t-butylsulfinyl)amino)-2-fluoro-3-hydroxypropyl)-4-fluorophenyl)-4-cyclopropyl-2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzamide At room temperature, 10 mg of sodium borohydride was added to a 2 mL methanol solution of 3-((t-butylsulfinyl)amino)-3-(5-(4-cyclopropyl-2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzamido)-2-fluorophenyl)-2-fluoropropionic acid ethyl ester (35 mg, 0.051 mmol) and 5 mg of lithium chloride, and the system was poured into 10 mL of water after stirring at room temperature for 4 hours. Extraction with ethyl acetate was performed, and the organic phase was dried and spun dry, and purified by Prep-TLC (DCM / MeOH=20 / 1) to obtain 15 mg of a white solid. Yield: 43%.
[0171] Step 5: Synthesis of N-(3-(1-amino-2-fluoro-3-hydroxypropyl)-4-fluorophenyl)-4-cyclopropyl-2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzamide N-(3-(1-((t-butylsulfinyl)amino)-2-fluoro-3-hydroxypropyl)-4-fluorophenyl)-4-cyclopropyl-2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzamide (15mg, 0.023mmol) in 2mL of hydrogen chloride / ethyl acetate solution (2M) was stirred at room temperature overnight, the system was spin-dried, added to 10mL of water, the pH value was adjusted to basic with sodium carbonate, extracted with ethyl acetate, the organic phase was dried and spin-dried, and then purified by Prep-HPLC to obtain 4mg of white solid. Yield: 32%. LC / MS: m / z=539.2[M+H] + . 1 H NMR (400MHz, d6-DMSO) δ 0.56-0.58(2H,m),0.99-1.07(2H,m),2.11-2.14(1H,m),2.16(3H,s),3. 50-3.72(2H,m),4.26-4.30(1H,m),4.37-4.45(0.5H,m),4.50-4.57(0.5H ,m),4.95(1H,brs),6.35(1H,s),7.07-7.16(3H,m),7.22(1H,d,J=8.1Hz) ,7.53-7.61(1H,m),7.77-7.83(1H,m),7.92(1H,s),10.40-10.42(1H,m).
[0172] <Example 23> N-(3-(1-amino-2,2-difluoro-3-hydroxypropyl)-4-fluorophenyl)-4-cyclopropyl-2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzamide JPEG0007591240000038.jpg49170
[0173] Step 1: Synthesis of 3-((t-butylsulfinyl)amino)-2,2-difluoro-3-(2-fluoro-5-nitrophenyl)propionic acid ethyl ester A solution of zinc powder (195 mg, 3.0 mmol) and ethyl 2-bromo-2,2-difluoroacetate (404 mg, 2.0 mmol) in anhydrous tetrahydrofuran was refluxed for 30 minutes. Then, at this temperature, a solution of N-(2-fluoro-5-nitrobenzylidene)-2-methylpropane-2-sulfinamide (272 mg, 1.0 mmol) in anhydrous THF was slowly added to the mixture. After refluxing for 1.5 hours, the reaction mixture was filtered and the filtrate was concentrated. The crude product was purified by Prep-TLC (DCM / MeOH=50 / 1) to obtain 190 mg of a white solid. The yield was 48%.
[0174] Step 2: Synthesis of N-(3-(1-amino-2,2-difluoro-3-hydroxypropyl)-4-fluorophenyl)-4-cyclopropyl-2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzamide Example 23 can be obtained by the same method as in Example 22 using the corresponding reagents as starting materials. LC / MS: m / z=557.2[M+H] + .
[0175] <Example 24> 4-Cyclopropyl-N-(3-(1,3-diaminopropyl)-4-fluorophenyl)-2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzamide JPEG0007591240000039.jpg51170
[0176] Step 1: Synthesis of t-butyl (3-amino-1-(5-(4-cyclopropyl-2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzamido)-2-fluorophenyl)propyl)carbamate A reaction flask was charged with 1-(5-(4-(4-cyclopropyl-2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzamido)-2-fluorophenyl)-3-hydroxypropyl)carbamic acid t-butyl ester (100 mg, 0.16 mmol), DIPEA (41 mg, 0.32 mmol) and 5 mL of dichloromethane, and methylflavinyl chloride (22 mg, 0.19 mmol) was added dropwise at room temperature, and the reaction mixture was stirred at room temperature for 1 hour. The reaction system was spin-dried and then dissolved in 5 mL of anhydrous tetrahydrofuran, and 10 mg of sodium amide was added and reacted at room temperature for 1 hour. The reaction solution was poured into 10 mL of ice water, extracted with ethyl acetate, the organic phase was dried and spin-dried, and purified by Prep-HPLC to obtain 6 mg of a yellow oil. The yield was 6%.
[0177] Step 2: Synthesis of (4-cyclopropyl-N-(3-(1,3-diaminopropyl)-4-fluorophenyl)-2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzamide (t-Butyl (3-amino-1-(5-(4-cyclopropyl-2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzamido)-2-fluorophenyl)propyl)carbamate (6 mg, 0.01 mmol) in 2 mL of hydrogen chloride / dioxane solution (2 M) was stirred at room temperature for 2 hours, the system was spin-dried, and then added to 10 mL of water. The pH value was adjusted to basic with sodium carbonate, extracted with ethyl acetate, the organic phase was dried, and spin-dried. Then, 2 mg of a white solid was obtained by purification using Prep-HPLC. The yield was 40%. LC / MS: m / z=520.2[M+H] + . 1H NMR(400MHz,d6-DMSO)δ 0.56-0.58(2H,m),0.99-1.07(2H,m),1.62-1.65(2H,m),2.11-2.16(4H,m),2.60-2.70(2H,m),4.12-4.14(1H,m),6 .35(1H,s),7.02-7.16(3H,m),7.20-7.23(1H,m),7.48-7.55(1H,m),7.76-7.78(1H,m),7.91(1H,s),10.38(1H,s).
[0178] <Example 25> 2-(4-fluoro-2-methylphenoxy)-N-(4-fluoro-3-(hydroxy(2-oxopyrrolidin-3-yl)methyl)phenyl)-5-(trifluoromethyl)benzamide JPEG0007591240000040.jpg70170
[0179] Step 1: Synthesis of methyl 2-fluoro-5-(2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzamido)benzoate 2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzoic acid (314 mg, 1.0 mmol), 5-amino-2-fluorobenzoic acid methyl ester (169 mg, 1.0 mmol), DIPEA (258 mg, 2.0 mmol) and 5 mL of tetrahydrofuran were added to a reaction flask, HATU (456 mg, 1.2 mmol) was added, and the reaction mixture was stirred at room temperature overnight. The reaction system was poured into 10 mL of water, extracted with ethyl acetate, the organic phase was dried and spun dry, and purified by silica gel column chromatography (PE / EA=3 / 1) to obtain 330 mg of a pale yellow solid. Yield: 71%.
[0180] Step 2: Synthesis of 2-fluoro-5-(2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzamido)benzoic acid Methyl 2-fluoro-5-(2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzamido)benzoate (330mg, 0.71mmol), sodium hydroxide (114mg, 2.84mmol), 5mL water and 5mL methanol were added to a reaction flask, and the reaction mixture was stirred at room temperature for 8 hours. TLC showed the reaction was complete. The reaction was poured into 20mL water, the pH value was adjusted to 5 with 1M hydrochloric acid, extracted with ethyl acetate, the organic phase was dried and spun to obtain 320mg of the desired product. Yield: 100%.
[0181] Step 3: Synthesis of 2-fluoro-5-(2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzamido)benzoyl chloride A solution of 2-fluoro-5-(2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzamido)benzoic acid (320 mg, 0.71 mmol) in 5 mL of thionyl chloride was stirred at 80 °C for 1 h, the system was spun dry and stripped twice with chloroform, and the resulting solid was used directly in the next step reaction.
[0182] Step 4: Synthesis of 3-(2-fluoro-5-(2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzamido)benzoyl)-2-oxopyrrolidine-1-carboxylic acid tert-butyl ester Under nitrogen gas protection, at -70°C, 2-oxopyrrolidine-1-carboxylic acid t-butyl ester (657mg, 3.55mmol) was added dropwise to 10mL of anhydrous tetrahydrofuran solution of n-butyllithium (2.5M, 1.8mL). After completion of the addition, the mixture was stirred for 0.5 hours, and 2mL of the solid obtained in the above step was added dropwise to the reaction system, and the temperature of the system was controlled to be less than -60°C. After stirring for 1.5 hours, the reaction system was poured into 20mL of aqueous ammonium chloride solution, extracted with ethyl acetate, the organic phase was dried and spin-dried, and purified by silica gel column (PE / EA=2 / 1) to obtain 180mg of yellow solid. The yield of the two steps was 41%.
[0183] Step 5: Synthesis of 3-((2-fluoro-5-(2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzamido)phenyl)(hydroxy)methyl)-2-oxopyrrolidine-1-carboxylic acid tert-butyl ester At room temperature, 10 mg of sodium borohydride was added to a solution of 3-(2-fluoro-5-(2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzamido)benzoyl)-2-oxopyrrolidine-1-carboxylic acid t-butyl ester (62 mg, 0.1 mmol) in 2 mL of tetrahydrofuran, and the system was poured into 10 mL of water after stirring at room temperature for 4 hours. Extraction was performed with ethyl acetate, and the organic phase was dried and spin-dried, and purified by Prep-TLC (DCM / MeOH=20 / 1) to obtain 40 mg of a white solid. Yield: 65%.
[0184] Step 6: Synthesis of 2-(4-fluoro-2-methylphenoxy)-N-(4-fluoro-3-(hydroxy(2-oxopyrrolidin-3-yl)methyl)phenyl)-5-(trifluoromethyl)benzamide 3-((2-fluoro-5-(2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzamido)phenyl)(hydroxy)methyl)-2-oxopyrrolidine-1-carboxylic acid t-butyl ester (40mg, 0.065mmol) in 2mL of hydrogen chloride / dioxane solution (2M) was stirred at room temperature for 2 hours, the system was spin-dried and then added to 10mL of water, the pH value was adjusted to basic with sodium carbonate, extracted with ethyl acetate, the organic phase was dried and spin-dried, and then purified by Prep-HPLC to obtain 25mg of white solid. Yield: 74%. LC / MS: m / z=521.1[M+H] + . 1H NMR(400MHz,d6-DMSO)δ 1.62-1.72(1H,m),2.04-2.16(4H,m),3.10-3.18(2H,m),5.31(1H,s),5.59(1H,d,J=7.2Hz),6.83(1H,d,J=8.0Hz ),7.10-7.25(4H,m),7.62-7.64(2H,m),7.78(1H,d,J=8.4Hz),7.89(1H,d,J=7.6Hz),7.97(1H,s),10.56(1H,s).
[0185] <Example 26> N-(3-(2-amino-1-hydroxy-2-oxoethyl)-4-fluorophenyl)-2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzamide JPEG0007591240000041.jpg48170
[0186] At room temperature, 10 mg of sodium borohydride was added to a solution of N-(3-(2-amino-2-oxoacetyl)-4-fluorophenyl)-2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzamide (48 mg, 0.10 mmol) in 2 mL of tetrahydrofuran, and the system was poured into 10 mL of water after stirring at room temperature for 4 hours. Extraction with ethyl acetate was performed, and the organic phase was dried and spun dry, and purified by Prep-TLC (DCM / MeOH=20 / 1) to obtain 25 mg of a white solid. Yield: 52%. LC / MS: m / z=481.1[M+H] + . 1 H NMR(400MHz,d6-DMSO)δ 2.14(3H,s),5.08(1H,d,J=7.2Hz),6.24(1H,d,J=7.2Hz),6.80(1H,d,J=8.0Hz),7.12-7.26(4H,m), 7.37(1H,s),7.45(1H,s),7.61-7.64(1H,m),7.75-7.80(2H,m),7.97(1H,d,J=2.4Hz),10.54(1H,s).
[0187] <Example 27> N-(3-(1-amino-1-oxopropan-2-yl)-4-fluorophenyl)-2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzamide JPEG0007591240000042.jpg33170
[0188] Step 1: Synthesis of methyl 2-(2-fluoro-5-nitrophenyl)propionate A solution of 2-(2-fluoro-5-nitrophenyl)acetic acid (199 mg, 1.0 mmol), potassium carbonate (414 mg, 3 mmol), and iodomethane (284 mg, 2.0 mmol) in 5 mL of tetrahydrofuran was stirred at room temperature overnight, the reaction system was filtered, and the filtrate was spin-dried and purified by silica gel column chromatography (PE / EA=20 / 1) to give 80 mg of a yellow solid. Yield: 35%.
[0189] Step 2: Synthesis of 2-(2-fluoro-5-nitrophenyl)propanamide A solution of methyl 2-(2-fluoro-5-nitrophenyl)propionate (80 mg, 0.35 mmol) in 5 mL of ammonia in methanol was stirred at 50° C. overnight, the reaction was spun dry and purified by Prep-TLC (PE / EA=5 / 1) to give 60 mg of a yellow solid. Yield: 80%.
[0190] Step 3: Synthesis of 2-(5-amino-2-fluorophenyl)propanamide A reaction flask was charged with 2-(2-fluoro-5-nitrophenyl)propanamide (60 mg, 0.28 mmol) and 5 mL of methanol, 10% Pd / C (10 mg) was added, and the reaction was stirred overnight at room temperature under hydrogen gas. The mixture was filtered with suction, the filter cake was washed with methanol, and the filtrate was spun dry to give 50 mg of a pale yellow solid. Yield: 98%.
[0191] Step 4: Synthesis of N-(3-(1-amino-1-oxopropan-2-yl)-4-fluorophenyl)-2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzamide 2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzoic acid (31 mg, 0.10 mmol), 2-(5-amino-2-fluorophenyl)propanamide (18 mg, 0.10 mmol), DIPEA (26 mg, 0.20 mmol) and 2 mL of tetrahydrofuran were added to a reaction flask, HATU (57 mg, 0.15 mmol) was added and the reaction mixture was stirred overnight at room temperature. The reaction was poured into 10 mL of water, extracted with ethyl acetate, the organic phase was dried and spun dry, and purified by Prep-TLC (PE / EA=2 / 1) to give 25 mg of a white solid. Yield: 52%. LC / MS: m / z=479.1 [M+H] + . 1 H NMR(400MHz,d6-DMSO)δ 0.56-0.59(2H,m),1.02-1.04(2H,m),1.31(3H,d,J=7.6Hz),2.10-2.14(1H,m),2.16(3H,s),3.82(1H,q,J=7.6Hz),6.35(1H,s),6. 94(1H,s),7.06-7.14(3H,m),7.21(1H,d,J=8.4Hz),7.41(1H,s),7.56-7.59(1H,m),7.66-7.68(1H,m),77.90(1H,s),10.42(1H,s).
[0192] <Example 28> 4-Cyclopropyl-2-(4-fluoro-2-methylphenoxy)-N-(4-fluoro-3-(4-hydroxybutan-2-yl)phenyl)-5-(trifluoromethyl)benzamide JPEG0007591240000043.jpg39170
[0193] Step 1: Synthesis of (E)-3-(2-fluoro-5-nitrophenyl)but-2-enoic acid ethyl ester Sodium hydrogen (308mg, 7.7mmol) with a content of 60% was suspended in 5mL of dry tetrahydrofuran, cooled to 0℃ under nitrogen gas protection, triethyl phosphonoacetate (1.48g, 6.6mmol) was slowly added dropwise, the mixture was stirred in an ice bath and reacted for 30 minutes, then 1-(2-fluoro-5-nitrophenyl)ethan-1-one (1.0g, 5.5mmol) was added dropwise to the reaction system in an ice bath, the reaction solution was stirred at room temperature for 2 hours, the reaction system was quenched with ammonium chloride solution, extracted with ethyl acetate, the organic phase was dried, spin-dried, and purified by silica gel column chromatography (PE / EA=5 / 1) to obtain 900mg of gray solid. Yield: 64%.
[0194] Step 2: Synthesis of ethyl 3-(5-amino-2-fluorophenyl)butyrate E)-3-(2-fluoro-5-nitrophenyl)but-2-enoic acid ethyl ester (900 mg, 3.56 mmol) was dissolved in 25 mL of methanol, and hydrogen gas was replaced. Palladium hydroxide (90 mg, 10% wt) was added, and the reaction was stirred under a hydrogen gas atmosphere for 4 hours. The reaction system was directly filtered, and the filtrate was spin-dried to obtain 750 mg of a gray solid. Yield: 95%.
[0195] Step 3: Synthesis of ethyl 3-(5-(4-cyclopropyl-2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzamido)-2-fluorophenyl)butyrate 4-Cyclopropyl-2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzoic acid (354 mg, 1 mmol), 3-(5-amino-2-fluorophenyl)ethyl butyrate (268 mg, 1.2 mmol), DIPEA (387 mg, 3 mmol) and 2 mL of tetrahydrofuran were added to a reaction flask, HATU (456 mg, 1.2 mmol) was added, and the reaction mixture was stirred at room temperature overnight. The reaction system was poured into 10 mL of water, extracted with ethyl acetate, the organic phase was dried and spun dry, and purified by silica gel column chromatography (PE / EA=2 / 1) to obtain 450 mg of a white solid. Yield: 80%.
[0196] Step 4: Synthesis of 4-cyclopropyl-2-(4-fluoro-2-methylphenoxy)-N-(4-fluoro-3-(4-hydroxybutan-2-yl)phenyl)-5-(trifluoromethyl)benzamide A reaction flask was charged with ethyl 3-(5-(4-cyclopropyl-2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzamido)-2-fluorophenyl)butyrate (450 mg, 0.8 mmol), anhydrous lithium chloride (13 mg, 0.3 mmol), and 15 mL of methanol, and sodium borohydride (152 mg, 4 mmol) was added in batches, and the reaction mixture was stirred at room temperature for 2 hours. The reaction was quenched by adding dilute hydrochloric acid, extracted with ethyl acetate, the organic phase was dried and spun dry, and purified by silica gel column chromatography (DCM / MeOH=30 / 1) to give 370 mg of a white solid. The yield was 90%. LC / MS: m / z=520.1 [M+H] + . 1 H NMR(400MHz,d6-DMSO)δ 0.54-0.60(2H,m),1.02-1.08(2H,m),1.16(3H,d,J=6.8Hz),1.74-1.78( 2H,m),2.07-2.19(4H,m),3.62-3.65(2H,m),4.42-4.44(1H,m),5.77(1H ,s),6.39(1H,s),7.01-7.14(3H,m),7.20(1H,dd,J=9.2Hz,2.8Hz),7.44 -7.52(1H,m),7.56(1H,dd,J=6.6Hz,2.4Hz),7.91(1H,s),10.36(1H,s).
[0197] <Example 29> N-(3-(4-aminobutan-2-yl)-4-fluorophenyl)-4-cyclopropyl-2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzamide JPEG0007591240000044.jpg46170
[0198] Step 1: Synthesis of 4-cyclopropyl-N-(3-(4-(1,3-dioxoisoindolin-2-yl)butan-2-yl)-4-fluorophenyl)-2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzamide 4-Cyclopropyl-2-(4-fluoro-2-methylphenoxy)-N-(4-fluoro-3-(4-hydroxybutan-2-yl)phenyl)-5-(trifluoromethyl)benzamide (104mg, 0.2mmol), phthalimide (44mg, 0.3mmol), and triphenylphosphine (105mg, 0.4mmol) were dissolved in 8mL of tetrahydrofuran, and DIAD (121mg, 0.6mmol) was added dropwise at room temperature under nitrogen gas protection, and the reaction solution was stirred at room temperature for 3 hours, water was added to the reaction system, and the organic phase was dried, spin-dried, and purified by silica gel column chromatography (PE / EA=3 / 1) to obtain 80mg of a gray solid. Yield: 62%.
[0199] Step 2: Synthesis of N-(3-(4-aminobutan-2-yl)-4-fluorophenyl)-4-cyclopropyl-2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzamide 4-Cyclopropyl-N-(3-(4-(1,3-dioxoisoindolin-2-yl)butan-2-yl)-4-fluorophenyl)-2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzamide (80 mg, 0.12 mmol) was dissolved in 8 mL of ethanol and 2 mL of hydrazine hydrate, water was added to the reaction system, extracted with ethyl acetate, the organic phase was dried, spun dry, and purified by Prep-TLC (DCM / MeOH=15 / 1) to give 25 mg of a white solid. Yield: 40%. LC / MS: m / z=519.1[M+H] + . 1H NMR(400MHz,d6-DMSO)δ 0.54-0.60(2H,m),1.02-1.08(2H,m),1.18(3H,d,J=6.8Hz),1.65-1.75(2H,m),2.07-2.19(4H,m),2.55-2.59(2H,m),3.05-3.10(1H,m),6 .39(1H,s),7.04-7.13(3H,m),7.19(1H,dd,J=9.2Hz,2.8Hz),7.44-7.52(1H,m),7.61(1H,dd,J=6.6Hz,2.4Hz),7.91(1H,s),10.38(1H,s).
[0200] <Example 30> N-(3-(1-aminopropan-2-yl)-4-fluorophenyl)-4-cyclopropyl-2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzamide JPEG0007591240000045.jpg39170
[0201] Step 1: Synthesis of (2-(2-fluoro-5-nitrophenyl)propyl)carbamic acid t-butyl ester 2-(2-fluoro-5-nitrophenyl)propanamide (212 mg, 1.0 mmol), BH3-THF (3 mL, 3 mmol, 1.0 M) and 10 mL of tetrahydrofuran solution were stirred at 50° C. for 2 hours, 15 mL of methanol was added to quench the reaction, the mixture was stirred for 30 minutes, and then (Boc)2O (436 mg, 2.0 mmol) was added directly to the reaction system and stirred at room temperature for 1 hour. The system was directly spun dry and purified by silica gel column chromatography (PE / EA=3 / 1) to give 180 mg of off-white solid. Yield: 60%.
[0202] Step 2: Synthesis of N-(3-(1-aminopropan-2-yl)-4-fluorophenyl)-4-cyclopropyl-2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzamide Example 30 was obtained according to the same scheme as in Example 3 using the corresponding substrate as the raw material. LC / MS: m / z=505.2[M+H] + . 1 H NMR(400MHz,d6-DMSO)δ 0.54-0.61(2H,m),1.00-1.08(2H,m),1.18(3H,d,J=6.9Hz),2.07-2.19(4H,m),2.64-2.69(1H,m),2.72-2.77(1H,m),2.94-3.01(1H,m),6 .39(1H,s),7.01-7.14(3H,m),7.20(1H,dd,J=9.2Hz,2.8Hz),7.44-7.52(1H,m),7.57(1H,dd,J=6.6Hz,2.4Hz),7.91(1H,s),10.37(1H,s).
[0203] <Example 31> 4-Cyclopropyl-2-(4-fluoro-2-methylphenoxy)-N-(4-fluoro-3-(1-fluoro-3-hydroxypropyl)phenyl)-5-(trifluoromethyl)benzamide JPEG0007591240000046.jpg37170
[0204] Step 1: Synthesis of methyl 3-(5-(4-cyclopropyl-2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzamido)-2-fluorophenyl)-3-oxopropionate Dimethyl carbonate (450mg, 5mmol) and 60% content sodium hydrogen (100mg, 2.5mmol) are suspended in 15mL of dry tetrahydrofuran, N-(3-acetyl-4-fluorophenyl)-4-cyclopropyl-2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzamide (245mg, 0.5mmol) is added at room temperature, the solution is stirred at 70℃ for 6 hours, the reaction system is cooled in an ice bath, and ammonium chloride solution is added to quench the reaction, extracted with ethyl acetate, the organic phase is dried and concentrated to dryness, and purified by silica gel column chromatography (PE / EA=2 / 1) to obtain 165mg of yellow solid. Yield: 60%.
[0205] Step 2: Synthesis of methyl 3-(5-(4-cyclopropyl-2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzamido)-2-fluorophenyl)-3-hydroxypropionate 3-(5-(4-cyclopropyl-2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzamido)-2-fluorophenyl)-3-oxopropionic acid methyl ester (165mg, 0.3mmol) and 5mL of methanol were added in batches to sodium borohydride (57mg, 1.5mmol), reacted at room temperature with stirring for 1 hour, then added dilute hydrochloric acid to quench the reaction, extracted with ethyl acetate, dried the organic phase and concentrated to dryness, purified by silica gel flash column chromatography (PE / EA=1 / 1) to obtain 125mg of yellow solid. Yield: 76%.
[0206] Step 3: Synthesis of methyl 3-(5-(4-cyclopropyl-2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzamido)-2-fluorophenyl)-3-fluoropropionate 3-(5-(4-cyclopropyl-2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzamido)-2-fluorophenyl)-3-hydroxypropionate methyl ester (125 mg, 0.23 mmol) and 5 mL of dichloromethane were added to a reaction flask, and DAST (74 mg, 0.46 mmol) was added to the reaction system at about -45°C, and the reaction system was stirred at -45°C for 2 hours. Water was added to the reaction system to quench the reaction, and the reaction system was extracted with ethyl acetate, the organic phase was dried and concentrated to dryness, and purified by silica gel column chromatography (PE / EA=2 / 1) to obtain 40 mg of an off-white solid. Yield: 32%.
[0207] Step 4: Synthesis of 4-cyclopropyl-2-(4-fluoro-2-methylphenoxy)-N-(4-fluoro-3-(1-fluoro-3-hydroxypropyl)phenyl)-5-(trifluoromethyl)benzamide 3-(5-(4-cyclopropyl-2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzamido)-2-fluorophenyl)-3-fluoropropionate methyl ester (40mg, 0.07mmol), anhydrous lithium chloride (4mg, 0.1mmol) and 3mL of methanol were mixed, and sodium borohydride (27mg, 0.7mmol) was added in batches. After stirring at room temperature for 1 hour, the reaction was quenched by adding dilute hydrochloric acid, extracted with ethyl acetate, the organic phase was dried and concentrated to dryness, and purified by silica gel Prep-TLC (DCM / MeOH=30 / 1) to obtain 25mg of white solid. Yield: 66%. LC / MS: m / z=524.2[M+H] + .
[0208] <Example 32> 4-Cyclopropyl-N-(3-(1,1-difluoro-3-hydroxypropyl)-4-fluorophenyl)-2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzamide JPEG0007591240000047.jpg49170
[0209] Step 1: Synthesis of methyl 3-(5-(4-cyclopropyl-2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzamido)-2-fluorophenyl)-3,3-difluoropropionate 3-(5-(4-cyclopropyl-2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzamido)-2-fluorophenyl)-3-oxopropionate methyl ester (200 mg, 0.37 mmol) and 15 mL of dichloromethane were added to the reaction flask, and DAST (119 mg, 0.74 mmol) was added to the reaction system at room temperature, and the reaction system was stirred at room temperature for 2 hours. Water was added to the reaction system to quench the reaction, and the reaction system was extracted with ethyl acetate, the organic phase was dried and concentrated to dryness, and purified by silica gel column chromatography (PE / EA=2 / 1) to obtain 45 mg of an off-white solid. Yield: 21%.
[0210] Step 2: Synthesis of 4-cyclopropyl-N-(3-(1,1-difluoro-3-hydroxypropyl)-4-fluorophenyl)-2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzamide Example 32 was obtained according to the same scheme as in Example 31 using the corresponding substrate as the starting material. LC / MS: m / z=542.2[M+H] + .
[0211] <Example 33> 4-Cyclopropyl-N-(3-(1,1-difluoro-2-((2-hydroxyethyl)amino)-2-oxoethyl)-4-fluorophenyl)-2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzamide JPEG0007591240000048.jpg42170
[0212] Step 1: Synthesis of N-(3-(2-((2-((t-butyldimethylsilyl)oxy)ethyl)amino)-2-oxoacetyl)-4-fluorophenyl)-4-cyclopropyl-2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzamide 4-Cyclopropyl-2-(4-fluoro-2-methylphenoxy)-N-(4-fluoro-3-(2-(((2-hydroxyethyl)amino)-2-oxoacetyl)phenyl)-5-(trifluoromethyl)benzamide (100 mg, 0.18 mmol) and TEA (101 mg, 1 mmol) were dissolved in 10 mL of dichloromethane, and TBSOTf (95 mg, 0.36 mmol) was added at room temperature. The reaction system was directly spun dry and purified by silica gel column chromatography (PE / EA=5 / 1) to obtain 90 mg. Yield: 74%.
[0213] Step 2: Synthesis of N-(3-(2-(((2-((t-butyldimethylsilyl)oxy)ethyl)amino)-1,1-difluoro-2-oxyethyl)-4-fluorophenyl)-4-cyclopropyl-2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzamide N-(3-(2-((2-((t-butyldimethylsilyl)oxy)ethyl)amino)-2-oxoacetyl)-4-fluorophenyl)-4-cyclopropyl-2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzamide (90mg, 0.13mmol) and 5mL of dichloromethane were added to the reaction flask, and DAST (65mg, 0.4mmol) was added to the reaction system at room temperature, and the reaction system was stirred at room temperature for 2 hours. Water was added to the reaction system to quench the reaction, and the reaction system was extracted with ethyl acetate, the organic phase was dried and concentrated to dryness, and purified by silica gel column chromatography (PE / EA=5 / 1) to obtain 18mg of off-white solid. Yield: 19%.
[0214] Step 3: Synthesis of 4-cyclopropyl-N-(3-(1,1-difluoro-2-((2-hydroxyethyl)amino)-2-oxoethyl)-4-fluorophenyl)-2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzamide A reaction flask was charged with N-(3-(2-((2-((t-butyldimethylsilyl)oxy)ethyl)amino)-1,1-difluoro-2-oxyethyl)-4-fluorophenyl)-4-cyclopropyl-2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzamide (18 mg), TBAF (0.2 mL, 1M) and 2 mL of tetrahydrofuran, and the reaction was stirred at room temperature for 1 hour. Water was added to the reaction, and the mixture was extracted with ethyl acetate. The organic phase was backwashed twice with dilute hydrochloric acid, dried and concentrated, and then purified by Prep-TLC (DCM / MeOH=20 / 1) to obtain 5 mg of an off-white solid. The yield was 31%. LC / MS: m / z=585.2[M+H] + .
[0215] <Example 34> N-(3-(2-aminoethoxy)-4-fluorophenyl)-4-cyclopropyl-2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzamide JPEG0007591240000049.jpg49170
[0216] Step 1: Synthesis of (2-(5-(4-(4-cyclopropyl-2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzamido)-2-fluorobenzeneoxy)ethyl)carbamic acid t-butyl ester A solution of 4-cyclopropyl-2-(4-fluoro-2-methylphenoxy)-N-(4-fluoro-3-hydroxyphenyl)-5-(trifluoromethyl)benzamide (46 mg, 0.1 mmol), potassium carbonate (41 mg, 0.3 mmol), and (2-bromoethyl)carbamic acid tert-butyl ester (33 mg, 0.15 mmol) in 3 mL of acetonitrile was stirred at 100° C. for 2 h, the reaction was filtered, and the filtrate was spun to dryness to give 90 mg of a yellow solid, which was used directly in the next step reaction without purification.
[0217] Step 2: Synthesis of N-(3-(2-aminoethoxy)-4-fluorophenyl)-4-cyclopropyl-2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzamide A solution of (2-(5-(4-(4-cyclopropyl-2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzamido)-2-fluorobenzeneoxy)ethyl)carbamic acid t-butyl ester (90 mg, crude product) in 5 mL of ethyl acetate hydrochloride was reacted at room temperature with stirring for 1 hour, the reaction system was spin-dried, water was added, the pH was adjusted to basic with sodium carbonate, extracted with ethyl acetate, spin-dried, and purified by Prep-TLC (DCM / MeOH=12 / 1) to obtain 20 mg of a white solid. Yield: 39% (2 steps). LC / MS: m / z=507.2[M+H] + . 1H NMR(400MHz,d6-DMSO)δ 0.56-0.61(2H,m),0.99-1.08(2H,m),2.11-2.13(1H,m),2.15(3H,s),2.91(2H,d,J=5.8Hz),3.9 4(2H,d,J=5.8Hz),6.38(1H,s),7.03-7.23(5H,m),7.52-7.61(1H,m),7.91(1H,s),10.41(1H,s).
[0218] Table 1: Following similar procedures as described in the above examples and starting from the corresponding reagents, the following compounds were prepared. JPEG0007591240000050.jpg122170JPEG0007591240000051.jpg184170JPEG0007591240000052.jpg124170
[0219] <Example 46> 4-Cyclopropyl-N-(3-(1,3-diaminobutyl)-4-fluorophenyl)-2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzamide JPEG0007591240000053.jpg51170
[0220] Step 1: Synthesis of t-butyl-(1-(5-(4-cyclopropyl-2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzamido)-2-fluorophenyl)-3-(hydroxyimino)butyl)carbamate A solution of (1-(5-(4-(4-cyclopropyl-2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzamido)-2-fluorophenyl)-3-oxobutyl)carbamic acid tert-butyl ester (63 mg, 0.1 mmol), sodium acetate (16 mg, 0.2 mmol) and hydroxylamine hydrochloride (14 mg, 0.2 mmol) in 3 mL of ethanol was stirred at room temperature overnight. The reaction was poured into 10 mL of water, extracted with ethyl acetate, and the organic phase was dried and then spun to dryness to give 70 mg of a yellow solid.
[0221] Step 2: Synthesis of 4-cyclopropyl-N-(3-(1,3-diaminobutyl)-4-fluorophenyl)-2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzamide The crude product obtained in the previous step was dissolved in 5 mL of methanol, and 0.1 mL of concentrated hydrochloric acid and 50 mg of Pd / C (10%) were added. The reaction system was stirred for 6 hours under a hydrogen gas atmosphere at 0.2 MPa pressure. After filtration and spin drying of the filtrate, it was purified by Prep-TLC (DCM / MeOH=10 / 1) to give 3 mg of a white solid. The two-step yield was 5%. LC / MS: m / z=534.2[M+H] + .
[0222] <Example 47> N-(3-(2-amino-1-fluoroethyl)-4-fluorophenyl)-4-cyclopropyl-2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzamide JPEG0007591240000054.jpg52170
[0223] Step 1: Synthesis of N-(3-(2-amino-1-hydroxyethyl)-4-fluorophenyl)-4-cyclopropyl-2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzamide N-(3-(2-amino-2-oxyacetyl)-4-fluorophenyl)-4-cyclopropyl-2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzamide (104 mg, 0.2 mmol) was dissolved in 3 mL of tetrahydrofuran, lithium aluminum hydride (23 mg, 0.6 mmol) was added at 0° C., and the reaction system was stirred at room temperature overnight. The reaction solution was poured into 10 mL of water, extracted with ethyl acetate, and the organic phase was dried and then spun dry, and purified by Prep-TLC (DCM / MeOH=10 / 1) to obtain 25 mg of a yellow solid. Yield: 25%.
[0224] Step 2: Synthesis of N-(3-(2-amino-1-fluoroethyl)-4-fluorophenyl)-4-cyclopropyl-2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzamide N-(3-(2-amino-1-hydroxyethyl)-4-fluorophenyl)-4-cyclopropyl-2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzamide (25 mg, 0.05 mmol) was dissolved in 3 mL of dichloromethane, and the system was cooled to -20°C. Then, diethylaminosulfur trifluoride (8 mg, 0.05 mmol) was added and reacted for 1 hour with stirring at 0°C. The reaction solution was poured into 10 mL of water, extracted with ethyl acetate, and the organic phase was spin-dried and purified by Prep-TLC (DCM / MeOH=15 / 1) to obtain 8 mg of an off-white solid. The yield was 32%. LC / MS: m / z=509.2[M+H] + . 1 H NMR(400MHz,d6-DMSO)δ 0.58-0.60(2H,m),1.02-1.07(2H,m),1.18(3H,d,J=7.0Hz),2.13-2.17(4H,m),2.64-2.69(1H,m),2.72-2.77(1H,m),2.94-3.01(1H,m),6 .28(1H,s),7.05-7.13(3H,m),7.20(1H,dd,J=9.2Hz,2.8Hz),7.47-7.51(1H,m),7.57(1H,dd,J=6.6Hz,2.4Hz),7.91(1H,s),10.37(1H,s).
[0225] <Example 48> N-(3-(4-amino-4-oxobutan-2-yl)-4-fluorophenyl)-4-cyclopropyl-2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzamide JPEG0007591240000055.jpg58170
[0226] Ethyl 3-(5-(4-cyclopropyl-2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzamido)-2-fluorophenyl)butyrate (56 mg, 0.1 mmol) in 5 mL of ammonia in methanol (7 M) was stirred at room temperature overnight, the reaction was directly spun dry, and the crude product was slurried in a small amount of ethyl acetate to give 35 mg of a white solid. Yield: 66%. LC / MS: m / z=533.2[M+H] + .
[0227] <Example 49> 4-Cyclopropyl-2-(4-fluoro-2-methylphenoxy)-N-(4-fluoro-3-(3-hydroxy-1-(1H-imidazol-1-yl)propyl)phenyl)-5-(trifluoromethyl)benzamide JPEG0007591240000056.jpg55170
[0228] Step 1: Synthesis of 4-cyclopropyl-N-(3-(1,3-dihydroxypropyl)-4-fluorophenyl)-2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzamide Methyl 3-(5-(4-cyclopropyl-2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzamido)-2-fluorophenyl)-3-oxopropionate (55 mg, 0.1 mmol) was dissolved in 3 mL of methanol, and sodium borohydride (38 mg, 1.0 mmol) was added at room temperature. The reaction was stirred at room temperature for 6 hours, then poured into 10 mL of water, extracted with ethyl acetate, and the organic phase was spin-dried and purified by Prep-TLC (DCM / MeOH=20 / 1) to give 30 mg of a yellow solid. Yield: 58%.
[0229] Step 2: Synthesis of 4-cyclopropyl-2-(4-fluoro-2-methylphenoxy)-N-(4-fluoro-3-(3-hydroxy-1-(1H-imidazol-1-yl)propyl)phenyl)-5-(trifluoromethyl)benzamide 4-Cyclopropyl-N-(3-(1,3-dihydroxypropyl)-4-fluorophenyl)-2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzamide (30 mg, 0.06 mmol) was dissolved in 3 mL of NMP and carbonyldiimidazole (16 mg, 0.1 mmol) was added. The reaction was stirred at 150° C. for 2 days. Direct purification by Prep-HPLC gave 8 mg of a white solid. Yield: 24%. LC / MS: m / z=572.2[M+H] + .
[0230] <Example 50> 4-Cyclopropyl-2-(4-fluoro-2-methylphenoxy)-N-(4-fluoro-3-(2-oxo-1,4-diazepin-5-yl)phenyl)-5-(trifluoromethyl)benzamide JPEG0007591240000057.jpg39170
[0231] Step 1: Synthesis of t-butyl (3-(2-bromoacetamido)-1-(5-(4-cyclopropyl-2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzamido)-2-fluorophenyl)propyl)carbamate t-Butyl (3-amino-1-(5-(4-cyclopropyl-2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzamido)-2-fluorophenyl)propyl)carbamate (62 mg, 0.1 mmol) and triethylamine (20 mg, 0.2 mmol) were dissolved in 5 mL of dichloromethane, and the system was cooled to 0° C., after which bromoacetyl bromide (20 mg, 0.1 mmol) was added. The reaction solution was stirred at room temperature for 1 hour, then spun dry, and the crude product was purified by Prep-TLC (PE / EA=2 / 1) to give 55 mg of a yellow solid. Yield: 74%.
[0232] Step 2: Synthesis of N-(3-(1-amino-3-(2-bromoacetamido)propyl)-4-fluorophenyl)-4-cyclopropyl-2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzamide t-Butyl (3-(2-bromoacetamido)-1-(5-(4-cyclopropyl-2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzamido)-2-fluorophenyl)propyl)carbamate (55 mg, 0.07 mmol) was dissolved in 5 mL of ethyl acetate hydrochloride solution and reacted with stirring for 1 hour, and the reaction was spun dry to give the hydrochloride salt of the desired product, which was used directly in the next step.
[0233] Step 3: Synthesis of 4-cyclopropyl-2-(4-fluoro-2-methylphenoxy)-N-(4-fluoro-3-(2-oxo-1,4-diazepin-5-yl)phenyl)-5-(trifluoromethyl)benzamide The product of the previous step was dissolved in 5 mL of tetrahydrofuran, potassium carbonate (37 mg, 0.2 mmol) was added, and the mixture was stirred at room temperature overnight. After filtration and spin drying of the filtrate, it was purified by Prep-TLC (DCM / MeOH=10 / 1) to give 16 mg of an off-white solid. The two-step yield was 39%. LC / MS: m / z=560.2[M+H] + .
[0234] <Example 51> 4-Cyclopropyl-2-(4-fluoro-2-methylphenoxy)-N-(4-fluoro-3-(2-oxahydropyrimidin-4-yl)phenyl)-5-(trifluoromethyl)benzamide JPEG0007591240000058.jpg64170
[0235] 4-Cyclopropyl-N-(3-(1,3-diaminopropyl)-4-fluorophenyl)-2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzamide (51 mg, 0.1 mmol) was dissolved in 3 mL of tetrahydrofuran, and potassium carbonate (37 mg, 0.2 mmol) and triphosgene (30 mg, 0.1 mmol) were added and stirred at room temperature for 6 hours. After filtration and spin drying of the filtrate, it was purified by Prep-TLC (DCM / MeOH=30 / 1) to obtain 20 mg of a white solid. The yield was 36%. LC / MS: m / z=546.2[M+H] + . 1 H NMR(400MHz,d6-DMSO)δ 0.57-0.60(2H,m),1.00-1.06(2H,m),1.70-1.77(1H,m),2.00-2.03(1H,m),2.12-2.16(4H,m),2.92-2.94(1H,m),3.09-3.11 (1H,m),4.72-4.74(1H,m),6.34-6.37(2H,m),6.48(1H,s),7.05-7.23(4H,m),7.63-7.67(2H,m),7.89(1H,s),10.53(1H,s).
[0236] <Example 52> N-(3-amino-4-fluorophenyl)-4-cyclopropyl-2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzamide JPEG0007591240000059.jpg48170
[0237] Step 1: Synthesis of 4-cyclopropyl-2-(4-fluoro-2-methylphenoxy)-N-(4-fluoro-3-nitrophenyl)-5-(trifluoromethyl)benzamide A reaction flask was charged with 4-cyclopropyl-2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzoic acid (35 mg, 0.1 mmol), 4-fluoro-3-nitroaniline (16 mg, 0.1 mmol), DIPEA (26 mg, 0.2 mmol) and 2 mL of tetrahydrofuran, HATU (38 mg, 0.1 mmol) was added, and the reaction mixture was stirred at room temperature overnight. The reaction was poured into 10 mL of water, extracted with ethyl acetate, and the organic phase was backwashed twice each with 1 M dilute hydrochloric acid, 1 M aqueous sodium hydroxide, and saturated saline, dried, and spun to give 40 mg of a yellow solid. Yield: 82%.
[0238] Step 2: Synthesis of N-(3-amino-4-fluorophenyl)-4-cyclopropyl-2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzamide 4-Cyclopropyl-2-(4-fluoro-2-methylphenoxy)-N-(4-fluoro-3-nitrophenyl)-5-(trifluoromethyl)benzamide (40 mg, 0.08 mmol) was dissolved in 5 mL of methanol, and 10 mg of Pd / C (10%) was added. The reaction system was stirred overnight under a hydrogen gas atmosphere at 0.2 MPa pressure. The reaction solution was filtered, and the filtrate was spin-dried and then purified by Prep-TLC (DCM / MeOH=30 / 1) to obtain 26 mg of a white solid. The yield was 68%. LC / MS: m / z=463.1 [M+H] + . 1 H NMR(400MHz,d6-DMSO)δ 0.55-0.58(2H,m),1.01-1.05(2H,m),2.08-2.15(4H,m),5.20(2H,s),6.34(1H,s),6.74-6.7 6(1H,m),6.90-6.92(1H,m),7.07-7.08(2H,m),7.19-7.21(2H,m),7.87(1H,s),10.13(1H,s).
[0239] <Example 53> N-(3-(4-amino-5,5,5-trifluoropentan-2-yl)-4-fluorophenyl)-4-cyclopropyl-2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzamide JPEG0007591240000060.jpg27170
[0240] Step 1: Synthesis of 4-cyclopropyl-2-(4-fluoro-2-methylphenoxy)-N-(4-fluoro-3-(4-oxobutan-2-yl)phenyl)-5-(trifluoromethyl)benzamide A solution of 3-(5-(4-cyclopropyl-2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzamido)-2-fluorophenyl)ethyl butyrate (281 mg, 0.5 mmol) in 5 mL of tetrahydrofuran was cooled to -70°C under nitrogen gas protection, and diisobutylaluminum hydride (1 M n-hexane solution, 0.5 mL, 0.5 mmol) was added dropwise. After the addition was completed, the reaction system was stirred at -70°C for 1 hour. The reaction was poured into 20 mL of water, extracted with ethyl acetate, the organic phase was dried and spun dry, and purified by Prep-TLC (PE / EA=3 / 1) to obtain 140 mg of a yellow solid. The yield was 54%.
[0241] Step 2: Synthesis of N-(3-(4-((t-butylsulfinyl)imino)butan-2-yl)-4-fluorophenyl)-4-cyclopropyl-2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzamide A solution of 4-cyclopropyl-2-(4-fluoro-2-methylphenoxy)-N-(4-fluoro-3-(4-oxobutan-2-yl)phenyl)-5-(trifluoromethyl)benzamide (140 mg, 0.27 mmol), cesium carbonate (88 mg, 0.27 mmol), and t-butylsulfinamide (33 mg, 0.27 mmol) in 3 mL of dichloromethane was stirred at 40° C. overnight, the reaction was filtered, and the filtrate was spun to dryness to give 165 mg of a yellow solid. The crude product was used directly in the next step reaction.
[0242] Step 3: Synthesis of N-(3-(4-((t-butylsulfinyl)amino)-5,5,5-trifluoropentan-2-yl)-4-fluorophenyl)-4-cyclopropyl-2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzamide N-(3-(4-((t-butylsulfinyl)imino)butan-2-yl)-4-fluorophenyl)-4-cyclopropyl-2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzamide (165 mg, 0.27 mmol) and tetrabutylammonium fluoride (26 mg, 0.1 mmol) in 5 mL of tetrahydrofuran solution were cooled to 0° C. under nitrogen gas protection, (trifluoromethyl)trimethylsilane (38 mg, 0.27 mmol) was added, and the reaction solution was stirred at 0° C. for 2 hours. The system was poured into 20 mL of water, extracted with ethyl acetate, the organic phase was dried and spin-dried, and purified by Prep-TLC (PE / EA=1 / 1) to obtain 30 mg of a yellow solid. Two-step yield: 16%.
[0243] Step 4: Synthesis of N-(3-(4-amino-5,5,5-trifluoropentan-2-yl)-4-fluorophenyl)-4-cyclopropyl-2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzamide A solution of N-(3-(4-((t-butylsulfinyl)amino)-5,5,5-trifluoropentan-2-yl)-4-fluorophenyl)-4-cyclopropyl-2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzamide (30 mg, 0.04 mmol) in 5 mL of ethyl acetate hydrochloride was stirred at room temperature for 1 hour, the reaction was spun dry, water was added, the pH was adjusted to basic with sodium carbonate, extracted with ethyl acetate, the organic phase was dried, spun dry, and purified by Prep-TLC (DCM / MeOH=10 / 1) to give 12 mg of an off-white solid. Yield: 48%. LC / MS: m / z=587.2[M+H] + . 1H NMR(400MHz,d6-DMSO)δ 0.57-0.59(2H,m),1.02-1.04(2H,m),1.16-1.22(3H,m),1.75-1.77(1H,m),1.90-1.98(2H,m),2.10-2.15(4H,m),2.70-2.75(0.5H ,m),3.21-3.26(0.5H,m),6.39(1H,s),7.00-7.19(4H,m),7.45-7.51(1H,m),7.55-7.60(1H,m),7.90(1H,s),10.37-10.38(1H,m).
[0244] <Example 54> N-(3-(5-(t-butylamino)-4-hydroxypentan-2-yl)-4-fluorophenyl)-4-cyclopropyl-2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzamide JPEG0007591240000061.jpg49170
[0245] Step 1: Synthesis of 4-cyclopropyl-2-(4-fluoro-2-methylphenoxy)-N-(4-fluoro-3-(1-(oxiran-2-yl)propan-2-yl)phenyl)-5-(trifluoromethyl)benzamide 4-Cyclopropyl-2-(4-fluoro-2-methylphenoxy)-N-(4-fluoro-3-(4-oxobutan-2-yl)phenyl)-5-(trifluoromethyl)benzamide (45mg, 0.087mmol) was dissolved in 2mL of DMSO, potassium t-butoxide (23mg, 0.20mmol) and trimethylsulfoxide iodide (22mg, 0.10mmol) were added in sequence, the reaction solution was stirred at room temperature for 4 hours, the system was poured into 10mL of water, extracted with ethyl acetate, the organic phase was dried and spun dry, and purified by Prep-TLC (PE / EA=2 / 1) to obtain 20mg of white solid. Yield: 43%.
[0246] Step 2: Synthesis of N-(3-(5-(t-butylamino)-4-hydroxypentan-2-yl)-4-fluorophenyl)-4-cyclopropyl-2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzamide 4-Cyclopropyl-2-(4-fluoro-2-methylphenoxy)-N-(4-fluoro-3-(1-(oxiran-2-yl)propan-2-yl)phenyl)-5-(trifluoromethyl)benzamide (20mg, 0.038mmol) was dissolved in 2mL of DMF, t-butylamine (15mg, 0.20mmol) was added, and the mixture was heated to 100°C and stirred for 6 hours. The system was poured into 10mL of water, extracted with ethyl acetate, the organic phase was dried and spin-dried, and purified by Prep-TLC (DCM / MeOH=10 / 1) to obtain 8mg of white solid. Yield: 35%. LC / MS: m / z=605.3[M+H] + . 1 H NMR(400MHz,d6-DMSO)δ 0.56-0.58(2H,m),1.02-1.23(14H,m),1.60-1.68(2H,m),1.97-2.02(1H,m),2.10-2.14(4H,m),3.24-3.26(2H,m),3.60-3.62(1H,m ),6.36-6.37(1H,m),7.06-7.12(3H,m),7.19-7.21(1H,m),7.41-7.44(1H,m),7.63-7.67(1H,m),7.89(1H,s),10.36-10.37(1H,m).
[0247] <Example 55> N-(3-(4-(t-butylamino)-3-hydroxybutan-2-yl)-4-fluorophenyl)-4-cyclopropyl-2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzamide JPEG0007591240000062.jpg72170
[0248] Step 1: Synthesis of 2-(2-fluoro-5-nitrophenyl)-N-methoxy-N-methylacetamide A reaction flask was charged with 2-fluoro-5-nitrophenylacetic acid (3000 mg, 15.1 mmol), N,O-dimethylhydroxylamine hydrochloride (1510 mg, 15.5 mmol), DIPEA (3870 mg, 30.0 mmol) and 50 mL of tetrahydrofuran, HATU (7600 mg, 20.0 mmol) was added, and the reaction mixture was stirred at room temperature for 4 hours. The reaction was poured into 200 mL of water, extracted with ethyl acetate, and the organic phase was backwashed twice each with 1 M dilute hydrochloric acid, 1 M aqueous sodium hydroxide and saturated saline, dried, and spun to dryness to obtain 2900 mg of a yellow solid. Yield: 79%.
[0249] Step 2: Synthesis of 2-(2-fluoro-5-nitrophenyl)-N-methoxy-N-methylpropionamide 2-(2-Fluoro-5-nitrophenyl)-N-methoxy-N-methylacetamide (1000 mg, 4.1 mmol) was dissolved in 10 mL of DMF, followed by the addition of cesium carbonate (2608 mg, 8.0 mmol) and iodomethane (582 mg, 4.1 mmol). The reaction was stirred overnight at room temperature. The system was poured into 100 mL of water, extracted with ethyl acetate, and the organic phase was backwashed twice with brine, dried, and spun to dryness to give 940 mg of a yellow solid. Yield: 89%.
[0250] Step 3: Synthesis of 2-(5-amino-2-fluorophenyl)-N-methoxy-N-methylpropionamide 2-(2-Fluoro-5-nitrophenyl)-N-methoxy-N-methylpropionamide (940 mg, 3.7 mmol) was dissolved in 20 mL of methanol, and 100 mg of Pd / C (10%) was added. The reaction system was stirred overnight under a hydrogen gas atmosphere at 0.2 MPa pressure. The reaction solution was filtered, and the filtrate was spin-dried to obtain 700 mg of a yellow solid. The yield was 84%.
[0251] Step 4: Synthesis of 4-cyclopropyl-2-(4-fluoro-2-methylphenoxy)-N-(4-fluoro-3-(1-(methoxy(methyl)amino)-1-oxypropan-2-yl)phenyl)-5-(trifluoromethyl)benzamide A reaction flask was charged with 4-cyclopropyl-2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzoic acid (210 mg, 0.6 mmol), 2-(5-amino-2-fluorophenyl)-N-methoxy-N-methylpropionamide (130 mg, 0.6 mmol), DIPEA (155 mg, 1.2 mmol) and 5 mL of tetrahydrofuran, HATU (340 mg, 0.9 mmol) was added and the reaction mixture was stirred at room temperature for 4 hours. The reaction was poured into 20 mL of water, extracted with ethyl acetate, and the organic phase was backwashed twice each with 1 M dilute hydrochloric acid, 1 M aqueous sodium hydroxide and saturated saline, dried and spun to give 230 mg of a yellow solid. Yield: 71%.
[0252] Step 5: Synthesis of 4-cyclopropyl-2-(4-fluoro-2-methylphenoxy)-N-(4-fluoro-3-(1-oxopropan-2-yl)phenyl)-5-(trifluoromethyl)benzamide A solution of 4-cyclopropyl-2-(4-fluoro-2-methylphenoxy)-N-(4-fluoro-3-(1-(methoxy(methyl)amino)-1-oxypropan-2-yl)phenyl)-5-(trifluoromethyl)benzamide (230 mg, 0.4 mmol) in 5 mL of tetrahydrofuran was cooled to -70°C under nitrogen gas protection, diisobutylaluminum hydride (1 M n-hexane solution, 0.4 mL, 0.4 mmol) was added dropwise, and after the addition was completed, the reaction system was stirred at -70°C for 1.5 hours. The reaction was poured into 20 mL of water, extracted with ethyl acetate, the organic phase was dried, and spin-dried to obtain 200 mg of a yellow solid. Yield: 97%.
[0253] Step 6: Synthesis of 4-cyclopropyl-2-(4-fluoro-2-methylphenoxy)-N-(4-fluoro-3-(1-(oxiran-2-yl)ethyl)phenyl)-5-(trifluoromethyl)benzamide 4-Cyclopropyl-2-(4-fluoro-2-methylphenoxy)-N-(4-fluoro-3-(1-oxopropan-2-yl)phenyl)-5-(trifluoromethyl)benzamide (100 mg, 0.20 mmol) was dissolved in 2 mL of DMSO, potassium t-butoxide (34 mg, 0.30 mmol) and trimethylsulfoxide iodide (44 mg, 0.20 mmol) were added in sequence, the reaction was stirred overnight at room temperature, the system was poured into 10 mL of water, extracted with ethyl acetate, the organic phase was dried, spun dry, and purified by Prep-TLC (PE / EA=2 / 1) to give 60 mg of a white solid. Yield: 58%.
[0254] Step 7: Synthesis of N-(3-(4-(t-butylamino)-3-hydroxybutan-2-yl)-4-fluorophenyl)-4-cyclopropyl-2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzamide 4-Cyclopropyl-2-(4-fluoro-2-methylphenoxy)-N-(4-fluoro-3-(1-(oxiran-2-yl)ethyl)phenyl)-5-(trifluoromethyl)benzamide (52mg, 0.10mmol) was dissolved in 2mL of DMF, t-butylamine (37mg, 0.50mmol) was added, and the mixture was heated to 100°C and stirred for 6 hours. The system was poured into 10mL of water, extracted with ethyl acetate, the organic phase was dried and spin-dried, and purified by Prep-TLC (DCM / MeOH=10 / 1) to obtain 25mg of white solid. Yield: 42%. LC / MS: m / z=591.3[M+H] + . 1H NMR(400MHz,d6-DMSO)δ 0.56-0.59(2H,m),0.96-1.05(11H,m),1.21-1.23(3H,m),2.10-2.14(5H,m),2.33-2.49(2H,m),3.00-3.04(1H,m),3.56(1H,brs), 4.80(1H,brs),6.37(1H,s),7.04-7.09(3H,m),7.18-7.21(1H,m),7.49-7.52(1H,m),7.58-7.60(1H,m),7.89(1H,s),10.36(1H,s).
[0255] <Example 56> 4-Cyclopropyl-2-(4-fluoro-2-methylphenoxy)-N-(4-fluoro-3-hydroxyphenyl)-5-(trifluoromethyl)benzamide
[0256] <Example 57> N-(3-(3-amino-2-hydroxypropoxy)-4-fluorophenyl)-4-cyclopropyl-2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzamide JPEG0007591240000063.jpg38170
[0257] Step 1: Synthesis of 4-cyclopropyl-2-(4-fluoro-2-methylphenoxy)-N-(4-fluoro-3-hydroxyphenyl)-5-(trifluoromethyl)benzamide A reaction flask was charged with 4-cyclopropyl-2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzoic acid (210 mg, 0.6 mmol), 5-amino-2-fluorophenol (76 mg, 0.6 mmol), DIPEA (155 mg, 1.2 mmol) and 5 mL of tetrahydrofuran, HATU (340 mg, 0.9 mmol) was added and the reaction mixture was stirred at room temperature for 4 hours. The reaction was poured into 20 mL of water, extracted with ethyl acetate, and the organic phase was backwashed twice each with 1 M dilute hydrochloric acid, 1 M aqueous sodium hydroxide and saturated saline, dried and spun to give 160 mg of a yellow solid. Yield: 58%. LC / MS: m / z=464.1[M+H] + . 1 H NMR(400MHz,d6-DMSO)δ 0.55-0.59(2H,m),1.01-1.06(2H,m),2.10-2.15(4H,m),6.37(1H,s),6.96-7.00(1H,m),7.03-7.10(3H, m),7.20(1H,dd,J=9.2Hz,2.8Hz),7.45(1H,dd,J=8.4Hz,2.4Hz),7.88(1H,s),9.92(1H,s),10.29(1H,s).
[0258] Step 2: Synthesis of 4-cyclopropyl-2-(4-fluoro-2-methylphenoxy)-N-(4-fluoro-3-(oxiran-2-ylmethoxy)phenyl)-5-(trifluoromethyl)benzamide 4-Cyclopropyl-2-(4-fluoro-2-methylphenoxy)-N-(4-fluoro-3-hydroxyphenyl)-5-(trifluoromethyl)benzamide (92 mg, 0.2 mmol) was dissolved in 3 mL of acetonitrile, and potassium carbonate (55 mg, 0.4 mmol) and epichlorohydrin (37 mg, 0.4 mmol) were added. The reaction was stirred overnight at 60° C. It was filtered, and the filtrate was spun dry and purified by Prep-TLC (PE / EA=2 / 1) to give 60 mg of an off-white solid. Yield: 58%.
[0259] Step 3: Synthesis of N-(3-(3-amino-2-hydroxypropoxy)-4-fluorophenyl)-4-cyclopropyl-2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzamide 4-Cyclopropyl-2-(4-fluoro-2-methylphenoxy)-N-(4-fluoro-3-(oxiran-2-ylmethoxy)phenyl)-5-(trifluoromethyl)benzamide (52mg, 0.10mmol) was dissolved in 2mL of DMF, 0.5mL of aqueous ammonia was added, the mixture was sealed, heated to 100℃ and stirred for 6 hours, the system was poured into 10mL of water, extracted with ethyl acetate, the organic phase was dried and spin-dried, and purified by Prep-TLC (DCM / MeOH=10 / 1) to obtain 30mg of white solid. Yield: 56%. LC / MS: m / z=537.2[M+H] + . 1 H NMR(400MHz,d6-DMSO)δ 0.55-0.59(2H,m),1.01-1.05(2H,m),2.10-2.14(4H,m),2.86-2.89(1H,m),3.03-3.06(1H,m),3.97-4.00(2H,m),4.04-4.08( 1H,m),5.83(1H,d,J=5.2Hz),6.36(1H,s),7.05-7.11(3H,m),7.17-7.22(2H,m),7.65-7.68(1H,m),7.89(1H,s),10.45(1H,s).
[0260] <Example 58> N-(3-(3-aminocyclobutoxy)-4-fluorophenyl)-4-cyclopropyl-2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzamide JPEG0007591240000064.jpg45170
[0261] Step 1: Synthesis of t-butyl (3-(5-(4-cyclopropyl-2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzamido)-2-fluorobenzeneoxy)cyclobutyl)carbamate 4-Cyclopropyl-2-(4-fluoro-2-methylphenoxy)-N-(4-fluoro-3-hydroxyphenyl)-5-(trifluoromethyl)benzamide (93 mg, 0.2 mmol), (3-hydroxycyclobutyl)carbamic acid t-butyl ester (37 mg, 0.2 mmol), and triphenylphosphine (105 mg, 0.4 mmol) were dissolved in 3 mL of tetrahydrofuran, and DIAD (80 mg, 0.4 mmol) was added dropwise at room temperature under nitrogen gas protection, and the reaction solution was stirred at room temperature for 3 hours. The system was poured into water, extracted with ethyl acetate, and the organic phase was dried, spin-dried, and purified by Prep-TLC (PE / EA=1 / 1) to obtain 85 mg of off-white solid. Yield: 67%.
[0262] Step 2: Synthesis of N-(3-(3-aminocyclobutoxy)-4-fluorophenyl)-4-cyclopropyl-2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzamide A solution of t-butyl (3-(5-(4-cyclopropyl-2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzamido)-2-fluorobenzeneoxy)cyclobutyl)carbamate (63 mg, 0.1 mmol) in 5 mL of ethyl acetate hydrochloride was stirred at room temperature for 1 hour, the reaction was spun dry, water was added, the pH was adjusted to basic with sodium carbonate, extracted with ethyl acetate, the organic phase was dried, spun dry, and purified by Prep-TLC (DCM / MeOH=10 / 1) to give 40 mg of an off-white solid. Yield: 75%. LC / MS: m / z=533.2[M+H] + . 1H NMR(400MHz,d6-DMSO)δ 0.57-0.61(2H,m),1.01-1.06(2H,m),1.75-1.81(1H,m),1.90-2.15(7H ,m),2.25-2.31(1H,m),2.71-2.76(1H,m),2.98-3.02(0.5H,m),3.56-3 .58(0.5H,m),4.22-4.25(0.5H,m),4.79-4.81(0.5H,m),6.40(1H,s),7 .00-7.21(5H,m),7.32-7.41(1H,m),7.89(1H,s),10.38-10.39(1H,m).
[0263] <Example 59> 4-Cyclopropyl-2-(4-fluoro-2-methylphenoxy)-N-(4-fluoro-3-(2-(methylsulfonamido)ethoxy)phenyl)-5-(trifluoromethyl)benzamide JPEG0007591240000065.jpg55170
[0264] N-(3-(2-aminoethoxy)-4-fluorophenyl)-4-cyclopropyl-2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzamide (51 mg, 0.1 mmol) and DIPEA (26 mg, 0.2 mmol) were dissolved in 3 mL of tetrahydrofuran, methanesulfonyl chloride (12 mg, 0.1 mmol) was added at room temperature, and the reaction solution was stirred at room temperature for 3 hours. The system was poured into water, extracted with ethyl acetate, and the organic phase was dried, spin-dried, and purified by Prep-TLC (PE / EA=1 / 1) to obtain 45 mg of a white solid. The yield was 78%. LC / MS: m / z=585.2[M+H] + . 1H NMR(400MHz,d6-DMSO)δ 0.56-0.60(2H,m),1.01-1.05(2H,m),2.10-2.15(4H,m),2.96(3H,s),3.37-3.40(2H,m),4.03-4.06(2H,m),6.3 7(1H,s),7.05-7.07(2H,m),7.16-7.22(3H,m),7.33-7.34(1H,m),7.55-7.57(1H,m),7.90(1H,s),10.41(1H,s).
[0265] <Example 60> 4-Cyclopropyl-2-(4-fluoro-2-methylphenoxy)-N-(4-fluoro-3-(3,3,3-trifluoro-2-hydroxypropoxy)phenyl)-5-(trifluoromethyl)benzamide JPEG0007591240000066.jpg59170
[0266] A solution of 4-cyclopropyl-2-(4-fluoro-2-methylphenoxy)-N-(4-fluoro-3-hydroxyphenyl)-5-(trifluoromethyl)benzamide (46 mg, 0.1 mmol), potassium carbonate (41 mg, 0.3 mmol) and 3-bromo-1,1,1-trifluoropropan-2-ol (19 mg, 0.1 mmol) in 3 mL of NMP was stirred at 110° C. overnight, the reaction was poured into 10 mL of water, extracted with ethyl acetate, the organic phase was dried, spun dry and purified by Prep-TLC (EA) to give 35 mg of a white solid. Yield: 52%. LC / MS: m / z=576.1[M+H] + .
[0267] <Example 61> 4-Cyclopropyl-2-(4-fluoro-2-methylphenoxy)-N-(4-fluoro-3-(2-oxo-2-(((2,2,2-trifluoroethyl)amino)ethoxy)phenyl)-5-(trifluoromethyl)benzamide JPEG0007591240000067.jpg37170
[0268] Step 1: Synthesis of ethyl 2-(5-(4-cyclopropyl-2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzamido)-2-fluorobenzeneoxy)acetate A solution of 4-cyclopropyl-2-(4-fluoro-2-methylphenoxy)-N-(4-fluoro-3-hydroxyphenyl)-5-(trifluoromethyl)benzamide (46 mg, 0.1 mmol), potassium carbonate (28 mg, 0.2 mmol), and ethyl bromoacetate (17 mg, 0.1 mmol) in 3 mL of acetonitrile was stirred at 60° C. for 2 h, the reaction was filtered, and the filtrate was spun to dryness to give 55 mg of a yellow solid, which was used directly crude in the next step reaction.
[0269] Step 2: Synthesis of 2-(5-(4-cyclopropyl-2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzamido)-2-fluorobenzeneoxy)acetic acid 2-(5-(4-cyclopropyl-2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzamido)-2-fluorobenzeneoxy)ethyl acetate (55 mg, 0.1 mmol) was dissolved in 2 mL of methanol, 1 mL of water and lithium hydroxide monohydrate (17 mg, 0.4 mmol) were added, and the reaction solution was stirred at room temperature for 6 hours. The reaction system was poured into 10 mL of water, and the pH value was adjusted to acidic with 1 M diluted hydrochloric acid, and extracted with ethyl acetate. The organic phase was dried and spun to dryness to obtain 45 mg of a white solid. Yield: 87%.
[0270] Step 3: Synthesis of 4-cyclopropyl-2-(4-fluoro-2-methylphenoxy)-N-(4-fluoro-3-(2-oxo-2-(((2,2,2-trifluoroethyl)amino)ethoxy)phenyl)-5-(trifluoromethyl)benzamide A reaction flask was charged with 2-(5-(4-cyclopropyl-2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzamido)-2-fluorobenzeneoxy)acetic acid (42 mg, 0.08 mmol), 2,2,2-trifluoroethylamine (10 mg, 0.1 mmol), DIPEA (26 mg, 0.2 mmol) and 3 mL of tetrahydrofuran, HATU (38 mg, 0.1 mmol) was added and the reaction mixture was stirred at room temperature for 4 hours. The reaction was poured into 10 mL of water, extracted with ethyl acetate, the organic phase was dried, spun dry and purified by Prep-TLC (PE / EA=1 / 1) to give 35 mg of a white solid. Yield: 73%. LC / MS: m / z=603.2[M+H] + . 1 H NMR(400MHz,d6-DMSO)δ 0.56-0.58(2H,m),1.03-1.06(2H,m),2.10-2.14(4H,m),3.90-3.99(2H,m),4.65(2H,s),6.35(1H,s),7.0 4-7.11(2H,m),7.20-7.22(2H,m),7.48(1H,d,J=7.6Hz),7.88(1H,s),7.17(1H,t,J=6.4Hz),10.44(1H,s).
[0271] <Example 62> (2-(5-(4-cyclopropyl-2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzamido)-2-fluorobenzeneoxy)ethyl)carbamate JPEG0007591240000068.jpg33170
[0272] Step 1: Synthesis of 4-cyclopropyl-2-(4-fluoro-2-methylphenoxy)-N-(4-fluoro-3-(2-hydroxyethoxy)phenyl)-5-(trifluoromethyl)benzamide A solution of 4-cyclopropyl-2-(4-fluoro-2-methylphenoxy)-N-(4-fluoro-3-hydroxyphenyl)-5-(trifluoromethyl)benzamide (92 mg, 0.2 mmol), potassium carbonate (41 mg, 0.3 mmol), and bromoethanol (25 mg, 0.2 mmol) in 3 mL of NMP was stirred at 110° C. for 5 h, the reaction was poured into 15 mL of water, extracted with ethyl acetate, the organic phase was dried, and spun to dryness to give 100 mg of a yellow solid.
[0273] Step 2: Synthesis of (2-(5-(4-cyclopropyl-2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzamido)-2-fluorobenzeneoxy)ethyl) 1H-imidazole-1-carboxylate A solution of 4-cyclopropyl-2-(4-fluoro-2-methylphenoxy)-N-(4-fluoro-3-(2-hydroxyethoxy)phenyl)-5-(trifluoromethyl)benzamide (80 mg, 0.16 mmol) and CDI (32 mg, 0.2 mmol) in 4 mL of tetrahydrofuran was stirred for 4 h at 50° C. The crude product obtained after spin drying the reaction was used directly in the next step reaction.
[0274] Step 3: Synthesis of (2-(5-(4-cyclopropyl-2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzamido)-2-fluorobenzeneoxy)ethyl)carbamate The reaction product of the previous step was dissolved in 5 mL of ammonia-dioxane solution (1 M), the reaction solution was stirred at 50° C. for 4 h, spin-dried, and the crude product was purified by Prep-HPLC to give 20 mg of a white solid. The two-step yield was 23%. LC / MS: m / z=551.2[M+H] + . 1H NMR(400MHz,d6-DMSO)δ 0.57-0.59(2H,m),1.03-1.06(2H,m),2.10-2.15(4H,m),4.16-4.17(2H,m),4.25-4.26 (2H,m),6.38(1H,s),7.05-7.22(5H,m),7.55-7.57(1H,m),7.91(1H,s),10.41(1H,s).
[0275] <Example 63> 4-Cyclopropyl-N-(2-(2,3-dihydroxypropoxy)pyridin-4-yl)-2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzamide
[0276] <Example 64> N-(2-(3-(t-butylamino)-2-hydroxypropoxy)pyridin-4-yl)-4-cyclopropyl-2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzamide JPEG0007591240000069.jpg31170
[0277] Step 1: Synthesis of 2-(((2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)pyridin-4-amine 2-Chloropyridin-4-amine (128mg, 1.0mmol) and acetonide (264mg, 2.0mmol) were weighed into a flask, metallic sodium (46mg, 2.0mmol) was added, the mixture was stirred at 130°C for 2 hours, the reaction system was cooled, and then poured into 15mL of water, extracted with ethyl acetate, the organic phase was dried, spin-dried, and purified by column chromatography (PE / EA=1 / 1) to obtain 100mg of yellow oil. Yield: 44%.
[0278] Step 2: Synthesis of 4-cyclopropyl-N-(2-(((2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)pyridin-4-yl)-2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzamide A reaction flask was charged with 4-cyclopropyl-2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzoic acid (142 mg, 0.4 mmol), 2-(((2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)pyridin-4-amine (100 mg, 0.44 mmol), DIPEA (103 mg, 0.8 mmol) and 5 mL of tetrahydrofuran, HATU (228 mg, 0.6 mmol) was added and the reaction mixture was stirred at room temperature for 4 hours. The reaction was poured into 20 mL of water and extracted with ethyl acetate, the organic phase was dried, spun dry and purified by Prep-TLC (PE / EA=3 / 1) to give 130 mg of a white solid. Yield: 58%.
[0279] Step 3: Synthesis of 4-cyclopropyl-N-(2-(2,3-dihydroxypropoxy)pyridin-4-yl)-2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzamide A solution of 4-cyclopropyl-N-(2-(((2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)pyridin-4-yl)-2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzamide (130 mg, 0.23 mmol) in 5 mL of ethyl acetate hydrochloride was stirred at room temperature for 1 hour, the reaction system was spin-dried, water was added, the pH was adjusted to basic with sodium carbonate, extracted with ethyl acetate, the organic phase was dried, spin-dried, and purified by Prep-TLC (DCM / MeOH=10 / 1) to give 105 mg of a white solid. The yield was 87%. LC / MS: m / z=521.2[M+H] + . 1 H NMR(400MHz,d6-DMSO)δ 0.58-0.60(2H,m),1.02-1.06(2H,m),2.10-2.13(4H,m),3.40-3.50(2H,m),3.74-3.79(1H,m),4.08-4.13( 1H,m),4.22-4.26(1H,m),6.39(1H,s),7.04-7.16(5H,m),7.91(1H,s),8.02(1H,d,J=5.6Hz),10.72(1H,s).
[0280] Step 4: Synthesis of 4-cyclopropyl-2-(4-fluoro-2-methylphenoxy)-N-(2-(oxiran-2-ylmethoxy)pyridin-4-yl)-5-(trifluoromethyl)benzamide A solution of 4-cyclopropyl-N-(2-(2,3-dihydroxypropoxy)pyridin-4-yl)-2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzamide (104 mg, 0.2 mmol), potassium carbonate (41 mg, 0.3 mmol), and methylflavinyl chloride (23 mg, 0.2 mmol) in 3 mL of acetonitrile was stirred at room temperature for 1 h, then heated to 60° C. and stirred for 2 h. The reaction was filtered and the filtrate was spun down to give 120 mg of a yellow solid, which was used directly crude in the next step reaction.
[0281] Step 5: Synthesis of N-(2-(3-(t-butylamino)-2-hydroxypropoxy)pyridin-4-yl)-4-cyclopropyl-2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzamide The product obtained in the previous step was dissolved in 2 mL of DMF, and t-butylamine (73 mg, 1.0 mmol) was added. The mixture was heated to 100° C. and stirred for 6 hours. The system was poured into 10 mL of water, extracted with ethyl acetate, the organic phase was dried and spun dry, and purified by Prep-TLC (DCM / MeOH=10 / 1) to obtain 15 mg of an off-white solid. The two-step yield was 13%. LC / MS: m / z=576.2[M+H] + .
[0282] <Example 65> 4-Cyclopropyl-2-(4-fluoro-2-methylphenoxy)-N-(4-fluoro-3-(2-hydroxy-3-(2-hydroxyacetamido)propoxy)phenyl)-5-(trifluoromethyl)benzamide JPEG0007591240000070.jpg37170
[0283] Step 1: Synthesis of 4-cyclopropyl-2-(4-fluoro-2-methylphenoxy)-N-(4-fluoro-3-(oxiran-2-ylmethoxy)phenyl)-5-(trifluoromethyl)benzamide 4-Cyclopropyl-2-(4-fluoro-2-methylphenoxy)-N-(4-fluoro-3-hydroxyphenyl)-5-(trifluoromethyl)benzamide (92 mg, 0.2 mmol) was dissolved in 3 mL of DMF, and potassium carbonate (55 mg, 0.4 mmol) and glycidyl m-nitrobenzenesulfonate (52 mg, 0.2 mmol) were added. The reaction was stirred at 60° C. for 6 hours. The system was poured into 20 mL of water, extracted with ethyl acetate, and the organic phase was dried, spun dry, and purified by Prep-TLC (PE / EA=3 / 1) to give 100 mg of an off-white solid. Yield: 96%.
[0284] Step 2: Synthesis of N-(3-(3-amino-2-hydroxypropoxy)-4-fluorophenyl)-4-cyclopropyl-2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzamide 4-Cyclopropyl-2-(4-fluoro-2-methylphenoxy)-N-(4-fluoro-3-(oxiran-2-ylmethoxy)phenyl)-5-(trifluoromethyl)benzamide (52mg, 0.10mmol) was dissolved in 2mL of DMF, 0.5mL of aqueous ammonia was added, the mixture was sealed, heated to 100℃ and stirred for 6 hours, the system was poured into 10mL of water, extracted with ethyl acetate, the organic phase was dried and spin-dried, and purified by Prep-TLC (DCM / MeOH=10 / 1) to obtain 30mg of white solid. Yield: 56%.
[0285] Step 3: Synthesis of 4-cyclopropyl-2-(4-fluoro-2-methylphenoxy)-N-(4-fluoro-3-(2-hydroxy-3-(2-hydroxyacetamido)propoxy)phenyl)-5-(trifluoromethyl)benzamide A reaction flask was charged with glycolic acid (5 mg, 0.06 mmol), N-(3-(3-amino-2-hydroxypropoxy)-4-fluorophenyl)-4-cyclopropyl-2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzamide (30 mg, 0.06 mmol), DIPEA (26 mg, 0.2 mmol) and 3 mL of tetrahydrofuran, HATU (38 mg, 0.1 mmol) was added and the reaction mixture was stirred at room temperature for 4 hours. The reaction was poured into 20 mL of water, extracted with ethyl acetate, the organic phase was dried, spun dry and purified by Prep-TLC (DCM / MeOH=20 / 1) to give 20 mg of a white solid. Yield: 61%. LC / MS: m / z=595.2[M+H] + . 1 H NMR (400MHz, d6-DMSO) δ 0.56-0.59(2H,m),1.01-1.06(2H,m),2.12-2.15(4H,m),3.18-3.23(1H,m) ,3.35-3.38(1H,m),3.81(2H,d,J=6.0Hz),3.85-3.92(3H,m),5.31(1H,d,J= 4.8Hz),5.50(1H,t,J=5.6Hz),6.37(1H,s),7.05-7.08(2H,m),7.15-7.21( 3H,m),7.54(1H,d,J=6.8Hz),7.70-7.73(1H,m),7.90(1H,s),10.40(1H,s).
[0286] Table 2: Following similar procedures as described in the above examples and starting from the corresponding reagents, the following compounds were prepared. JPEG0007591240000071.jpg233170JPEG0007591240000072.jpg196170JPEG000 7591240000073.jpg207170JPEG0007591240000074.jpg213170JPEG0007591240 000075.jpg208170JPEG0007591240000076.jpg201170JPEG0007591240000077. jpg204170JPEG0007591240000078.jpg202170JPEG0007591240000079.jpg86170
[0287] <Example 113> (S)-5-Chloro-N-(2-(2,3-dihydroxypropoxy)pyridin-4-yl)-2-(4-fluoro-2-methylphenoxy)-4-(trifluoromethyl)benzamide JPEG0007591240000080.jpg38170
[0288] Step 1: Synthesis of (R)-2-((2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)pyridin-4-amine 2-Chloropyridin-4-amine (128mg, 1.0mmol) and (R)-(-)-glycerol acetonide (264mg, 2.0mmol) were weighed in a flask, metallic sodium (46mg, 2.0mmol) was added, the mixture was stirred at 130°C for 2 hours, the reaction system was cooled, and then poured into 15mL of water, extracted with ethyl acetate, the organic phase was dried, spin-dried, and purified by column chromatography (PE / EA=1 / 1) to obtain 120mg of yellow oil. Yield: 54%.
[0289] Step 2: Synthesis of (R)-5-chloro-N-(2-((2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)pyridin-4-yl)-2-(4-fluoro-2-methylphenoxy))-4-(trifluoromethyl)benzamide A reaction flask was charged with 5-chloro-2-(4-fluoro-2-methylphenoxy)-4-(trifluoromethyl)benzoic acid (186 mg, 0.54 mmol), (R)-2-((2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)pyridin-4-amine (120 mg, 0.54 mmol), DIPEA (129 mg, 1.00 mmol) and 5 mL of tetrahydrofuran, HATU (266 mg, 0.7 mmol) was added and the reaction mixture was stirred at room temperature for 4 hours. The reaction was poured into 20 mL of water, extracted with ethyl acetate, the organic phase was dried, spun dry and purified by Prep-TLC (PE / EA=3 / 1) to give 180 mg of a white solid. Yield: 60%.
[0290] Step 3: Synthesis of (S)-5-chloro-N-(2-(2,3-dihydroxypropoxy)pyridin-4-yl)-2-(4-fluoro-2-methylphenoxy)-4-(trifluoromethyl)benzamide A solution of (R)-5-chloro-N-(2-((2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)pyridin-4-yl)-2-(4-fluoro-2-methylphenoxy))-4-(trifluoromethyl)benzamide (100 mg, 0.18 mmol) in 5 mL of ethyl acetate hydrochloride was stirred at room temperature for 1 hour, the reaction system was spin-dried, water was added, the pH was adjusted to basic with sodium carbonate, extracted with ethyl acetate, the organic phase was dried, spin-dried, and purified by Prep-TLC (DCM / MeOH=10 / 1) to give 80 mg of a white solid. Yield: 86%. LC / MS: m / z=515.1[M+H] + . 1 H NMR(400MHz,d6-DMSO)δ 2.16(3H,s),3.40-3.43(2H,m),3.75-3.79(1H,m),4.09-4.13(1H,m),4.23-4.27(1H,m),4.64(1H,t,J=5.6Hz),4 .92(1H,d,J=5.2Hz),7.09-7.16(5H,m),7.21(1H,d,J=9.2Hz),8.05(1H,d,J=5.6Hz),8.08(1H,s),10.94(1H,s).
[0291] <Example 114> (R)-5-Chloro-N-(2-(2,3-dihydroxypropoxy)pyridin-4-yl)-2-(4-fluoro-2-methylphenoxy)-4-(trifluoromethyl)benzamide JPEG0007591240000081.jpg37170
[0292] Step 1: Synthesis of (S)-2-((2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)pyridin-4-amine 2-Chloropyridin-4-amine (128mg, 1.0mmol) and (S)-(+)-glycerol acetonide (264mg, 2.0mmol) were added to a flask, and metallic sodium (46mg, 2.0mmol) was added, and the resulting mixture was stirred at 130°C for 2 hours, and the reaction system was cooled and then poured into 15mL of water, extracted with ethyl acetate, and the organic phase was dried, spin-dried, and purified by column chromatography (PE / EA=1 / 1) to obtain 130mg of a yellow oil. Yield: 58%.
[0293] Step 2: Synthesis of (S)-5-chloro-N-(2-((2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)pyridin-4-yl)-2-(4-fluoro-2-methylphenoxy))-4-(trifluoromethyl)benzamide A reaction flask was charged with 5-chloro-2-(4-fluoro-2-methylphenoxy)-4-(trifluoromethyl)benzoic acid (186 mg, 0.54 mmol), (S)-2-((2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)pyridin-4-amine (120 mg, 0.54 mmol), DIPEA (129 mg, 1.00 mmol) and 5 mL of tetrahydrofuran, HATU (266 mg, 0.7 mmol) was added and the reaction mixture was stirred at room temperature for 4 hours. The reaction was poured into 20 mL of water, extracted with ethyl acetate, the organic phase was dried, spun dry and purified by Prep-TLC (PE / EA=3 / 1) to give 205 mg of a white solid. Yield: 68%.
[0294] Step 3: Synthesis of (R)-5-chloro-N-(2-(2,3-dihydroxypropoxy)pyridin-4-yl)-2-(4-fluoro-2-methylphenoxy)-4-(trifluoromethyl)benzamide A solution of (S)-5-chloro-N-(2-((2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)pyridin-4-yl)-2-(4-fluoro-2-methylphenoxy))-4-(trifluoromethyl)benzamide (100 mg, 0.18 mmol) in 5 mL of ethyl acetate hydrochloride was stirred at room temperature for 1 hour, the reaction system was spin-dried, water was added, the pH was adjusted to basic with sodium carbonate, extracted with ethyl acetate, the organic phase was dried, spin-dried, and purified by Prep-TLC (DCM / MeOH=10 / 1) to give 75 mg of a white solid. Yield: 81%. LC / MS: m / z=515.1[M+H] + . 1 H NMR(400MHz,d6-DMSO)δ 2.16(3H,s),3.40-3.43(2H,m),3.75-3.79(1H,m),4.09-4.13(1H,m),4.23-4.27(1H,m),4.64(1H,t,J=5.6Hz),4 .92(1H,d,J=5.2Hz),7.09-7.16(5H,m),7.21(1H,d,J=9.2Hz),8.05(1H,d,J=5.6Hz),8.08(1H,s),10.94(1H,s).
[0295] <Example 117> (R)-5-Chloro-2-(4-fluoro-2-methylphenoxy)-N-(4-fluoro-3-(2-hydroxy-3-(2-hydroxyacetamido)propoxy)phenyl)-4-(trifluoromethyl)benzamide JPEG0007591240000082.jpg32170
[0296] Step 1: Synthesis of 5-chloro-2-(4-fluoro-2-methylphenoxy)-N-(4-fluoro-3-hydroxyphenyl)-4-(trifluoromethyl)benzamide 5-Chloro-2-(4-fluoro-2-methylphenoxy)-4-(trifluoromethyl)benzoic acid (209 mg, 0.6 mmol), 5-amino-2-fluorophenol (76 mg, 0.6 mmol), DIPEA (155 mg, 1.2 mmol) and 5 mL of tetrahydrofuran were added to the reaction flask, HATU (340 mg, 0.9 mmol) was added and the reaction mixture was stirred at room temperature for 4 hours. The reaction system was poured into 20 mL of water, extracted with ethyl acetate, and the organic phase was backwashed twice each with 1 M dilute hydrochloric acid, 1 M aqueous sodium hydroxide and saturated saline, dried and spun to give 185 mg of a yellow solid. Yield: 68%.
[0297] Step 2: Synthesis of (R)-5-chloro-2-(4-fluoro-2-methylphenoxy)-N-(4-fluoro-3-(oxiran-2-ylmethoxy)phenyl)-4-(trifluoromethyl)benzamide 5-Chloro-2-(4-fluoro-2-methylphenoxy)-N-(4-fluoro-3-hydroxyphenyl)-4-(trifluoromethyl)benzamide (91 mg, 0.2 mmol) was dissolved in 3 mL of DMF, and potassium carbonate (55 mg, 0.4 mmol) and (R)-(-)-glycidyl m-nitrobenzenesulfonate (52 mg, 0.2 mmol) were added. The reaction was stirred at 60° C. for 6 hours. The system was poured into 20 mL of water, extracted with ethyl acetate, and the organic phase was dried, spun dry, and purified by Prep-TLC (PE / EA=3 / 1) to give 100 mg of an off-white solid. Yield: 96%.
[0298] Step 3: Synthesis of (R)-N-(3-(3-amino-2-hydroxypropoxy)-4-fluorophenyl)-5-chloro-2-(4-fluoro-2-methylphenoxy)-4-(trifluoromethyl)benzamide (R)-5-chloro-2-(4-fluoro-2-methylphenoxy)-N-(4-fluoro-3-(oxiran-2-ylmethoxy)phenyl)-4-(trifluoromethyl)benzamide (100mg, 0.19mmol) was dissolved in 2mL of DMF, 0.5mL of aqueous ammonia was added, the mixture was sealed, heated to 100℃ and stirred for 6 hours, the system was poured into 10mL of water, extracted with ethyl acetate, the organic phase was dried and spin-dried, and purified by Prep-TLC (DCM / MeOH=10 / 1) to obtain 75mg of white solid. Yield: 73%.
[0299] Step 4: Synthesis of (R)-5-chloro-2-(4-fluoro-2-methylphenoxy)-N-(4-fluoro-3-(2-hydroxy-3-(2-hydroxyacetamido)propoxy)phenyl)-4-(trifluoromethyl))benzamide A reaction flask was charged with glycolic acid (10 mg, 0.12 mmol), (R)-N-(3-(3-amino-2-hydroxypropoxy)-4-fluorophenyl)-5-chloro-2-(4-fluoro-2-methylphenoxy)-4-(trifluoromethyl)benzamide (64 mg, 0.12 mmol), DIPEA (52 mg, 0.4 mmol) and 3 mL of tetrahydrofuran, HATU (76 mg, 0.2 mmol) was added and the reaction mixture was stirred at room temperature for 4 hours. The reaction was poured into 20 mL of water, extracted with ethyl acetate, the organic phase was dried, spun dry and purified by Prep-TLC (DCM / MeOH=20 / 1) to give 45 mg of a white solid. Yield: 63%. LC / MS: m / z=589.1[M+H] + . 1H NMR(400MHz,d6-DMSO)δ 2.18(3H,s),3.17-3.24(1H,m),3.34-3.39(1H,m),3.81-3.83(2H,m),3.88-3.93(3H,m),5.33(1H,d,J=4.8Hz),5.5 2(1H,t,J=5.6Hz),7.09-7.23(6H,m),7.53(1H,dd,J=7.6Hz,2.0Hz),7.72-7.75(1H,m),8.04(1H,s),10.63(1H,s).
[0300] <Example 118> (S)-5-Chloro-2-(4-fluoro-2-methylphenoxy)-N-(4-fluoro-3-(2-hydroxy-3-(2-hydroxyacetamido)propoxy)phenyl)-4-(trifluoromethyl)benzamide JPEG0007591240000083.jpg38170
[0301] Step 1: Synthesis of (S)-5-chloro-2-(4-fluoro-2-methylphenoxy)-N-(4-fluoro-3-(oxiran-2-ylmethoxy)phenyl)-4-(trifluoromethyl)benzamide 5-Chloro-2-(4-fluoro-2-methylphenoxy)-N-(4-fluoro-3-hydroxyphenyl)-4-(trifluoromethyl)benzamide (91 mg, 0.2 mmol) was dissolved in 3 mL of DMF, and potassium carbonate (55 mg, 0.4 mmol) and (S)-(+)-glycidyl m-nitrobenzenesulfonate (52 mg, 0.2 mmol) were added. The reaction was stirred at 60° C. for 6 hours. The system was poured into 20 mL of water, extracted with ethyl acetate, and the organic phase was dried, spun dry, and purified by Prep-TLC (PE / EA=3 / 1) to give 95 mg of an off-white solid. Yield: 92%.
[0302] Step 2: Synthesis of (S)-N-(3-(3-amino-2-hydroxypropoxy)-4-fluorophenyl)-5-chloro-2-(4-fluoro-2-methylphenoxy)-4-(trifluoromethyl)benzamide (S)-5-chloro-2-(4-fluoro-2-methylphenoxy)-N-(4-fluoro-3-(oxiran-2-ylmethoxy)phenyl)-4-(trifluoromethyl)benzamide (95mg, 0.19mmol) was dissolved in 2mL of DMF, 0.5mL of aqueous ammonia was added, the mixture was sealed, heated to 100℃ and stirred for 6 hours, the system was poured into 10mL of water, extracted with ethyl acetate, the organic phase was dried and spin-dried, and purified by Prep-TLC (DCM / MeOH=10 / 1) to obtain 80mg of white solid. Yield: 82%.
[0303] Step 3: Synthesis of (S)-5-chloro-2-(4-fluoro-2-methylphenoxy)-N-(4-fluoro-3-(2-hydroxy-3-(2-hydroxyacetamido)propoxy)phenyl)-4-(trifluoromethyl))benzamide A reaction flask was charged with glycolic acid (10 mg, 0.12 mmol), (S)-N-(3-(3-amino-2-hydroxypropoxy)-4-fluorophenyl)-5-chloro-2-(4-fluoro-2-methylphenoxy)-4-(trifluoromethyl)benzamide (64 mg, 0.12 mmol), DIPEA (52 mg, 0.4 mmol) and 3 mL of tetrahydrofuran, HATU (76 mg, 0.2 mmol) was added and the reaction mixture was stirred at room temperature for 4 hours. The reaction was poured into 20 mL of water, extracted with ethyl acetate, the organic phase was dried, spun dry and purified by Prep-TLC (DCM / MeOH=20 / 1) to give 50 mg of a white solid. Yield: 70%. LC / MS: m / z=589.1[M+H] + . 1H NMR(400MHz,d6-DMSO)δ 2.18(3H,s),3.17-3.24(1H,m),3.34-3.39(1H,m),3.81-3.83(2H,m),3.88-3.93(3H,m),5.33(1H,d,J=4.8Hz),5.5 2(1H,t,J=5.6Hz),7.09-7.23(6H,m),7.53(1H,dd,J=7.6Hz,2.0Hz),7.72-7.75(1H,m),8.04(1H,s),10.63(1H,s).
[0304] Table 3: Following similar procedures as described in the above examples and starting from the corresponding reagents, the following compounds were prepared. JPEG0007591240000084.jpg29170JPEG0007591240000085.jpg203170JPEG0007591240000086.jpg202170JPEG0007591240000087.jpg201170
[0305] Drug discovery feasibility study Test Example 1: Test of the inhibitory activity of compounds against human NaV1.8 ion channels in HEK293 cells 1: Formulation of test compound All reagents except NaOH and KOH for acid-base titration were purchased from Sigma (St. Louis, MO). All final concentrations of test compounds were prepared on the day and redissolved in extracellular solution. Extracellular solution (mM) was NaCl, 137, KCl, 4, CaCl2, 1.8, MgCl2, 1, HEPES, 10, glucose, pH 7.4 (NaOH titration). Intracellular solution (mM) was Aspartic acid, 140, MgCl2, 2, EGTA, 11, HEPES, 10, pH 7.2 (CsOH titration). All test compound solutions contained 1 μM TTX.
[0306] The stock concentration of the test compound was 3 mM. It was soluble in dimethyl sulfoxide (DMSO). On the day of the test, it was redissolved in extracellular fluid and adjusted to the required concentration.
[0307] Test compound solvent JPEG0007591240000088.jpg31170
[0308] 2: Testing method 2.1: Cell All experiments were performed at room temperature, and each cell served as its own control.
[0309] 2.1.1: Compound testing All compounds were perfused using a gravity-assisted perfusion system. At least one cell was tested for each concentration. After current stabilization (or 5 min), the change in current magnitude before and after compound application was compared to calculate the blocking effect of the compound.
[0310] 2.1.2: Test cells HEK293 cells stably expressing the NaV1.8 ion channel.
[0311] 2.1.3: Experimental equipment Patch clamp amplifier: patch clamp PC-505B (WARNER instruments) / MultiClamp 700A (Axon instrument) D / A converter: Digidata 1440A (Axon CNS) / Digidata 1550A (Axon instruments) Micromanipulator: MP-225 (SUTTER Instruments) Inverted microscope: TL4 (Olympus) Glass Microelectrode Puller: PC-10 (NARISHIGE) Microelectrode glass capillary: B12024F (Wuhan Microscopy Instruments Co., Ltd.)
[0312] 2.2: Electrophysiology The cells were transferred to a perfusion tank and perfused with extracellular solution. The intracellular solution (mM) was aspartic acid 140, MgCl2 2, EGTA 11, and HEPES 10, pH 7.2 (titrated with CsOH). The intracellular solution was stored in small batches in a refrigerator at -80°C and thawed on the day of the experiment. Electrodes were stretched with a PC-10 (Narishige, Japan). For whole-cell patch-clamp recordings, noise was filtered at one-fifth the sampling frequency.
[0313] 2.3: Test voltage formula (resting) and results The cells were clamped at -80mV and then depolarized to 10mV with a square wave lasting 10ms to obtain NaV1.8 current. This procedure was repeated every 5 seconds. After the maximum current induced by the square wave was detected and stabilized, the test compound was perfused, and the blocking strength was calculated after the response was stabilized.
[0314] Table 4: Inhibition rate of compounds against Nav1.8 (Inhibition rate / % at 100 nm concentration: A ≥ 80, 80 > B ≥ 50, 50 > C ≥ 20, D < 20) JPEG0007591240000089.jpg81137
[0315] Table 5 (continuation of Table 4): Inhibition rate of compounds against Nav1.8 (inhibition rate / % at 100 nm concentration: A ≥ 80, 80 > B ≥ 50, 50 > C ≥ 20, D < 20) JPEG0007591240000090.jpg121137
[0316] Many examples of this patent have clear activity advantages over VX-150 (clinical Phase II), and some other examples have comparable activity.
[0317] Test Example 2: Test of the inhibitory activity of compounds against the hERG ion channel of HEK293 cells This study serves as a cardiac safety study of the compound. 1: Test equipment Patch clamp equipment: PC-505B, MC-700A Microcontroller: MP-225 Electrode stretching device: PC-10 (Narishige, Japan)
[0318] 2: Drug preparation All compounds except NaOH and KOH for acid-base titration were purchased from Sigma (St. Louis, MO). All final concentrations of test compounds were prepared on the day and redissolved in extracellular solution. Extracellular solution (mM) was NaCl 137, KCl 4, CaCl2 1.8, MgCl2 1, HEPES 10, glucose 10, pH 7.4 (NaOH titration). All test and control compound solutions contained 0.3% DMSO. Intracellular solution (mM) was K Aspartate 130, MgCl2 5, EGTA 5, HEPES 10, Tris-ATP 4, pH 7.2 (KOH titration).
[0319] 3: Testing method Cells: All experiments were performed at room temperature. Each cell was used as its own control.
[0320] Compound testing: All compounds were perfused using their own gravity-assisted perfusion system. At least two cells were tested for each concentration. After current stabilization (or 5 min), the change in current magnitude before and after compound application was compared to calculate the blocking effect of the compound.
[0321] Positive control: The concentration of positive control Cisapride is selected based on the sensitivity test for cells, and the concentration with a blocking rate of about 90% is the optimal concentration of the positive control. When the test Cisapride is 100 nM, the blocking rate is about 90%, so the positive control Cisapride is set to 100 nM. The method is the same as that of the test compound.
[0322] Electrophysiology: Cells were transferred to a perfusion tank and perfused with extracellular solution. Intracellular solution (mM) was K Aspartate 130, MgCl2 5, EGTA 5, HEPES 10, Tris-ATP 4, pH 7.2 (titrated with KOH). Intracellular solution was stored in small aliquots in a refrigerator at -80°C and thawed on the day of the experiment. Electrodes were prepared by stretching PC-10 (Narishige, Japan). For whole-cell patch clamp recordings, noise was filtered at one-fifth of the sampling frequency.
[0323] Test process and results: The cell was clamped at -80mV, then depolarized to 40mV with a square wave lasting 4 seconds, and hyperpolarized to -40mV with a square wave lasting 2 seconds to obtain hERG tail current (see attached drawing). This procedure was repeated every 20 seconds. The hERG tail current is the pure hERG current. After the maximum tail current caused by the second square wave was detected and stabilized, the test compound was perfused, and the blocking strength was calculated after the reaction was stabilized.
[0324] Table 6: IC of compounds for hERG inhibition 50 Test results JPEG0007591240000091.jpg36170
[0325] The strong inhibition of the compounds against hERG poses serious cardiac safety risks, such as prolongation of the cardiac QT interval. The data in Table 6 show that the inhibition of some compounds in this patent against hERG is significantly weaker than that of VX-150 (clinical Phase II), and therefore may represent a better cardiac safety profile.
[0326] Test Example 3: Selectivity test of compounds for Nav ion channel subtypes The purpose of the experiment is to investigate the effect of compounds on stably expressing human Na ion channel cells (NaV1.1, NaV1.3, NaV1.4, NaV1.5, NaV1.6, NaV1.7). After the Na ion current is stabilized, the effect of the compound on the Na ion channel can be obtained by comparing the magnitude of the Na channel current before and after the application of the compound.
[0327] 1: Formulation of test compound All compounds except NaOH and KOH for acid-base titration were purchased from Sigma (St. Louis, MO). All final concentrations of test compounds were prepared on the day and redissolved in extracellular solution. The extracellular solution (mM) was NaCl, 137, KCl, 4, CaCl2, 1.8, MgCl2, 1, HEPES, 10, glucose 10, pH 7.4 (NaOH titration).
[0328] The stock concentration of the test compound was 9 mM. It was soluble in dimethyl sulfoxide (DMSO). On the day of the test, it was redissolved in extracellular fluid and prepared to a screening concentration of 1 uM.
[0329] 2: Testing method 2.1: Cell All experiments were performed at room temperature, and each cell served as its own control.
[0330] 2.1.1: Compound testing All compounds were perfused using a gravity-assisted perfusion system. At least one cell was tested for each concentration. After current stabilization (or 5 min), the change in current magnitude before and after compound application was compared to calculate the blocking effect of the compound.
[0331] 2.1.2: Experimental cells / reagents HEK293 cells stably expressing NaV1.1, NaV1.3, NaV1.4, NaV1.5, and NaV1.6 ion channels. CHO cells stably expressing NaV1.7 ion channel.
[0332] 2.1.3: Experimental equipment Patch clamp amplifier: patch clamp PC-505B (WARNER instruments) / MultiClamp 700A (Axon instrument) D / A converter: Digidata 1440A (Axon CNS) / Digidata 1550A (Axon instruments) Micromanipulator: MP-225 (SUTTER Instruments) Inverted microscope: TL4 (Olympus) Glass Microelectrode Puller: PC-10 (NARISHIGE) Microelectrode glass capillary: B12024F (Wuhan Microscopy Instruments Co., Ltd.)
[0333] 2.2: Electrophysiology The cells were transferred to a perfusion tank and perfused with extracellular solution. The intracellular solution (mM) was aspartic acid 140, MgCl2 2, EGTA 11, HEPES 10, pH 7.2 (titrated with CsOH). The intracellular solution was stored in small aliquots in a refrigerator at -80°C and thawed on the day of the experiment. Electrodes were prepared by stretching a PC-10 (Narishige, Japan). For whole-cell patch clamp recordings, noise was filtered at one-fifth the sampling frequency.
[0334] 2.3: Test voltage formula (resting) and results The cells were clamped at -80 mV and then depolarized to -10 mV with a square wave lasting 10 ms to obtain Na ion channel currents (see figure). This procedure was repeated every 5 seconds. After the maximum current evoked by the square wave was detected and stabilized, the test compound was perfused and the blocking strength was calculated after the response was stabilized.
[0335] Table 7: Inhibition rate of compounds against Nav subtypes at 1uM concentration JPEG0007591240000092.jpg39170
[0336] It can be seen that some compounds of this patent have good subtype selectivity for Nav ion channels. In particular, for Nav1.5, which may cause cardiac side effects, the inhibitory effect of some compounds of this patent is significantly weaker than that of VX-150 (clinical phase II), which may represent a better safety profile.
[0337] Test Example 4: In vivo pharmacokinetic study of the compound in rats SD rats, male (purchased from Shanghai Xipuer-Beikai Laboratory Animal Co., Ltd.). Each test compound was orally administered once to SD rats (100 mg / kg, 3 rats per group) to study the pharmacokinetics. The test compounds were prepared on the day of administration, and the test compounds were suspended in 5% DMSO + 95% saline, vortexed for 2 minutes, and sonicated for 5 minutes to prepare the drug delivery system. Before oral administration, the animals were fasted for 10-14 hours and fed 4 hours after administration. After oral gavage, pharmacokinetic samples were collected from the jugular vein, and the collection times were before administration, 15 minutes, 30 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 8 hours, and 24 hours after administration. Three whole blood samples were collected at each time point, with the collection volume of about 0.2 mL, and anticoagulated with sodium heparin. Blood samples were placed on ice immediately after collection and centrifuged within 1 hour to separate plasma (centrifugation conditions: 6800 rpm / min, 6 min, 2-8°C). Collected plasma was stored in a refrigerator at -80°C prior to analysis.
[0338] Table 8: Pharmacokinetic study results of some compounds at a dose of 100 mg / kg. JPEG0007591240000093.jpg45170
[0339] In this rat pharmacokinetic experiment, the comparative compound VX-150 was a prodrug (WO2015089361, compound 9), and after administration, the plasma concentration of its drug substance (WO2014120808, compound 10) was detected. All of the aforementioned in vitro drug discovery feasibility experiments were conducted using the drug substance (WO2014120808, compound 10).
[0340] The drug substance of VX-150 has very low solubility and very poor absorption effect in solid administration, so it was developed as a prodrug to solve the solubility problem. In the absence of prodrug modification, the rat pharmacokinetic performance of some compounds in this patent is significantly better than VX-150.
[0341] From the above drug feasibility research data, it can be seen that the compounds of the present invention have obvious inhibitory effects on Nav1.8 ion channel activity, and the drug feasibility parameters of some compounds, such as cellular activity, ion channel selectivity, hERG safety, and rat pharmacokinetics, have obvious advantages over VX-150 in clinical phase II, and can be used as Nav1.8 inhibitors, with broad application prospects in the fields of analgesia, atrial fibrillation, Budd-Chiari syndrome and so on.
Claims
1. A compound comprising: having the structure shown in Formula I or a tautomer, mesomeric, racemic, enantiomer, diastereomer or mixture thereof, in the form of a pharma- ceutically acceptable hydrate, solvate or salt thereof; A 1 , A 3 are each independently 1 or N, A 2 is OR 12 where z is 0; R 1 , R 2 , R 3 are each independently selected from hydrogen, a halogen, a hydroxyl group, a cyano group, an amino group, a substituted or unsubstituted alkyl group, a substituted or unsubstituted cycloalkyl group, a substituted or unsubstituted heteroalkyl group, a substituted or unsubstituted heterocycloalkyl group, a substituted or unsubstituted aryl group, a substituted or unsubstituted heteroaryl group, a substituted or unsubstituted amido group, an ester group, an acyl group, a carboxyl group, a sulfonyl group, a sulfonamide group, a boric acid group, a boric acid ester group, a phosphoryl group, a substituted or unsubstituted alkenyl group, and a substituted or unsubstituted alkynyl group; Here, R 1 , R 2 , R 3 are each independently selected from deuterium, halogen, hydroxyl, amino, alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, cyano, ester, acyl, carboxyl, amide, aryl, heteroaryl, sulfonyl, and sulfonamide; n is selected from 0, 1, 2, 3, 4; m is selected from 0, 1, 2, 3, 4, 5; R 13 , R 14 are each independently a hydrogen atom, an acyl group, a substituted or unsubstituted alkyl group, a substituted or unsubstituted cycloalkyl group, a substituted or unsubstituted heterocycloalkyl group, or a substituted or unsubstituted heteroaryl group; Z 1 , Z 2are each independently 1 to 5.
2. having the structure of formula II or II', or a tautomer, mesomeric, racemic, enantiomer, diastereomer, or mixture thereof, in the form of a pharma- ceutically acceptable hydrate, solvate, or salt thereof; n is selected from 0, 1, and 2; and m is selected from 0, 1, and 2. The compound of claim 1.
3. having the structure of formula IV or IV″ or an isomer, tautomer, mesomeric, racemic, enantiomer, diastereomer or mixture thereof, a pharma- ceutically acceptable hydrate, solvate or salt thereof; Where: A 1 is N or -CR 1 is selected from R 1 is selected from hydrogen, halogen, a substituted or unsubstituted C1-C3 alkyl group, a substituted or unsubstituted 2-4 membered heteroalkyl group, wherein the substituents are selected from halogen, a hydroxy group, an amino group, a C1-C3 alkyl group, a 2-4 membered heteroalkyl group, and an acyl group; R 6 , R 7 , R 8 , R 9are each independently a hydrogen atom, a halogen atom, a hydroxyl group, a cyano group, an amino group, a substituted or unsubstituted alkyl group, a substituted or unsubstituted cycloalkyl group, a substituted or unsubstituted heteroalkyl group, a substituted or unsubstituted heterocycloalkyl group, a substituted or unsubstituted aryl group, a substituted or unsubstituted heteroaryl group, an ester group, an acyl group, a carboxyl group, an amide group, a sulfonyl group, a sulfonamide group, a boric acid group, a borate ester group, a phosphoryl group, a substituted or unsubstituted alkenyl group, or a substituted or unsubstituted alkynyl group; wherein the substituents are selected from deuterium, a halogen atom, a hydroxyl group, an amino group, an alkyl group, a heteroalkyl group, a cycloalkyl group, a heterocycloalkyl group, a cyano group, an ester group, an acyl group, a carboxyl group, an amide group, an aryl group, a heteroaryl group, a sulfonyl group, and a sulfonamide group.
4. R 6 , R 7 are each independently selected from hydrogen, a halogen, a hydroxyl group, a cyano group, an amino group, a substituted or unsubstituted alkyl group, a substituted or unsubstituted cycloalkyl group, a substituted or unsubstituted heteroalkyl group, a substituted or unsubstituted heterocycloalkyl group, an ester group, an acyl group, a carboxyl group, an amide group, a sulfonyl group, a sulfonamide group, a boric acid group, a borate ester group, a phosphoryl group, a substituted or unsubstituted alkenyl group, and a substituted or unsubstituted alkynyl group; wherein the substituent is selected from halogen, a hydroxyl group, an amino group, a C1-C6 alkyl group, a 3- to 6-membered cycloalkyl group, a 2- to 7-membered heteroalkyl group, a 3- to 6-membered heterocycloalkyl group, a cyano group, an ester group, an acyl group, an amide group, an aryl group, a heteroaryl group, a sulfonyl group, and a sulfonamide group; R 8 , R 9are each independently selected from hydrogen, a halogen, a substituted or unsubstituted alkyl group, a substituted or unsubstituted cycloalkyl group, a substituted or unsubstituted heteroalkyl group, a substituted or unsubstituted heterocycloalkyl group, a hydroxyl group, a cyano group, an amino group, an ester group, an acyl group, an amide group, and a sulfonamide group, wherein the substituents are selected from deuterium, an alkyl group, a heteroalkyl group, a cycloalkyl group, a heterocycloalkyl group, a halogen, a hydroxyl group, a cyano group, an amino group, an acyl group, and a sulfonamide group.
5. R 6 , R 7 are each independently selected from hydrogen, a halogen, a hydroxyl group, a cyano group, an amino group, a substituted or unsubstituted C1-C6 alkyl group, a substituted or unsubstituted 3- to 10-membered cycloalkyl group, a substituted or unsubstituted 2- to 7-membered heteroalkyl group, a substituted or unsubstituted 3- to 10-membered heterocycloalkyl group, an ester group, an acyl group, a phosphoryl group, a substituted or unsubstituted alkenyl group, and a substituted or unsubstituted alkynyl group; wherein the substituent is selected from a halogen, a hydroxyl group, an amino group, a C1-C6 alkyl group, a 2- to 7-membered heteroalkyl group, a cyano group, an ester group, an acyl group, an amide group, an aryl group, a heteroaryl group, a sulfonyl group, and a sulfonamide group; R 8 , R 9 are each independently hydrogen, halogen, a substituted or unsubstituted alkyl group, a substituted or unsubstituted cycloalkyl group, a substituted or unsubstituted heteroalkyl group, or a substituted or unsubstituted heterocycloalkyl group, wherein the substituents are selected from deuterium, a C1-C6 alkyl group, a 2-7 membered heteroalkyl group, a 3-6 membered cycloalkyl group, a 3-6 membered heterocycloalkyl group, a halogen, a hydroxyl group, and an amide group.
6. R 8 is a halogen, a substituted or unsubstituted C1-C3 alkyl group, a substituted or unsubstituted C1-C3 alkoxy group, R 9The compound according to claim 3, characterized in that is selected from halogen, a methyl group, a trifluoromethyl group, and a substituted or unsubstituted alkoxy group.
7. The compound according to claim 1, wherein the halogen is selected from F, Cl, and Br, the substituted or unsubstituted C1-C3 alkyl group is selected from a methyl group and a trifluoromethyl group, and the substituted or unsubstituted C1-C3 alkoxy group is selected from a methoxy group and a trifluoromethoxy group.
8. A pharmaceutical composition, characterized in that the active ingredient is selected from one or a combination of two or more of the compounds according to claim 1 or their stereoisomers, solvates, hydrates, or pharma- ceutically acceptable salts.
9. 13. Use of a compound of claim 1 or a stereoisomer, solvate, hydrate, or pharma- ceutically acceptable salt thereof in the preparation of a Nav1.8 inhibitor.
10. The use according to claim 9, wherein the Nav1.8 inhibitor is a drug for treating a disease that causes overexpression of Nav1.8 or a drug for treating a disease caused by overexpression of Nav1.
8.
11. Use of a compound of claim 1 or a stereoisomer, solvate, hydrate, or pharma- ceutically acceptable salt thereof in the preparation of a medicament for treating any one or more of the following diseases: chronic pain, intestinal pain, neuropathic pain, musculoskeletal pain, acute pain, inflammatory pain, cancer pain, primary pain, multiple sclerosis, Charcot-Marie-Tooth syndrome, incontinence, and arrhythmia.
12. The neuropathic pain is selected from one or more of the following: post-herpetic neuralgia, diabetic neuralgia, painful HIV-associated sensory neuropathy, trigeminal neuralgia, burning mouth syndrome, post-amputation pain, phantom limb pain, painful neuroma, traumatic neuroma, Morton's neuroma, nerve contusion, spinal canal stenosis, carpal tunnel syndrome, radicular pain, sciatica, nerve avulsion, brachial plexus avulsion, complex regional pain syndrome, medication-induced neuralgia, cancer chemotherapy-induced neuralgia, antiretroviral therapy-induced neuralgia, pain after spinal cord injury, primary small fiber neuropathy, primary sensory neuropathy, trigeminal autonomic headache; the musculoskeletal pain is selected from one or more of osteoarthritis pain, back pain, cold pain, burn pain, and dental pain; the inflammatory pain is selected from rheumatoid arthritis pain and / or vulvodynia; The primary pain is selected from fibromyalgia.
12. The use according to claim 11.
13. R 6 , R 7 are each independently hydrogen, halogen, a substituted or unsubstituted C1-C3 alkyl group, a substituted or unsubstituted cyclopropyl group, R 6 , R 7 The compound according to claim 3, characterized in that
14. R 6 , R 7 are each independently selected from hydrogen, halogen, a trifluoromethyl group, and a substituted or unsubstituted cyclopropyl group; R 6 , R 7 The compound according to claim 3, characterized in that
15. R 8 , R 9are each independently selected from hydrogen, halogen, a substituted or unsubstituted C1-C6 alkyl group, and a substituted or unsubstituted C1-C6 alkoxy group, wherein the substituents are selected from deuterium, halogen, a C1-C6 alkyl group, a 2-7 membered heteroalkyl group, a 3-6 membered cycloalkyl group, a 3-6 membered heterocycloalkyl group, a hydroxy group, and an amido group.
16. R 1 The compound according to claim 1, characterized in that is selected from hydrogen and halogen.
17. R 1 The compound according to claim 1, characterized in that is selected from H and F.
18. R 8 is selected from substituted or unsubstituted C1-C3 alkyl groups; R 9 The compound according to claim 3, characterized in that is selected from F, Cl, Br, a methyl group, a trifluoromethyl group, a methoxy group, and a trifluoromethoxy group.
19. R 8 is a methyl group, R 9 The compound according to claim 3, characterized in that
20. 2. The compound according to claim 1, wherein the compound structure is selected from one of the following:
Citation Information
Patent Citations
Arylamides are useful as inhibitors of voltage-opening sodium channels.
JP2011500600A
Amides as modulators of sodium channels
JP2016508500A
Prodrugs of pyridoneamides useful as modulators of sodium channels
JP2017504591A
Carboxamides as modulators of sodium channels
JP2020526561A
Esters and carbamates as modulators of sodium channels
WO2020146612A1
